

CURRICULUM VITAE

Myron Max Levine, M.D., D.T.P.H., F.A.A.P., F.A.C.P.M., F.I.D.S.A., F.A.S.T.M.H.

Grollman Distinguished Professor

and

Associate Dean for Global Health, Vaccinology and Infectious Diseases

Founding and Past Director, Center for Vaccine Development, 1974-2014

Date: December 19, 2017

Personal Information:

Business Address: Center for Vaccine Development
685 W. Baltimore Street – HSF 1 Room 480
Baltimore, Maryland 21201

Business Telephone No.: 410/706-7588
Business Fax No.: 410/706-6205
Email: mlevine@som.umaryland.edu

Language Proficiency:

	<u>Speaks</u>	<u>Reads</u>	<u>Writes</u>
French	well	well	well
Spanish	well	well	well
Hebrew	poor	fair	poor

Education:

Preliminary: 1959 Evander Childs High School, Bronx, New York

Degrees: 1963 B.S. City College of New York

1967 M.D. Medical College of Virginia

1974 D.T.P.H. (with Distinction) London School of Hygiene and Tropical Medicine

Scholarship: 1966 Aaron Brown Memorial Scholarship Award

Student Fellowships:

June-September 1966 Louisiana State University - N.I.H. Fellow in Tropical Medicine, I.C.M.R.T., San Jose, Costa Rica
Supervisor: Antonio Peña-Chavarría, M.D.

March - June, 1967 H.E.W. Fellow in Pediatric Clinical Research, Jinnah Children's Hospital, Karachi, West Pakistan
Supervisor: Kathryn Bain, M.D.

Exchangeships:

June-September, 1964 Student AMA exchange student to the Hebrew University Medical School, Jerusalem, Israel

June - September, 1965 Exchange student to Department of Dermatology,
L'Hôpital Saint-Louis, Paris, France
- Sponsored by the Parisian Society of Medical Students.

Post Graduate Education and Training:

Internship & Residency Training: Bronx Municipal Hospital Center, Albert Einstein College of Medicine,
Bronx, New York
July 1967-June 1968 Internship (Pediatric)-
July 1968-June 1969 Assistant Pediatric Resident
July 1969-June 1970 Senior Pediatric Resident
Supervisors: Henry Barnett, M.D., Lewis Fraad, M.D.

Post-Doctoral Fellowship Training:

January - June 1970 Fellow in Pediatric Infectious Diseases
Division of Pediatric Infectious Diseases and Immunology
Department of Pediatrics
Albert Einstein College of Medicine
Supervisor: John B. Robbins, M.D.

August 1970 - July 1972 Fellow, Division of Infectious Diseases, University of Maryland
School of Medicine
Supervisors: Richard B. Hornick, M.D.; Herbert L. DuPont.

Certifications:

1970 Pediatric Boards, Part I (Written)
1972 Pediatric Boards, Part II (Oral)
1975 Preventive Medicine Boards

Medical Licensure:

Maryland License – D12258 (Current through 9/2010)

Expired:

National Boards New York State License
Virginia Boards Virginia License

Military Service:

Lt. Commander
U.S. Public Health Service Commissioned Corps
Epidemic Intelligence Service Officer
Bacterial Diseases Branch
Epidemiology Program, Center for Disease Control, Atlanta, Georgia
Supervisors: Eugene J. Gangarosa, M.D.
Phillip Brachman, M.D.

July 1970 - September 1973 Active Duty Assignment - Medical Epidemiologist assigned to the
Shigella Vaccine Development Program
Division of Infectious Diseases
University of Maryland School of Medicine, Baltimore, Maryland

1981 - 1997 Inactive Reserve

Employment History:

Primary Faculty Appointments:

	University of Maryland School of Medicine: Department of Medicine: Division of Infectious Diseases
July 1972 - June 1975	- Assistant Professor
July 1975 - June 1981	- Associate Professor
July 1981 - June 1982	- Research Professor
July 1982	- Professor
Jan. 1984 - Dec. 2014	- Head, Division of Geographic Medicine

	Department of Pediatrics:
July 1971 - June 1972	- Instructor
July 1972 - June 1982	- Assistant Professor
July 1982 - July 1983	- Associate Professor
July 1983	- Professor
July 1984 - September 1985	- Acting Head, Division of Infectious Diseases
October 1985 – July 2005	- Head, Division of Infectious Diseases and Tropical Pediatrics

Secondary and External Faculty Appointments:

	Department of Epidemiology and Preventive Medicine:
July 1974 - June 1978	- Assistant Professor
July 1978	- Associate Professor
July 1990	- Professor
	Department of Microbiology and Immunology:
July 1989	- Professor
1985 - Present	Senior Associate, Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health
1980 - Present	Visiting Professor Facultad de Medicina Universidad Peruana Cayetano Heredia Lima, Peru
2001-Present	Visiting Professor Faculty of Tropical Medicine Mahidol University Bangkok, Thailand,

Other Appointments:

Effective January 2015	Associate Dean for Global Health, Vaccinology and Infectious Diseases. University of Maryland School of Medicine
July 1974 – Dec. 2014	Director, Center for Vaccine Development University of Maryland School of Medicine
1987 – 1990	Acting Co-Director, Medical Biotechnology Center, University of Maryland

Professional Societies:

	Society for Epidemiologic Research
	Society for Intestinal Microbial Ecology and Disease
1972	Royal Society of Tropical Medicine & Hygiene
1973	Fellow of the American Academy of Pediatrics
1974 1977 – 1978	Medical and Chirurgical Faculty of Maryland - Chairman, Subcommittee on Infectious Diseases
1976	Fellow of the American College of Preventive Medicine
Elected 1976	Fellow of the Infectious Diseases Society of America (F.I.D.S.A.)
1976	Baltimore City Medical Society-Subcommittee on International Health
1977 - 1981	Baltimore City Medical Society- Chairman, Public Health Committee
Elected 1986	American Society for Clinical Investigation
Elected 1982 2000 - 2001	American Epidemiological Society - President
October 1991	Sociedad Latinoamericana de Infectologia Pediatrica - Corresponding member inducted
Elected 1993	Association of American Physicians
1995	American Society for Microbiology
1995	American Academy of Microbiology
Elected October 1995	Member, Institute of Medicine (now the National Academy of Medicine), National Academy of Sciences
2004 - 2005 2005 - 2006 Elected 2011	American Society of Tropical Medicine & Hygiene - President-Elect - President Fellow of the American Society of Tropical Medicine & Hygiene (F.A.S.T.M.H.)
2017	- Honorary International Fellow of ASTMH Committee
2011	The Edward Jenner Society, Councilor and Founding Member - Executive Committee

Editorial Boards:

1985 – 1997	Editor, Epidemiological Reviews
1986 – 1988	Editorial Board, Journal of Infectious Diseases
1990	Editorial Board, 15th ed. of Control of Communicable Diseases, APHA

1991 – 2000	International Editorial Board, Public Health Reviews
1993	Advisory Editor, Molecular Medical Microbiology
1994 – 1998	International Advisory Board, GUT
1994	Editorial Board, 16th ed. of Control of Communicable Diseases, APHA
1996	International Advisory Board, Annals of Tropical Medicine & Parasitology
1997 – 2004	Board of Editors, American Journal of Epidemiology,
1998 – 2004	Editorial Board, Infection and Immunity
2000 – 2010	Editorial Board, Vaccine
2004 - present	Editorial Board, Human Vaccines (Now Human Vaccines & Immunotherapeutics)

Honors and Awards:

Teaching Awards:

1995	The Colonel George W. Hunter III Award for Excellence as Senior Lecturer in Tropical Medicine at the Walter Reed Army Institute of Research Tropical Medicine Course
2015	University of Maryland School of Medicine, Department of Medicine Teaching Award

Other Honors:

Presented October 17, 1995	Life Sciences Achievement Award of the University of Maryland at Baltimore
Presented June 3, 1998	Albert B. Sabin Gold Medal Award of the Albert B. Sabin Vaccine Institute for contributions in the field of vaccinology.
Presented November 9, 1999	State of Maryland Governor's Citation "in recognition of contributions made in the medical profession". Presented at the Silver Anniversary celebration of the Center for Vaccine Development.
November 9, 1999	In conjunction with the Silver Anniversary celebration of the Center for Vaccine Development, Baltimore City Mayor Kurt L. Schmoke proclaimed this day as "Dr. Myron M. Levine Day" in recognition of contributions made in the field of vaccinology.
November 2000	"Highly Cited Researcher in Immunology" awarded by Institute for Science Information (ISI)/Thomson Scientific as one of the top 100 most highly cited, influential researchers in the field of immunology.
2001	Voted by the editors of <u>Baltimore Magazine</u> as "Baltimorean of the Year." This honor was bestowed upon ten individuals in recognition of their contribution to improving the way of life in Baltimore in 2001. Featured in the January, 2002 issue.
Presented February 2005	"Mary Betty Stevens Award for Clinical Research" from the Maryland Chapter of the American College of Physicians.
Presented June 6, 2005	Rank of "Grand Officer of the National Order of Mali" presented on behalf of the President of Mali, Amadou Toumani Touré, for efforts in developing and distributing vaccines to the children of Mali. This honor is traditionally bestowed only to heads of state.

Presented January 10, 2006	Medalla Rectoral (Rector's Medal), University of Chile, Santiago, Chile. Highest award presented to individuals external to the university for their academic assistance to the university.
Presented August 9, 2006	Simon and Bessie Grollman Distinguished Professorship (Endowed Chair) of the University of Maryland School of Medicine, awarded in recognition of outstanding medical research.
April 27, 2007	2007 Outstanding Medical Alumnus Award presented by the Medical Division of the Medical College of Virginia Alumni Association, awarded for distinguished contributions to health care.
Presented Oct. 1, 2009	2009 Entrepreneur of Year of the University of Maryland at Baltimore
Presented Oct. 14, 2009	Awarded the Maryland Daily Record's 2009 Maryland Innovator of the Year for having the vision and spirit to contribute to the health of the Maryland community
Awarded June 17, 2012	Maurice Hilleman/Merck Award of the American Society for Microbiology. For vaccine discovery, vaccine development and control of vaccine-preventable diseases
Awarded November 2013	Donald Mackay Medal of the American Society of Tropical Medicine and Hygiene in recognition of outstanding research on tropical health
Awarded May 16, 2014	Dean's Distinguished Gold Medal, University of Maryland School of Medicine
Awarded April 30, 2015	American College of Physicians Award for Outstanding Work in Science as Related to Medicine
Awarded May 18, 2017	2017 Maxwell Finland Award for Scientific Achievement presented by the National Foundation for Infectious Diseases

Fraternities and Honor Societies:

	Sigma Zeta Science Honor Society
1965 - 1966 1964 - 1965	Phi Delta Epsilon Medical Fraternity - President Alpha Mu Chapter, - Secretary
1967	Alpha Omega Alpha Medical Honor Society

Administrative Service/Consultantships

Institutional Service:

University Committees:

1983	University of Maryland Task Force on High Technology/Biotechnology
1993 - 1995	Scientific Advisory Committee, Medical Biotechnology Center
1997 - Present	Scientific Advisory Committee, Institute for Human Virology
2009 - 2010	Search Committee for President, University of Maryland, Baltimore
2009	Chair, Misconduct in Scholarly Work Inquiry Committee
2011 - Present	University of Maryland, Baltimore Strategic Planning Committee

2012 – Present Internal Advisory Board, University of Maryland Institute for Clinical and Translational Sciences (ICTS)

Medical School Committees:

1982 - 1984 Student Research Day Committee
1984 Medical Biotechnology Task Force
1984 Chairman, Subcommittee on Molecular Biology
1986 – 1987 Search Committee for a Chairperson for the Department of Microbiology
1998 - 1999 Objectives Subcommittee, Institutional Self-Study Committee
2000 - 2005 Research Subcommittee of SOM Strategic Plan
2000 Steering Committee
2008 - Present Executive Committee of the School of Medicine Council
2010 Faculty Excellence Recognition and Awards Committee (FERAC)

Departmental Committees:

1984 - 1988 Department of Medicine Research Committee
1985 - 1992 Department of Medicine Promotions Committee
1985 - 1991 Committee Chairman
2010 - 2012 Department of Medicine Strategic Research Planning Committee

Local and National Service:

July 1980 - Sept. 1984 Recombinant DNA Advisory Committee
National Institutes of Health
May 1984 Member Organizing Committee, NIH National Consensus
Conference on Travelers' Diarrhea
August 1984 National Research Council, National Academy of Sciences
Steering Committee for the Study of the U.S. Capacity to Address
Tropical Disease Problems
1986 – 1988 Member, Technical Advisory Group for the AID-sponsored
Applied Diarrheal Diseases Research Project of the
Harvard Institute for International Development,
1986 – 1990 Member, Technical Advisory Group for the
U.S.-Aid-sponsored DiaTech Project
1991 Nominating Committee, American Epidemiological Society
1991 - 1993 Data and Safety Monitoring Board, AIDS/HIV trials Conducted by the
U.S. Department of Defense
1995 - 1999 National Vaccine Advisory Committee
1997 - 1999 Chair, Future Vaccines Sub-committee
1997 – Present Institute of Human Virology, University of Maryland, Baltimore, Scientific
Advisory Board
June 1997 Member, Blue Ribbon Panel that evaluated the NIAID research plan for
malaria vaccine development
1998 - 2013 Scientific Program Committee of the Annual Conference on Vaccine
Research, National Foundation for Infectious Diseases (NFID)

1999	NIAID Strategic Plan Task Force
2000 -2003	Data and Safety Monitoring Board, Cytomegalovirus (HCMV) protocol evaluated by DMID
2000 - Present	Department of Defense Blue Ribbon Panel on Analysis of Alternatives for Biological Defense Vaccine Production Capability,
2001 - 2002	Institute of Medicine, National Academy of Sciences <i>E. coli</i> O157:H7 Risk Assessment Committee,
January 2002	Institute of Medicine, Anti-Infectives Planning Committee to initiate a study on bioterror agents and orphan vaccines,
2002	NIAID Blue Ribbon Panel on Bioterrorism and its Implications for Biomedical Research on Category B & C Agents,
2003 – 4/2006	Committee Member, Board of the Medical Follow-up Agency (MFUA), Institute of Medicine, National Academies
11/2005 – 8/2006	- Chair, U.S. Military Malaria Vaccine Research – A Program Review
2003 - 2009	Member, US Cholera Panel, US-Japan Cooperative Medical Science Program, NIAID
February 2004	Institute of Medicine, Panel on Microbial Threats, Accelerating Vaccine Development, Production, and Deployment.
Aug. 2004 – Present	NIAID Vaccine Research Center Board of Scientific Counselors (VRCBSC)
2004 - 2005	Member, Committee on the Review of the National Immunization Program's Procedures and Data Sharing Program, Institute of Medicine
2005 - 2008	Member, Infectious Diseases Society of America, Program Committee
2005 – 2010	Scientific Advisory Board, Avant Immunotherapeutics, Inc. Cholera-gard Steering Committee
2006	Chair, Committee on US Military Vaccine Research: a Program Review, Institute of Medicine
2006 – 2009	Member, Board on Military and Veterans Health (BMVH), Institute of Medicine, National Academies.
2006-	Member, American Institute of Biological Sciences (AIBS), Scientific Advisory Board on Department of Defense Malaria Vaccine Development
2006-2007	Chair of the Institute of Medicine Committee reviewing the Department of Defense Global Emerging Infections Surveillance and Response System (GEIS)
2007 – 2010	Member, Infectious Diseases Society of American, Joint Research Awards Committee

12/2007 – 7/2008	Member and Chair, Institute of Medicine Committee: Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants (IPTi)
8/28/2008 - 2010	Member, Ebola Vaccination Initiative Scientific Committee. Multi organizational effort to develop and deploy a vaccine to protect African great apes from the Ebola virus
7/2009 – 5/31/10	Committee Member, Board on the Health of Select Populations. Institute of Medicine, National Academies Previously the Board of the Medical Follow-up Agency (MFUA).
2017 - 2020	External Scientific Advisory Board, Emerging Pathogens Institute, University of Florida

International Service:

1992 - 1994	Steering Committee on Diarrhoeal Disease Vaccines, Programme for Vaccine Development, World Health Organization
1995	Steering Committee on Diarrhoeal Disease Vaccines, Global Programme for Vaccines, World Health Organization
1995 - Present	Member, Task Force on Vaccines, International Association of Biological Standardization
1995	Member International Advisory Committee, Oxford Vaccine Group
March 1997	Ad Hoc member, WHO Steering Committee Meeting on Vaccines against <i>Leishmania</i>
1997	Member, Steering Committee on New Vaccination Approaches, Global Programme for Vaccines and Immunization, World Health Organization
December 1997-1999	Chairman, Working Group on Mucosal Vaccines, Steering Committee on New Vaccination Approaches, Global Programme for Vaccines and Immunization, World Health Organization
1998 – Present	Scientific Program Committee, Conference on Vaccine Research
July 1998-March 1999	Member, World Bank/World Health Organization/UNICEF/Industry/Rockefeller Foundation Working Group on Vaccine Development and Immunization
April 1999- July 1999	Member, Working Group of the Global Coalition for Vaccines and Immunization
July 1999 – June 2002	Member, Working Group of the Global Alliance for Vaccines and Immunization (GAVI)
June 2000 - 2002	Co-Chair, Task Force on Research and Development, GAVI
August 2002 - 2005	Member, WHO Product Development Group for Aerosol Measles Vaccine
2003 - Present	Member, Advisory Board to the Center for Clinical Vaccinology and Tropical Medicine, Oxford University, UK

2004 – 2006	Member, WHO Vaccine Advisory Committee (IVAC)
August 2004	Co-Chair of Review Panel “Create New Vaccines (GCs 4-6)” of the Grand Challenges in Global Health (GCGH) Initiative, managed by the Foundation for the National Institutes of Health and sponsored by the Bill & Melinda Gates Foundation
2005	Program Committee, 2005 Global Vaccine Research Forum, Initiative for Vaccine Research (IVR), WHO
2006 – 2012	Technical Advisory Group – International Vaccine Institute (IVI)
2007 – 11/2008	Scientific Organizing Committee, 7 th International Conference on Typhoid Fever and Other Invasive Samonellooses, April 20-23, 2008, Kilifi, Kenya
January 16, 2007	Panel on Strategic Review of Vaccine Research, Medical Research Council (MRC), London
June 29, 2007	Beth Israel Deaconess Medical Center, Harvard Medical School, Letvin-Gates Scientific Advisory Board
2005 – 2020	Member, WHO International Health Regulations (IHR) Roster of Experts
2008 – Present	Institute of Human Virology, Vaccine Development Antibody Consortium Scientific Advisory Board (Funded by Gates Foundation)
2009 – Present	Country Studies Task Force of the WHO Initiative to Estimate the Global Burden of Foodborne Diseases (FERG)
2009 - 2010	Chair, International Advisory Committee, Malaria Eradication Research Agenda (malERA)
2009 - Present	Sabin Vaccine Institute, Coalition Against Typhoid (CaT)
2010 - Present	AfriChol – Consortium supports cholera prevention and control in Africa. External Advisory Board (Funded by Gates Foundation)
2010 - Present	Pasteur Institute, STOPENTERICS Program – Scientific Advisory Board (Funded by European Union)
2010 - Present	Ad-Hoc Scientific Consultation on Cholera Vaccination, PAHO/HQ, Washington, DC, 17 Dec. 2010
2010 - Present	Member, Ad Hoc Advisory Group for CDC response to cholera in Haiti
March 2013	WHO Consultant, Typhoid Fever in Samoa
2016 - Present	Strategic Advisory Group of Experts on immunization (SAGE) Working Group on Typhoid Vaccines
11/2016 - 11/2017	Data Safety Monitoring Board for African-Canadian Study of HIV-infected adults and a vaccine for Ebola - ACHIV-Ebola being conducted at Dalhousie University, Halifax, Nova Scotia

INDUSTRY ADVISORIES (SINCE 2000):

2001 – 2010	Aus Bio Ltd (Australia), Scientific Advisory Board
2004 – 2008	VaxGen, Inc. Member, Board of Directors
2005 – 2008	Avant Immunotherapeutics, Inc., CholeraGard Steering Committee
2006 – 2007	CruCell Holland BV Scientific Advisory Board
2005 – 2007	Merck & Co., Inc. Data Safety Monitoring Board, STEP
2/2006 – 2010	AlphaVax Human Vaccines Inc. Scientific Advisory Board
2007 – Present	Variation Biotechnologies, Inc., Scientific Advisory Board
2009- Present	Medicago, Inc., Scientific Advisory Council
10/2016 – 10/2017	Dalhousie Univ., IWK Health Centre, Ebola Data Safety Monitoring Brd
2016 - 2019	International Vaccine Institute (IVI) Scientific Advisory Board (SAG)
2016 - 2019	Merck & Co., Expert Input Forum for Ebola Vaccine

Grant Support since 2009 with M Levine as Principal Investigator:

Bill and Melinda Gates Foundation	Current prevalence of chronic typhoid carriers and residual transmission of typhoid fever in Santiago, Chile	\$3,499,799	12/2016 to 12/2019
NIH	Enteric Center of Excellence for Translational Research (Enteric-CETR): Immunoprophylactic Strategies to Control Emerging Enteric Infections	\$24,990,278	3/2014 to 2/2019
NIH	Fellowship Training Program in Vaccinology (T32)	\$1,086,685	7/2013 to 5/2018
Wellcome Trust, UK	Parenteral conjugate vaccines to prevent invasive non-typhoidal <i>Salmonella</i> infections in infants and young children in sub-Saharan Africa	\$3,999,620	4/2012 to 3/2018
Leidos	Accelerated Clinical Evaluation of Monovalent and Bivalent vectored Ebola vaccines	\$1,879,200	11/21/14 to 1/2017
Bill & Melinda Gates Foundation	A Point-of-Care Rapid Assessment Tool to Detect Protective Levels of Vaccine-Related Antibodies in Oral (Crevicular) Fluid of Infants, Toddlers & Older Subjects	\$2,514,226	11/2012 to 2/2017
Wellcome Trust	Accelerated Clinical Evaluation of Monovalent Vectored Ebola Vaccine	\$1,224,680	9/01/14 to 2/29/2016
University of Oxford	Large scale biomanufacture of monovalent EBOLA vaccine	\$638,752	12/01/14 to 11/30/2015
Norwegian Institute of Public Health	GCP Training and Monitoring in the Ebola Vaccine Phase III trial in Guinea	\$75,000	2/23/15 to 9/30/2015
National Aeronautical and Space Administration (NASA)	Incorporation of novel attenuating mutations identified in microgravity conditions into the construction of a live bacterial vaccine against enteric fever caused by <i>Salmonella enterica</i> serovar Paratyphi	\$997,960	7/2013 to 7/2015

NIH	Middle Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MARCE 2)	\$41,950,256	3/2009 to 2/2015
Bill & Melinda Gates Foundation	Influenza incidence measurement & randomized trial of the effectiveness of inactivated influenza vaccine in preventing influenza in pregnant (3rd trimester) women & in their infants during the first six months of life	\$11,995,926	11/2009 to 12/2014
Bill & Melinda Gates Foundation	Diarrheal Disease in Infants and Young Children in Developing Countries (GEMS-1A)	\$15,299,114	6/2011 to 10/2014
JSI	Universal Immunization Project (Ethiopia)	\$1,369,069	8/2011 to 9/2014
Bill & Melinda Gates Foundation	Ultra-fast and Sensitive Detection of Typhoidal and Non-typhoidal <i>Salmonella</i> in Blood Using Microwave-Accelerated Metal-Enhanced Fluorescence	\$1,421,301	11/2011 to 6/2014
Univ. of Massachusetts subcontract from DARPA grant	Vectored Delivery of Oligoclonal Antibodies for Protection Against Enterotoxin Mediated Diarrheal Diseases	\$1,120,451	7/2013-5/2014
NIH	Middle Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MARCE 2)	\$41,950,256	3/2009 to 3/2014
Bill & Melinda Gates Foundation	Diarrheal Disease in Infants and Young Children in Developing Countries (The Global Enteric Multi-Center Study ["GEMS"])	\$27,991,702	5/2006 to 4/2011
PATH Vaccine Solutions	Safety, immunogenicity, and efficacy following experimental challenge of CVD 1208S, a Δ guaBA, Δ sen, Δ set <i>Shigella flexneri</i> 2a live oral vaccine	\$2,488,445	10/2008 to 10/2010
Wyeth Vaccines	Prospective Systematic Surveillance for Hospitalized and Ambulatory Invasive Pneumococcal Disease in Infants and Children Served by Four Health Services of the Metropolitan Region of Santiago, Chile	\$1,202,802	12/2007 to 6/2009
NIH	Recombinant and live oral <i>Salmonella</i> Typhi hybrid vaccines Development of a <i>Salmonella</i> -based vaccine against SARS. R01 AI029471	\$2,512,924	3/2004 to 2/2009
Bill & Melinda Gates Foundation	Development of a "stealth" measles vaccine that can immunize young infants (2-6 months of age) in developing countries, despite the presence of maternal antibodies"	\$20,830,454	9/2000 to 2/2005
PATH/Merck	Randomized, double-blind (and in-house blind), placebo-controlled trial in Africa to evaluate the efficacy, safety, and immunogenicity of a 3-dose regimen of oral RotaTeq™	\$337,614	7/2007 to 7/2009
NIH	Evaluation of control measures against infectious diseases other than AIDS. Clinical testing of vaccines and related products in pediatric and geriatric populations. Vaccine Treatment and Evaluation Unit (VTEU) (N01-AI-25461)	\$17,361,080	6/2002 to 12/2008
NIH	Defense against biowarfare and emerging infection agents	\$53,541,000	9/2003 to 2/2008

	Development and testing of vaccines, diagnostics, and therapeutics against agents of biowarfare. (U54 AI057168)		
--	---	--	--

Patents, Inventions and Copyrights:

Kaper James B., Levine Myron M. US patent Nos. 4,935,364, 5,135,862 and 5,470,729.
"Method of isolating restriction fragment deletions in *Vibrio cholerae* and products thereof".
South African patent # 91/4286, Issued March 25, 1992.
EPO patent # 0119031 "Virulent *Vibrio cholerae* and methods for its production.

Kaper James B. and Levine Myron M.. U.S. Patent Nos. 5,399,494 and 5,628,994, Issued May 13, 1997
"*Vibrio cholerae* strain CVD103HgR, Method of Making Same, and Vaccines Derived Therefrom"

Kaper James B. and Levine Myron M. U.S. Patent No. 5,882,653
"*Vibrio cholerae* O1 (CVD111) and non-O1 (CVD112 and CVD112RM) Serogroup Vaccine Strains, Methods of Making Same and Products Thereof"

Baudry B, Levine MM. US patent # 5,189,151, Issued February 23, 1993.
"Highly specific DNA probe for enteroaggregative *Escherichia coli*."

Fasano A, Levine MM, Noriega F, Nataro JP. US patent #5,468,639
"Isolated DNA molecule encoding ShET2 of *Shigella flexneri* 2a."

Fasano A, Levine MM, Noriega F, Nataro JP. US patent #5,589,380
"Isolated DNA molecule encoding ShET1 of *Shigella flexneri* 2a."

Noriega F, Levine MM. US patent #5,783,196, Issued July 21, 1998.
 Δ Gua mutants of *Shigella* spp. and vaccines containing the same.

Levine MM, Noriega F, Sztein MB. US patent # 6,190,669, Issued Feb. 20, 2001. "Attenuated mutants of *Salmonella* which constitutively express the Vi antigen."
Foreign patent Nos. 1076566, 754795, 2,328,056

Altbaum Zeev, Levine Myron M., Barry Eileen M. US patent #6,902,736 B2 Issued June 7, 2005.
"Isolation and characterization of the CSA operon (ETEC-CS4 pili) and methods of using same."
Foreign patent Nos. 200125543, 1280912, 2002/9042,246230, 522272

Barry Eileen, Levine Myron M., Vindurampulle Christofer. US patent # 8,475,810 Issued July 2, 2013.
"Attenuated *Salmonella* Enterica Serovar Paratyphi and Uses Thereof".
Foreign Patent No. 1941024

Vindurampulle Christofer, Levine Myron, Barry Eileen, Galen James. US Patent # 8,137,930, Issued March 20, 2012
"Attenuated *Salmonella* enterica Paratyphi A and uses thereof".

Levine Myron, Galen James, Simon Raphael, Tennant Sharon.
US patent 9,050,283
"Broad spectrum vaccine against non-typhoidal *Salmonella*"

Levine Myron, Galen James, Simon Raphael, Tennant Sharon. US application filed Nov. 6, 2013
US patent 9,011,871
"Broad Spectrum Vaccine Against Typhoidal and Non-Typhoidal *Salmonella* Disease"

Levine Myron, Simon Raphael, Tennant Sharon. US application filed April 13, 2016.
US Provisional Application Number: 62/146,545.

“Compositions and Methods for Producing Bacterial Conjugate Vaccines”

Miscellaneous:

Sabbatical Activity:

Sept. 1987 - Feb. 1988 Fellow of the Sackler Institute of Advanced Studies, Tel Aviv University, Israel

Publications:

Peer-Reviewed Journal Articles

1. Clyde DF, Miller RM, Schwartz AR, Levine MM. The treatment of falciparum malaria with sulfalene and trimethoprim. *Am J Trop Med Hyg* 20:804-811, 1971.
2. Levine MM, DuPont HL, Gangarosa EJ, Hornick RB, Snyder MJ, Libonati JP, Glaser K, Formal SB. Shigellosis in custodial institutions. II. Clinical, immunologic, and bacteriologic response of institutionalized children to oral attenuated *Shigella* vaccines. *Am J Epidemiol* 96:40-49, 1972.
3. Levine MM, DuPont HL, Formal SB, Hornick RB, Takeuchi A, Gangarosa EJ, Snyder MJ, Libonati JP. Pathogenesis of *Shigella dysenteriae*-I (Shiga) dysentery. *J Infect Dis* 127:261-270, 1973.
4. Levine MM, DuPont HL, Khodabandelou M, Hornick RB. Long-term Shigella-carrier state. *New Eng J Med* 288:1169-1171, 1973.
5. Wald ER, Levine MM, Togo Y. Concomitant Varicella and staphylococcal Scalded Skin Syndrome. *J Pediatr* 83:1017-1019, 1973.
6. Levine MM, Rice PA, Gangarosa EJ, Morris GK, Snyder MJ, Formal SB, Wells JG, Gemski P, Jr., Hammond J. An outbreak of Sonnei shigellosis in a population receiving oral attenuated *Shigella* vaccines. *Am J Epidemiol* 99:30-36, 1974.
7. Levine MM, Gangarosa EJ, Werner M, Morris GK. Shigellosis in custodial institutions. III. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated *Shigella* vaccine. *J Pediatr* 84:803-806, 1974.
8. Levine MM, Togo Y, Wald ER. Practicability of influenza surveillance by virus culture of children. *Am J Epidemiol* 100:272-276, 1974.
9. Levine MM, Edsall G, Bruce-Chwatt LJ. Live virus vaccines in pregnancy: risks and recommendations. *Lancet* II:34-38, 1974.
10. Levine MM, Gangarosa EJ, Barrow WB, Norris GK, Wells JG, Weiss CF. Shigellosis in custodial institutions. IV. *In Vivo* stability and transmissibility of oral attenuated streptomycin-dependent *Shigella* vaccines. *J Infect Dis* 131:704-707, 1975.
11. Levine MM, Hornick RB, DuPont HL. Lactulose in the therapy of acute Shigella dysentery and Shigella-carrier state. *Antimicrob Agents Chemother* 8:581-584, 1975.
12. Gilman RH, Terminel M, Levine MM, Mendosa PH, Calderone E, Vasquez V, Martinez E, Snyder MJ, Hornick RB. Comparison of trimethoprim-sulfamethoxazole and amoxicillin in chloramphenicol-resistant and sensitive typhoid fever. *J Infect Dis* 132:630-635, 1975.

13. Gilman RH, Termini M, Levine MM, Mendoza PH, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone marrow, and rose-spot cultures for recovery of *Salmonella typhi* in typhoid fever. *Lancet* I:1211-1215, 1975.
14. Levine MM. Use of live virus vaccines in pregnant women in the tropics. *Tropical Doctor* 5:83-85, 1975.
15. Levine MM, Ashman R, Heald FP. Anaerobic (putrid) lung abscess in adolescence. *Am J Dis Child* 130:77-81, 1976.
16. Wald ER, Levine MM. Frequency of detection of *Haemophilus Influenzae* type B capsular polysaccharide in infants and children with pneumonia. *Pediatrics* 57:266-267, 1976.
17. Keusch GT, Jacewicz M, Levine MM, Hornick RB, Kochwa S. Pathogenesis of Shigella Diarrhea. Serum anti-toxin antibody response produced by toxigenic and "non-toxigenic" *S. dysenteriae* I. *J Clin Invest* 57: 194-202, 1976.
18. Levine MM, DuPont HL, Hornick RB, Snyder MJ, Woodward WE, Gilman RH, Libonati JP. Attenuated Streptomycin-dependent *Salmonella typhi* oral vaccine: potential deleterious effects of lyophilization. *J Infect Dis* 133:424-429, 1976.
19. Levine MM, Gangarosa EJ, Barrow WB, Weiss CF. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent *Shigella sonnei* vaccine in an institution with endemic disease. *Am J Epidemiol* 104:88-92, 1976.
20. Richman DD, Murphy BR, Chanock RM, Gwaltney JM, Douglas RG, Betts RF, Blacklow NR, Rose FB, Parrino TA, Levine MM, Caplan ES. Temperature-sensitive mutants of influenza A Virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-I(E) recombinant temperature-sensitive viruses in adult volunteers. *J Infect Dis* 134:585-594, 1976.
21. Hornick RB, DuPont HL, Levine MM, Gilman RH, Woodward WE, Snyder MJ, Woodward TE. Efficacy of a live oral typhoid vaccine in human volunteers. *Develop Biol Standard* 33:89-92, 1976.
22. Miller RM, Garbus J, Schwartz A, DuPont H, Levine MM, Clyde DF, Hornick RB. A modified leukocyte nitroblue tetrazolium test in acute bacterial infection. *Am J Clin Path* 66:905-910, 1976.
23. Richman D, Murphy B, Rusten H, Blacklow N, Levine M, Caplan E, Chanock RM. Temperature-sensitive mutants of influenza virus, XIV. Evaluation of influenza A/Georgia/101/74-ts-I(E) recombinant viruses in human adults. *J Infect Dis* 136:256-262, 1977.
24. Gilman RH, Hornick RB, Woodward WE, DuPont HL, Snyder MJ, Levine MM, Libonati JP. Immunity in typhoid fever: evaluation of Ty21a - an epimerase-less mutant of *S. typhi* as a live oral vaccine. *J Infect Dis* 136:717-723, 1977.
25. Levine MM, Caplan ES, Waterman D, Cash RA, Hornick RB, Snyder MJ. Diarrhea due to *Escherichia coli* that produce only heat-stable enterotoxin. *Infect Immun* 17:78-82, 1977.
26. Levine MM, Hughes T, Simon P, O'Donnell S, Grauel S, Levine SG. Monovalent inactivated A/New Jersey/8/76 (HswINI) vaccine studies in healthy children age 3-5 years. *J Infect Dis (Suppl)* 136:S571-S574, 1977.
27. Caplan ES, Hughes TP, O'Donnell S, Levine MM, Hornick RB. Evaluation of the reactogenicity and immunogenicity of parenteral monovalent A/Victoria/3/75 (H3N2) influenza vaccine in healthy adults. *J Infect Dis (Suppl)* 136:S484-S490, 1977.
28. Levine MM. Parasitology for the U.S. practitioner. *Medical Digest* 23:11-21, 1977.
29. Levine MM, Woodward WE, Formal SB, Gemski P, Jr., DuPont HL, Hornick RB, Snyder MJ. Studies with a new generation of oral attenuated *Shigella* vaccine: *Escherichia coli* bearing *Shigella* surface antigens. *J Infect Dis* 136:577-582, 1977.

30. Wald ER, Levine MM. *Haemophilus Influenzae* type b pneumonia. Arch Dis Child 53:316-318, 1978.
31. Levine MM, Grados O, Gilman RH, Woodward WE, Solis-Plaza R, Waldman W. Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg 27:795-800, 1978.
32. Murphy BR, Markoff LJ, Hosier NT, Rusten HM, Chanock RM, Kendal AP, Douglas RG, Betts RF, Cate TR Jr, Couch RB, Levine MM, Waterman DH, Holley HP, Jr. Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-l(E) recombinant viruses in volunteers. Infect Immun 20:665-670, 1978.
33. Levine MM, Hughes TP, Young CR, O'Donnell S, Craig JP, Holley P, Bergquist E. Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. Infect Immun 21:158-162, 1978.
34. Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR, Sotman S, Rowe B. *Escherichia coli* strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet I:1119-1122, 1978.
35. Nalin DR, Levine MM, Young CR, Bergquist EJ, MacLaughlin J. Concentrating *Escherichia coli* culture supernates increases detection of heat-stable enterotoxin in the infant mouse assay. J Clin Microbiol 8:700-703, 1978.
36. Nalin DR, Levine MM, Mata L, DeCespedes C, Vargas W, Lizano C, Loria AR, Simhon A. Comparison of sucrose with glucose in oral therapy of infant diarrhoea. Lancet II:277-279, 1978.
37. Nalin CR, Levine MM, Rhead J, Bergquist E, Rennels M, Hughes T, O'Donnell S, Hornick RB. Cannabis, hypochlorhydria, and cholera. Lancet II:859-861, 1978.
38. Nalin DR, Levine RJ, Levine MM, Hoover D, Bergquist E, McLaughlin J, Libonati J, Alam J, Hornick RB. Cholera, non-*Vibrio cholerae*, and stomach acid. Lancet II:856-859, 1978.
39. Nalin DR, Levine MM, Mata L, DeCespedes C, Vargas W, Lizano C, Loria AR, Simhon A, Mohs E. Oral rehydration and maintenance of children with bacterial and rotavirus diarrheas. Bull Wld Hlth Org 57:453-459, 1979.
40. Greenberg HB, Levine MM, Merson MH, Sack RB, Sack DA, Valdesuso JR, Nalin DR, Hoover D, Chanock RM, Kapikian AZ. Solid phase microtiter radioimmunoassay blocking test for detection of antibodies to *Escherichia coli* heat-labile enterotoxin. J Clin Microbiol 9:60-64, 1979.
41. Nalin DR, Levine MM, Hornick RB, Bergquist EJ, Hoover D, Holley HP, Jr., Waterman DH, Van Blerk J, Matheny S, Sotman S, Rennels M. The Problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. Trans Roy Soc Trop Med Hyg 73:10-14, 1979.
42. Levine MM, Nalin DR, Craig JP, Hoover D, Bergquist EJ, Waterman D, Holley HP, Jr., Hornick RB, Pierce NF, Libonati JP. Immunity to cholera in man: relative role of antibacterial versus antitoxic immunity. Trans Roy Soc Trop Med Hyg 73:3-9, 1979.
43. Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB, Young CR. Immunity to enterotoxigenic *Escherichia coli*. Infect Immun 23:729-736, 1979.
44. Murphy BR, Chanock RM, Levine MM, Van Blerk GA, Bergquist EJ, Douglas RG, Betts RF, Couch RB, Cate TR, Jr. Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-lA2 temperature sensitive recombinant virus in seronegative adult volunteers. Infect Immun 23:249-252, 1979.
45. Murphy BR, Holley HP, Jr., Bergquist EJ, Levine MM, Spring SB, Maassab HF, Kendal AP, Chanock RM. Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun 23:253-259, 1979.

46. Levine MM. *Shigella* and *Salmonella* diarrhoeal disease. *Tropical Doctor* 9:4-9, 1979.
47. Levine MM, Barua D, Nalin DR, Rennels MB, Hornick RB, Sotman S, Van Blerk G, Hughes TP, O'Donnell S. Genetic susceptibility to cholera. *Ann Human Biol* 6:369-374, 1979.
48. Douglas RG Jr., Markoff LJ, Murphy BR, Chanock RM, Betts RF, Levine MM, Van Blerk GA, Sotman SB, Nalin DR. Evaluation of live Vic/75-ts-1 (E) influenza virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus. *Infect Immun* 26:274-179, 1979.
49. Gunn RA, Kimball AM, Dutta SP, Matthew PP, Mahmood RA, Pollard RA, Feeley JC, Levine MM, Feldman RA. Bottle feeding as a risk factor for cholera in infants. *Lancet* II:730-732, 1979.
50. Levine MM, Edelman R. Acute diarrheal infections in infants. I. Epidemiology, treatment and immunoprophylaxis. *Hosp Pract* 14:89-100, 1979.
51. Nalin DR, Daya V, Reid A, Levine MM, Cisneros L. Absorption and growth of *V. cholerae* on chitin. *Infect Immun* 25:768-770, 1979.
52. Pizarro D, Posada G, Nalin DR, Mohs E, Levine MM. Evaluation of oral therapy for infant diarrhea in an emergency room setting: utilization of acute episode for instructing mothers in oral therapy method. *Bull Wld Hlth Org* 57:983-986, 1979.
53. Young CR, Levine MM, Craig JP, Robins-Browne R. Microtiter enzyme-linked immunosorbent assay (ELISA) for IgG cholera antitoxin in man. I. Method and correlation with rabbit skin vascular permeability factor technique. *Infect Immun* 27:492-496, 1980.
54. Murphy BR, Rennels MB, Douglas RG, Jr., Betts RF, Couch RB, Cate TR, Jr., Chanock RM, Kendall AP, Maassab HF, Suwanagool S, Sotman SB, Cisneros LA, Anthony WC, Nalin DR, Levine MM. Evaluation of influenza A/Hong Kong/I23/77 (H1N1) ts-IA2 and cold-adapted recombinant viruses in seronegative adult volunteers. *Infect Immun* 29:348-355, 1980.
55. Levine MM, Rennels MB, Cisneros L, Hughes TP, Nalin DR, Young CR. Lack of person-to-person transmission of enterotoxigenic *Escherichia coli* despite intimate contact. *Am J Epidemiol* 111:347-355, 1980.
56. Huang TL, Levine MM, Daoud GS, Nalin DR, Nichols BL. Fecal steroids in diarrhea. III. Experimentally - induced travelers' diarrhea. *Am J Clin Nutr* 33:40-44, 1980.
57. Robins-Browne RM, Young CR, Levine MM, Craig JP. Microtiter enzyme-linked immunosorbent assay (ELISA) for IgG cholera antitoxin in man. II. Sensitivity and specificity. *Infect Immun* 27:497-500, 1980.
58. Edelman R, Levine MM. Acute diarrheal infections in infants. II. Bacterial and viral causes. *Hosp Pract* 14:341-347, 1979
59. Levine MM. Cholera in Louisiana: Old problem, new light. (Editorial). *N Eng J Med* 302:345-347, 1980.
60. Levine MM, Rennels MB, Daya V, Hughes TP. Hemagglutination and colonization factors in enterotoxigenic and enteropathogenic *Escherichia coli* that cause diarrhea. *J Infect Dis* 141:733-737, 1980.
61. Rennels MB, Levine MM, Daya V, Angle P, Young C. Selective vs. non-selective media and direct plating vs. enrichment technique in isolation of *Vibrio cholerae*: recommendations for clinical laboratories. *J Infect Dis* 142:328-331, 1980.
62. Pizarro D, Posada G, Levine MM, Mohs E. Oral rehydration of infants with acute diarrhoeal dehydration: a practical method. *J Trop Med Hyg* 83:241-245, 1980.

63. Levine MM, Hughes TP, Black RE, Clements ML, Matheny S, Siegel A, Cleaves F, Gutierrez C, Foote D, Smith W. Variability of sodium and sucrose levels of simple sugar/salt oral rehydration solutions prepared under optimal and field condition. *J Pediatr* 97:324-327, 1980.
64. Nalin DR, Harland E, Ramlal A, Swaby D, McDonald J, Gangarosa R, Levine M, Akierman A, Antoine M, Mackenzie K, Johnson B. Comparison of low and high sodium and potassium content in oral rehydration solutions. *J Pediatr* 97:848-853, 1980.
65. Murphy BR, Chanock RM, Douglas RG, Betts RF, Waterman DH, Holley HP Jr, Hoover DL, Suwanagool S, Nalin DR, Levine MM. Temperature-sensitive mutants of influenza A virus: evaluation of the A/Alaska/77-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers. *Arch Virol* 65:169-173, 1980.
66. Murphy BR, Markoff LJ, Chanock RM, Spring SB, Maassab HF, Kendal AP, Cox NJ, Levine MM, Douglas RG Jr, Betts RF, Couch RB, Cate TF Jr. Genetic approaches to attenuation of influenza A viruses for man. *Philos Trans R Soc Lond (Biol.)* 228:401-415, 1980.
67. Clements ML, Levine MM, Black RE, Robins-Browne RM, Cisneros LA, Drusano GL, Lanata CF, Saah AJ. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic *Escherichia coli*. *Antimicrob Ag Chemother* 20:104-108, 1981.
68. Murphy BR, Chanock RM, Clements ML, Anthony WC, Saah AJ, Cisneros LA, Rennels MB, Miller EH, Black RE, Levine MM, Maassab HF, Cox NJ, Kendal AP. Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from the A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers. *Infect Immun* 32:693-697, 1980.
69. Robins-Browne RM, Levine MM. The fate of ingested Lactobacilli in the proximal small intestine. *Am J Clin Nutr* 34:514-519, 1981.
70. Robins-Browne R, Levine MM. Effect of chlorpromazine on intestinal secretion mediated by *Escherichia coli* heat-stable enterotoxin and 8-Br-Cyclic GMP in mice. *Gastroenterology* 80:321-326, 1981.
71. Huang C, Levine MM, Woodward WE, Gopalakrishna GS, Nalin DR, Hornick RB, Nichols BL. Biohydrogenation of cholesterol as an index of bacterial 7 - dehydroxylase activity. *Lipids* 16:670-675, 1981.
72. Levine MM, Clements ML, Black RE, Hughes TP, Blum D, Andino R, Corrales G. A practical, reliable method for preparing simple sugar/salt oral rehydration solutions. *J Trop Med Hyg* 84:73-76, 1981.
73. Clements ML, Levine MM, Cleaves F, Hughes TP, Caseres M, Aleman E, Black RE, Rust J. Comparison of simple sugar/salt versus glucose/electrolyte oral rehydration solutions in infant diarrhoea. *J Trop Med Hyg* 84:189-194, 1981.
74. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. The quality and duration of infection-derived immunity to cholera. *J Infect Dis* 143:818-820, 1981.
75. Levine MM, Young CR, Hughes TP, O'Donnell S, Black RE, Clements ML, Robins-Browne T, Lim YL. Duration of serum antitoxin response following *Vibrio cholerae* infection in North Americans: relevance for seroepidemiology. *Am J Epidemiol* 114:348-354, 1981.
76. Mendoza HR, Levine MM, Kapikian AZ, Martinez JD, Dominguez JA, Montero MM. Factores etiológicos de la diarrea aguda del lactante en la Republica Dominicana. *Arch Dom Pediat* 17:3-51, 1981.
77. Levine MM, Kaper JB. The significance of *Vibrio cholerae* in the United States. *Clin Microbiol Newsletter* 3:162-164, 1981.
78. Pizarro D, Posada G, Levine MM, Mohs E. Tratamiento oral de la deshidratación hipernatremica. *Act Med Cost* 24:341-346, 1981.

79. Snyder JD, Allegra DT, Levine MM, Craig JP, Feeley JC, DeWitt WE, Blake PA. Serologic studies of naturally acquired infection with *Vibrio cholerae* O Group 1 in the United States. *J Infect Dis* 143:182-187, 1981.
80. Candy DCA, Leuang TSM, Mak RHK, Harries JT, Marshall WC, Phillips AD, Robins-Browne R, Chadwick MV, Levine MM. A fimbrial antigen mediating adhesion and hemagglutination of *Escherichia coli* from children. *FEMS Microbiol Lett* 15:325-329, 1982.
81. Hobbins TE, Hughes TP, Rennels MB, Murphy BR, Levine MM. Bronchial reactivity in experimental influenza virus infections. *J Infect Dis* 146:468-471, 1982.
82. Levine MM. Oral therapy for diarrhoea: past, present and future. *J Trop Med Hyg* 84:185-187, 1982.
83. Clements ML, Levine MM, Young CR, Black RE, Lim YL, Robins-Browne RM, Craig JP. Magnitude, kinetics and duration of vibriocidal responses in North Americans following ingestion of *Vibrio cholerae*. *J Infect Dis* 145:465-473, 1982.
84. Black RE, Levine MM, Clements ML, Angle P, Robins-Browne R. Proliferation of enteropathogens in oral rehydration solutions prepared with river water from Honduras and Surinam. *J Trop Med Hyg* 84:195-197, 1982.
85. Levine MM. Bacillary dysentery - mechanism and treatment. *Med Clin N Amer* 66:623-638, 1982.
86. Levine MM, Black RE, Clements ML, Cisneros L, Saah A, Nalin DR, Gill MD, Craig JP, Young CR, Ristaino R. Pathogenicity of non-enterotoxigenic *Vibrio cholerae* El Tor isolated from sewage water in Brazil. *J Infect Dis* 145:296-299, 1982.
87. Levine MM, Black RE, Brinton CC Jr, Clements ML, Fusco P, Hughes TP, O'Donnell S, Robins-Browne R, Wood S, Young CR. Reactogenicity, immunogenicity and efficacy studies of *Escherichia coli* type 1 somatic pill parenteral vaccine in man. *Scand J Infect Dis Supplement* 33:83-95, 1982.
88. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally induced enterotoxigenic *Escherichia coli* diarrhea with trimethoprim, trimethoprim/sulfamethoxazole, or placebo. *Rev Infect Dis* 4:550-545, 1982.
89. Huang CTL, Levine MM, Daoud GS, Nalin DR, Nichols BL. Fecal steroids in diarrhea. IV. Cholera. *Lipids* 17:612-616, 1982.
90. Tolpin MD, Clements ML, Levine MM, Black RD, Saah AJ, Anthony WC, Cisneros L, Chanock RM, Murphy BR. Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses. *Infect Immun* 36:645-650, 1982.
91. Black RE, Levine MM, Young CR, Rooney J, Levine S, Clements ML, O'Donnell S, Hughes TP, Chilean Typhoid Committee, Germanier R. Immunogenicity of Ty21a attenuated *Salmonella typhi* given with sodium bicarbonate or in enteric-coated capsules. *Develop Biol Standard* 53:9-14, 1982.
92. Levine MM. Conceptos Tradicionales sobre Diarrea Aguda: Viejos y nuevos agentes y agentes equívocos. *Gen (Revista de la Sociedad Venezolana de Gastroenterología)*. 36:9-11, 1982.
93. Levine MM. Diarreas bacterianas producidas por toxinas. *Gen (Revista de la Sociedad Venezolana de Gastroenterología)*. 36:39-40, 1982.
94. Levine M.M. Empleo de los antibióticos y otras drogas en el tratamiento de la diarrea aguda. *Gen (Revista de la Sociedad Venezolana de Gastroenterología)*. 36:107-108, 1982.
95. Levine MM. Vacunas contra agentes bacterianos. *Gen (Revista de la Sociedad Venezolana de Gastroenterología)*. 36:121-122, 1982.

96. Wyatt RG, Kapikian AZ, Greenberg HA, Kalica AR, Flores J, Hoshino Y, Chanock RM, Levine MM. Development of vaccines against rotavirus disease. *Prog Food Nutr Sci* 7:189-192, 1982.
97. Robins-Browne RM, Levine MM, Rowe B, Gabriel EM. Failure to detect conventional enterotoxin in classical enteropathogenic (serotyped) *Escherichia coli* strains of proven pathogenicity. *Infect Immun* 38:798-801, 1982.
98. Levine MM, Black RE, Lanata C, Chilean Typhoid Committee. A precise estimation of chronic *Salmonella typhi* carriers in Santiago, Chile, an endemic area. *J Infect Dis* 146:724-726, 1982.
99. Kapikian AZ, Wyatt RG, Levine MM, Yolken RH, Van Kirk DH, Dolin R, Greenberg HB, Chanock RM. Oral administration of a human rotavirus to volunteers: induction of illness and correlates of resistance. *J Infect Dis* 147:95-106, 1983.
100. Clements ML, Levine MM, Ristaino P, Daya VE, Hughes TP. Exogenous Lactobacilli fed to man - their fate and ability to prevent diarrheal disease. *Prog Food Nutr Sci* 7:29-37, 1983.
101. Levine MM, Lanata C. Progresos en vacunas contra diarrea bacteriana. *Adelantos Microbiol Enferm Infecc* 2:67-117, 1983.
102. Levine MM, Ristaino P, Sack RB, Kaper JB, Orskov F, Orskov I. Colonization factor antigens I and II and type 1 somatic pili in enterotoxigenic *Escherichia coli*: relation to enterotoxin type. *Infect Immun* 39:889-897, 1983.
103. Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR. Dose response of A/Alaska/6/77 (H3N2) cold-adapted recombinant vaccine virus in adult volunteers - role of local antibody in resistance to infection with vaccine virus. *Infect Immun* 40:1044-1051, 1983.
104. Pizarro D, Posada G, Villavicencio N, Mohs E, Levine MM. Hypernatremic and hyponatremic diarrheal dehydration treated with oral glucose/electrolyte solution (90 mmol/1 sodium). *Am J Dis Child* 137:730-734, 1983.
105. Baldini MM, Kaper JB, Levine MM, Candy DCA, Moon HW. Plasmid mediated adhesion in enteropathogenic *Escherichia coli*. *J Ped Gastroenterol* 2:534-538, 1983.
106. Levine MM. Vaccines to prevent travelers' diarrhea. *Therapeutische Umschau* 40:253-256, 1983.
107. Levine MM. Traveller's diarrhoea: prospects for successful immunoprophylaxis. *Scand J Gastroenterol* vol. 18 (supplement 84):121-134, 1983.
108. Ristaino P, Levine MM, Young CR. An improved GM₁-enzyme-linked immunosorbent assay for the detection of *Escherichia coli* heat-labile enterotoxin. *J Clin Microbiol* 18:808-815, 1983.
109. Levine MM, Kaper JB, Lockman H, Black RE, Clements ML. Recombinant DNA risk assessment studies in man: efficacy of poorly-mobilized plasmids in biologic containment. *J Infect Dis* 148:699-709, 1983.
110. Levine MM, Black RE, Clements ML, Young CR, Lanata C, Sears S, Honda T, Finkelstein R. Texas Star-SR: Attenuated *Vibrio cholerae* oral vaccine candidate. *Develop Biol Standard* 53:59-65, 1983.
111. Moon HW, Whipp SC, Argenzio RA, Levine MM, Gianella RA. Attaching and effacing activities of rabbit and human enteropathogenic *Escherichia coli* in pig and rabbit intestines. *Infect Immun* 41:1340-1351, 1983.
112. Lanata CF, Levine MM, Ristori C, Black RE, Jimenez L, Salcedo M, Garcia J, Sotomayor V. Vi Serology in the detection of chronic *Salmonella typhi* carriers in an endemic area. *Lancet* II:441-443, 1983.
113. Edelman RE, Levine MM. Summary of a workshop on enteropathogenic *Escherichia coli*. *J Infect Dis* 147:1108-1118, 1983.

114. Clements ML, Wisseman CL, Woodward TE Jr, Fiset P, Dumler JS, McNamee W, Black RE, Rooney J, Hughes TP, Levine MM. Reactogenicity, immunogenicity, and efficacy of a chick embryo cell-derived vaccine for Rocky Mountain Spotted Fever. *J Infect Dis* 148:922-930, 1983.
115. Clements ML, Dumler JS, Fiset P, Wisseman CL Jr, Levine MM. Serodiagnosis of Rocky Mountain Spotted Fever: comparison of IgM and IgG enzyme-linked immunosorbent assay and indirect fluorescent antibody test. *J Infect Dis* 148:876-880, 1983.
116. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. *Microbiol Rev* 47:510-550, 1983.
117. Taylor DN, Harris JR, Barrett TJ, Hargrett NT, Valdivieso C, Palomino C, Levine MM, Blake PA. Detection of urinary Vi antigen as a diagnostic test for typhoid fever. *J Clin Microbiol* 18:872-876, 1983.
118. Levine MM, Pizarro D. Advances in therapy of diarrheal dehydration. *Adv Pediatr* 31: , 1993.
119. Kapikian AZ, Wyatt RG, Levine MM, Black RE, Greenberg HB, Flores J, Kalica AR, Hoshino Y, Chanock R.M. Studies in volunteers in human rotaviruses. *Develop Biol Standard* 53:209-218, 1983.
120. Svennerholm A-M, Holmgren J, Black R, Levine M, Merson M. Serologic differentiation between antitoxin responses to infection with *Vibrio cholerae* and enterotoxin-producing *Escherichia coli*. *J Infect Dis* 147:514-522, 1983.
121. Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant nontoxigenic *Vibrio cholerae* strains as attenuated cholera vaccine candidates. *Nature* 308:655-658, 1984.
122. Levine MM, Black RE, Clements ML, Kaper JB. Present status of cholera vaccines. *Biochem Soc Trans* 12:200-202, 1984.
123. Levine MM, Black RE, Clements ML, Lanata C, Sears S, Honda T, Young CR, Finkelstein RA. Evaluation in man of attenuated *Vibrio cholerae* El Tor Ogawa strain Texas Star-SR as a live oral vaccine. *Infect Immun* 43:515-522, 1984.
124. Levine MM, Edelman R. Enteropathogenic *Escherichia coli* of classical serotypes associated with infant diarrhea- epidemiology and pathogenesis. *Epidemiol Rev* 6:31-51, 1984.
125. Pizarro D, Posada G, Levine MM. Hypernatremic diarrheal dehydration treated with "slow" (12 hour) oral rehydration therapy: a preliminary report. *J Pediat* 104:316-319, 1984.
126. Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant live oral cholera vaccine. *Biotechnology* 2:345-349, 1984.
127. Ferreccio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Prentzel I, Black RE, Mancuso T, Bulas D. Benign bacteremia due to *Salmonella typhi* and *paratyphi* in children less than two years of age. *J Pediat* 104:899-901, 1984.
128. Sears SD, Ferreccio C, Levine MM, Cordano AM, Monreal J, Black RE, D'Ottone K, Rowe B, Chilean Typhoid Committee. Isolation of *Salmonella typhi* from irrigation water in Santiago, Chile using Moore swabs. *J Infect Dis* 149:640-642, 1984.
129. Booth IW, Levine MM, Harries JT. Oral rehydration therapy in acute diarrhoea in childhood. *J Pediat Gastro Nutr* 3:491-499, 1984.
130. Levine MM, Ristaino P, Marley G, Smyth C, Knutton S, Boedeker E, Black R, Young C, Clements ML, Cheney C, Patnaik R. Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic *Escherichia coli*: morphology, purification, and immune responses in humans. *Infect Immun* 44:409-420, 1984.

131. Sears SD, Richardson K, Young C, Parker CD, Levine MM. Evaluation of the human response to outer membrane proteins of *Vibrio cholerae*. *Infect Immun* 4:439-444, 1984.
132. O'Brien AD, Chen ME, Holmes RK, Kaper J, Levine MM. Environmental and human isolates of *Vibrio cholerae* and *Vibrio parahaemolyticus* produce a *Shigella dysenteriae* 1 (Shiga)-like cytotoxin. *Lancet* I:77-78, 1984.
133. Morris JG Jr, Ferreccio C, Garcia J, Lobos H, Black RE, Rodriguez H, Levine MM. Typhoid fever in Santiago, Chile: a study of household contacts of pediatric patients. *Am J Trop Med Hyg* 33:1198-1202, 1984.
134. Svennerholm AM, Levine MM, Holmgren J. Weak serum and intestinal antibody responses to *Vibrio cholerae soluble* hemagglutinin in cholera patients. *Infect Immun* 45:792-794, 1984.
135. Nataro JP, Scaletsky ICA, Kaper JB, Levine MM, Trabulsi LR. Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic *Escherichia coli*. *Infect Immun* 48:378-383, 1985.
136. Murray BE, Levine MM, Cordano AM, D'Ottone K, Jayanetra P, Kopecko D, Pan-Urai R, Prenzel I. Possible reasons for the paucity of resistance plasmids in *Salmonella typhi*. *J Infect Dis* 151:551-555, 1985.
137. Levine MM, Young CR, Black RE, Takeda Y, Finkelstein RA. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of *Escherichia coli* and to cholera toxin: application in serodiagnosis and seroepidemiology. *J Clin Microbiol* 21:174-179, 1985.
138. Black RE, Cisneros L, Levine MM, Banfi A, Lobos H, Rodriguez H. A case-control study to identify risk factors for endemic typhoid fever in Santiago, Chile. *Bull Wld Hlth Org* 63:899-904, 1985.
139. Nataro JP, Baldini MM, Kaper JB, Black RE, Levine MM. Detection of an adherence factor of enteropathogenic *Escherichia coli* with a DNA probe. *J Infect Dis* 152:560-565, 1985.
140. Levine MM, Nataro JP, Baldini MM, Kaper JB, Black RE, Clements ML, O'Brien AD. The diarrheal response of humans to some classical serotype enteropathogenic *Escherichia coli* is dependent on a plasmid encoding an enteroadhesiveness factor. *J Infect Dis* 152:550-559, 1985.
141. Lanata CF, Kaper JB, Baldini MM, Black RE, Levine MM. Sensitivity and specificity of DNA probes for the detection of *E. coli* enterotoxins using the stool blot technique. *J Infect Dis* 152:1087-1090, 1985.
142. Levine MM. *Escherichia coli* infections. *N Eng J Med* 313:445-447, 1985.
143. Levine MM, Losonsky G, Herrington D, Kaper JB, Tacket C, Rennels MB, Morris JG. Pediatric diarrhea: the challenge of prevention. *J Pediat Infect Dis* 5(supplement):S29-S43, 1986.
144. Losonsky GA, Rennels MB, Kapikian AZ, Midthun K, Ferra PJ, Fortier DN, Hoffman KM, Baig A, Levine MM. Safety, infectivity, transmissibility and immunogenicity of Rhesus rotavirus vaccine (MMU 18006) in infants. *J Pediat Infect Dis* 5:25-29, 1986.
145. Harris JR, Holmbert SC, Parker RDR, Kay DE, Barrett TJ, Young CR, Levine MM, Blake PA. Impact of epidemic cholera in a previously uninfected island population: evaluation of a new seroepidemiologic method. *Am J Epidemiol* 123:424-30, 1986.
146. Levine MM. Antimicrobial therapy for infectious diarrhea. *Rev Infect Dis* 8(supplement):S207-S216, 1986.
147. Avendano A, Herrera P, Horwitz I, Duarte E, Prenzel I, Lanata C, Levine MM. Duodenal string cultures: practicality and sensitivity for diagnosing enteric fever in children. *J Infect Dis* 159:356-362, 1986.
148. Edelman RE, Levine MM. Summary of an international workshop on typhoid fever. *Rev Infect Dis* 8:329-349, 1986.

149. Rennels MB, Levine MM. Classical bacterial diarrhea: perspectives and update -- *Salmonella*, *Shigella*, *Escherichia coli*, *Aeromonas* and *Plesiomonas*. J Pediat Infect Dis 5:(supplement):S91-S100, 1986.
150. Maher K, Morris JG Jr, Gotuzzo E, Benavente L, Black RE, Ward LR, Levine MM. Molecular techniques in the study of *Salmonella typhi* in epidemiologic studies in endemic areas: comparison with Vi phage typing. Am J Trop Med Hyg 35:831-835, 1986.
151. Tacket CO, Ferreccio C, Robbins JB, Tsai-C-M, Schulz D, Cadoz M, Goudeau A, Levine MM. Safety and immunogenicity of two *Salmonella typhi* Vi capsular polysaccharide vaccines. J Infect Dis 154:342-345, 1986.
152. Thompson MR, Jordan RL, Luttrell MA, Brandwein H, Kaper JB, Levine MM, Gianella RA. A blinded two laboratory comparative analysis of *E. coli* STa production using monoclonal antibody ELISA, radioimmunoassay, suckling mouse assay and gene probe analysis. J Clin Microbiol 24:753-758, 1986.
153. Rennels MB, Losonsky GA, Staciak JY, Hughes TP, Levine MM. A preliminary evaluation of the efficacy of Rhesus rotavirus vaccine strain MMU 18006 in young children. J Pediat Infect Dis 5:587-5588, 1986.
154. Sears SD, Ferreccio C, Levine MM. Sensitivity of Moore Sewer swabs for isolating *Salmonella typhi*. Appl Environ Microbiol 51:425-426, 1986.
155. Levine MM, Ferreccio C, Black RE, Chilean Typhoid Committee, Germanier R. New Vaccines against typhoid fever. World Pediatrics and Child Care 3:15-126, 1987.
156. Rennels MB, Losonsky GA, Shindlecker C, Hughes TP, Kapikian AZ, Levine MM, Clinical Study Group. Immunogenicity and reactogenicity of lowered doses of Rhesus rotavirus vaccine strain MMU 18006 in young children. J Pediat Infect Dis 6:260-264, 1987.
157. Pizarro DT, Posada GS, Levine MM, Nalin DR, Mohs EV. Comparison of efficacy of oral rehydration fluids administered at 37°C or 23°C. J Trop Pediat 33:48-51, 1987.
158. Karch H, Heeseman J, Laufs R, O'Brien AD, Tacket CO, Levine MM. A plasmid of enterohemorrhagic *Escherichia coli* 0157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun 55:455-461, 1987.
159. Herrington DA, Tzipori S, Robins-Browne R, Tall BD, Levine MM. *Plesiomonas shigelloides* - In vitro and In vivo studies of pathogenicity. Infect Immun 55:979-985, 1987.
160. Black RE, Levine MM, Clements ML, Losonsky G, Herrington D, Berman S, Formal SB. Prevention of shigellosis by a *Salmonella typhi*-*shigella sonnei* bivalent vaccine. J Infect Dis 155:1260-1265, 1987.
161. Levine MM. *Escherichia coli* that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic and enteroadherent. J Infect Dis 155:377-389, 1987.
162. Levine MM, Herrington D, Murphy JR, Morris JG, Losonsky G, Tall B, Lindberg A, Svenson S, Baqar S, Edwards MF, Stocker B. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of *Salmonella typhi*, 541Ty and 543Ty, as live oral vaccines in man. J Clin Invest 79:888-902, 1987.
163. Levine MM, Ferreccio C, Black RE, Chilean Typhoid Committee, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet I:1049-1052, 1987.
164. Levine MM, Xu J-G, Kaper JB, Lior H, Prado V, Tall B, Nataro J, Karch H, Wachsmuth IK. A DNA probe to identify enterohemorrhagic *Escherichia coli* 0157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis 156:175-182, 1987.
165. Black RE, Levine MM, Clements ML, Hughes T, O'Donnell S. Association between O blood group and occurrence and severity of diarrhoea due to *Escherichia coli*. Trans Royal Soc Trop Med Hyg 81:120-123, 1987.

166. Black RE, Levine MM, Clements ML, Young CR, Svennerholm A, Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera Toxin. *Infect Immun* 55:1116-1120, 1987.
167. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillesen D, Nardin EH, Nussenzweig RS, Nussenzweig V, Hollingdale MR, and Levine MM. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against *Plasmodium falciparum* sporozoites. *Nature* 328:257-259, 1987.
168. Nash TE, Herrington DA, Losonsky GA, Levine MM. Experimental human infections with *Giardia lamblia*. *J Infect Dis* 156:974-984, 1987.
169. Nataro JP, Kaper JB, Robins-Browne R, Prado V, Vial PA, Levine MM. Patterns of adherence of diarrheagenic *Escherichia coli* to HEp-2 cells. *Pediatr Infect Dis J* 6:829-831, 1987.
170. Losonsky GA, Ferreccio C, Kotloff KL, Kaintuck S, Robbins JB, Levine MM. Development and evaluation of an enzyme-linked immunosorbent assay for Vi antibodies in the detection of chronic *Salmonella typhi* carriers. *J Clin Micro* 25:2266-2269, 1987.
171. Shaw RD, Fong KJ, Losonsky GA, Levine MM, Maldonado Y, Yolken R, Flores J, Kapikian AZ, Vo PT, Greenberg HB. Epitope-specific immune responses to rotavirus. *Gastroenterology* 93:941-950, 1987.
172. Gotuzzo E, Morris JGJr, Benavente L, Wood PK, Levine O, Black RE, Levine MM. Association between specific plasmids and relapse in typhoid fever. *J Clin Microb* 25:1779-1781, 1987.
173. Tzipori S, Karch H, Wachsmuth KI, Robins-Browne RM, O'Brien AD, Lior H, Cohen ML, Smithers J, Levine MM. Role of a 60-megadalton plasmid and Shiga-Like toxins in the pathogenesis of infection caused by enterohemorrhagic *Escherichia coli* O157:H7 in gnotobiotic piglets. *Infect Immun* 55:3117-3125, 1987.
174. Murphy JR, Baqar S, Munoz C, Schlesinger L, Ferreccio C, Lindberg AA, Svenson S, Losonsky G, Koster F, Levine MM. Characteristics of humoral and cellular immunity to *Salmonella typhi* in residents of typhoid-endemic and typhoid-free regions. *J Infect Dis* 156:1005-1009, 1987.
175. Murphy JR, Baqar S, Losonsky GA, Tacket CO, Lindberg AA, Levine MM. Human immunogenicity of orally administered typhoid vaccines, Ty21a and 541Ty-543-Ty. *Microecology and Therapy* 17:107-116, 1987.
176. Nash TE, Herrington DA, Levine MM. Usefulness of an enzyme-linked immunosorbent assay for detection of *Giardia* antigen in feces. *J Clin Microbiol* 25:1169-1171, 1987.
177. Tacket CO, Maneval DR, Levine MM. Purification, morphology and genetics of a new fimbrial putative colonization factor of enterotoxigenic *Escherichia coli* O159:H4. *Infect Immun* 55:1063-1069, 1987.
178. Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hilpert H, Levine MM. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic *Escherichia coli*. *N Eng J Med* 318:1240-1243, 1988.
179. Levine MM, Kaper KB, Herrington DA, Losonsky GA, Morris JG, Clements ML, Black RE, Tall BD, Hall R. Volunteer studies of deletion mutants of *Vibrio cholerae* 01 prepared by recombinant techniques. *Infect Immun* 56:161-167, 1988.
180. Kaper JB, Levine MM. Progress towards a vaccine against enterotoxigenic *Escherichia coli*. *Vaccines* 6:197-199, 1988.
181. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental *Campylobacter jejuni* infection in humans. *J Infect Dis* 157:472-479, 1988.
182. Hall RE, Vial PA, Kaper JB, Mekalanos JJ, Levine MM. Morphological studies on fimbriae expressed by *Vibrio cholerae* 01. *Microb Pathogen* 4:257-265, 1988.

183. Levine MM, Prado V, Robins-Browne R, Lior H, Kaper JB, Moseley SL, Gicquelais K, Nataro JP, Vial P, Tall B. DNA probes and HEp-2 cell adherence assay to detect diarrheagenic *Escherichia coli*. J Infect Dis 158:224-228, 1988.
184. Vial P, Robins-Browne R, Lior H, Prado V, Nataro J, Kaper J, Elsayed A, Maneval D, Levine MM. Characterization of enteroadherent-aggregative *Escherichia coli*: a newly-defined agent of diarrheal disease. J Infect Dis 158:70-79, 1988.
185. Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, do Rosario V, Hollindale MR. A model for *Plasmodium falciparum* sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Trop Geog Med 40:124-127, 1988.
186. Herrington DA, Hall RH, Losonsky GA, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the *toxR* regulon are essential for *Vibrio cholerae* pathogenesis in humans. J Exp Med 168: 1487-1492, 1988.
187. Levine MM, Herrington DA, Clyde D, Murphy J, Davis J, Nussenzweig R, Nardin E, Felix A, Heimer E, Gillesen D, Baqar S, Hollingdale M, Nussenzweig V. Malaria vaccines: experience with sporozoite vaccines against falciparum malaria. SE Asian J Trop Med Publ Hlth 19:360-374, 1988.
188. Levine MM, Kaper JB, Herrington DA, Losonsky GA, Tacket C, Tall B. The current status of cholera vaccine development and experience with cholera vaccine trials in volunteers. SE Asian J Trop Med Pub Hlth 19:401-415, 1988.
189. Levine MM, Tacket CO, Herrington DA, Losonsky GA, Murphy J, Ferreccio C. The current status of typhoid vaccine development and clinical trials with typhoid vaccines. SE Asian J Trop Med Publ Hlth 19:459-469, 1988.
190. Levine MM, Kaper JB, Herrington DA, Ketley J, Losonsky GA, Tacket CO, Tall, Cryz S. Safety, immunogenicity and efficacy in man of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet II:467-470, 1988.
191. Levine MM, Vial PA. *Escherichia coli* that cause diarrhea. Indian J Pediatr 55:183-190, 1988.
192. Losonsky GA, Rennels MB, Lim Y, Krall G, Kapikian AZ, Levine MM. Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006. Pediatr Infect Dis J 7:388-393, 1988.
193. Herrington D, Rennels MB, Levine MM. Vacunas y otras medidas de prevención de gastroenteritis viral y bacteriana. Boletín Escuela de Medicina, P Universidad Católica de Chile 18:45-50, 1988.
194. Finch MJ, Morris JG Jr, Kaviti J, Kagwanja W, Levine MM. Molecular epidemiology of antimicrobial-resistant cholera in Kenya and East Africa. Am J Trop Med Hyg 39:484-490, 1988.
195. Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine 6:307-308, 1988.
196. Cryz SC, Furer E, Levine MM. Zur Wirkamset des oralen, attenuierten Lebendimpfstoffes *Salmonella typhi* Ty21a in kontrollierten Feldversuchen. Schweiz Med Wschr 118:467-470.
197. Ferreccio C, Morris JG Jr, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, Levine MM. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J Infect Dis 157:1235-1239, 1989.
198. DiJohn D, Torres JR, Murillo J, Herrington DA, Wasserman SS, Cortesia MJ, Losonsky GA, Sturcker D, Levine MM. Effect of priming with carrier on response to conjugate vaccine. Lancet: 1415-1418, 1989.
199. Kotloff KL, Wasserman SS, Steciak JY, Tall BD, Losonsky GA, Nair P, Morris JG, Levine MM. Acute diarrhea in Baltimore children attending an outpatient clinic. Pediatr Infect Dis J 7:753-759, 1989.

200. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. *J Infect Dis* 159:1126-1128, 1989.
201. Ferreccio C, Levine MM, Rodriguez H, Contreras R, Chilean Typhoid Committee. Comparative efficacy of two, three, or four doses of Ty21A live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. *J Infect Dis* 159:766-769, 1989.
202. Murphy JR, Wasserman SS, Baqar S, Schlesinger L, Ferreccio C, Lindberg AA, Levine MM. Immunity to *Salmonella typhi*: considerations relevant to measurement of cellular immunity in typhoid-endemic regions. *Clin Exp Immunol* 75:228-233, 1989.
203. Bhan MK, Raj P, Levine MM, Kaper JB, Bhandari N, Srivastava R, Kumar R, Sazawal S. Enteraggregative *Escherichia coli* associated with persistent diarrhea in a cohort of rural children in India. *J Infect Dis* 159:1061-1064, 1989.
204. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. *Pediatr Infect Dis J* 8:374-381, 1989.
205. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. *Rev Infect Dis* 2 (supplement 3):S552-S567, 1989.
206. Kotloff KL, Losonsky GA, Morris JG, Wasserman SS, Singh-Naz N, Levine MM. Enteric adenovirus infection and childhood diarrhea: an epidemiologic study in three clinical settings. *Pediatrics* 84:219-225, 1989.
207. Richardson K, Kaper JB, Levine MM. Human immune response to *Vibrio cholerae* whole cells and isolated outer membrane antigens. *Infect Immun* 57:495-501, 1989.
208. Sharma DP, Thomas C, Hall RH, Levine MM, Attridge SR. Significance of toxin-coregulated pili as protective antigens of *Vibrio cholerae* in the infant mouse model. *Vaccine* 7:451-456, 1989.
209. Davis JR, Murphy JR, Baqar S, Clyde DF, Herrington DA, Levine MM. Estimate of anti-*Plasmodium falciparum* sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)₃. *Trans Royal Soc Trop Med and Hygiene* 83:748-750, 1989.
210. Bhan MK, Bhandari N, Sazawal S, Clemens J, Raj P, Levine MM, Kaper JB. Descriptive epidemiology of persistent diarrhoea among young children in rural northern India. *Bull Wild Hlth Org* 67:281-288, 1989.
211. Hall RH, Maneval DR, Collins JH, Theibert JL, Levine MM. Purification and analysis of colonization factor antigen I, coli surface antigen 1, and coli surface antigen 3 fimbriae from enterotoxigenic *Escherichia coli*. *J Bacteriol* 171:6372-6374, 1989.
212. Levine MM, Hone D. Prospects for oral enteric vaccines. *Microecology and Therapy*. 18:85-94, 1989.
213. Nardin E, Herrington D, Davis JR, Levine M, Stuber D, Takacs B, Caspers P, Barr P, Altszuler R, Clavijo P, Nussenzweig RS. A conserved epitope is recognized by CD4⁺ clones from a malaria immunized volunteer. *Science* 246:1603-1606, 1989.
214. Migasena S, Pitisuttitham P, Prayurahong B, Suntharasami P, Supanaranond W, Desakorn V, Vongsthongsri U, Tall B, Ketley J, Losonsky G, Cryz S, Kaper JB, Levine MM. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. *Infect Immun* 57:3261-3264, 1989.
215. Levine MM. Vaccines against enteric infections. *Lancet* 335:958-961, 1990.
216. Tacket CO, Forrest B, Morono R, Attridge SR, LaBrooy J, Tall BD, Reymann M, Rowley D, Levine MM. Safety, Immunogenicity, and efficacy against cholera challenge in man of a typhoid-cholera hybrid vaccine derived from *S. typhi* Ty21a. *Infect Immun* 58:1620-1627, 1990.

217. Baudry B, Savarino SJ, Vial PA, Kaper JB, Levine MM. A sensitive and specific DNA probe to identify enteroaggregative *Escherichia coli*, a recently-discovered diarrheal pathogen. *J Infect Dis* 161:1249-1251, 1990.
218. Tacket CO, Moseley SL, Kay BA, Losonsky GA, Levine MM. Challenge studies in volunteers using *Escherichia coli* strains with diffuse adherence to HEP-2 cells. *J Infect Dis* 162:550-552, 1990.
219. Van de Verg L, Herrington DA, Murphy JR, Wasserman SS, Formal SB, Levine MM. Specific IgA secreting cells in peripheral blood following oral immunization with bivalent *Salmonella typhi/Shigella sonnei* vaccine or infection with pathogenic *S. sonnei* in humans. *Infect Immun* 58:2002-2004, 1990.
220. Levine MM, Hone D, Heppner DG, Noriega F, Sriwathana B. Attenuated *Salmonella* as carriers for the expression of foreign antigens. *Microecology and Therapy* 19:23-32, 1990.
221. Rennels MB, Losonsky GA, Young AE, Levine MM. An efficacy trial of the rhesus rotavirus vaccine in Maryland. *Am J Dis Child* 144:601-604, 1990.
222. Herrington DA, Van De Verg L, Formal SB, Hale TL, Tall BD, Cryz SJ, Tramont EC, Levine MM. Studies in volunteers to evaluate candidate *Shigella* vaccines: further experience with a bivalent *Salmonella typhi-Shigella sonnei* vaccine and protection conferred by previous *Shigella sonnei* disease. *Vaccine* 8:353-357, 1990.
223. Cryz SJ, Levine MM, Kaper JB. Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in adult Swiss. *Vaccine* 8:577-580, 1990.
224. Ferreccio C, Levine MM, Solari V, Misraji A, Astroza EL, Berrios G, Pefaur C. Deteccion de portadores cronicos de *S. typhi*: metodo practico aplicado a manipuladores de alimentos del centro de Santiago. *Rev Med Chile* 118:33-37, 1990.
225. Gicquelais KG, Baldini MM, Martinez J, Maggi L, Martin WC, Prado V, Kaper JB, Levine MM. Practical and economical method for using biotinylated DNA probes with bacterial colony blots to identify diarrhea-causing *Escherichia coli*. *J Clin Micro* 28:2485-2490, 1990.
226. Fasano A, Kay BA, Russell RG, Maneval DR, Levine MM. Enterotoxin and cytotoxin production by Enteroinvasive *Escherichia coli*. *Infect Immun* 58:3717-3723, 1990.
227. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in a randomized controlled field trial. *Lancet* 336:891-894, 1990.
228. Levine MM, Edelman R. Future vaccines against enteric pathogens. *Infect Disease Clin N Amer* 4:105-121, 1990.
229. Servos S, Chatfield S, Hone D, Levine MM, Dimitriadis G, Pickard D, Dougan G, Fairweather N, Charles I. Molecular cloning and characterization of the *aro D* gene encoding 3-dehydroquinate from *Salmonella typhi*. *J Gen Micro* 137:147-152, 1990.
230. Levine MM, Hone D, Tacket C, Ferreccio C, Cryz S. Clinical and field trials with attenuated *Salmonella typhi* as live oral vaccines and as "carrier vaccines". *Res Microbiol* 141:807-816, 1990.
231. Vial PA, Mathewson JJ, DuPont HL, Guers L, Levine MM. Comparison of two assay methods for patterns of adherence to HEP-2 cells of *Escherichia coli* from patients with diarrhea. *J Clin Microbiol* 28:882-885, 1990.
232. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, and the Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a *Salmonella typhi* vaccine in enteric-coated capsules in a controlled field trial. *Vaccine* 8:81-84, 1990.
233. Ferreccio C, Ortiz E, Astroza L, Rivera C, Clemens J, Levine MM. A population-based retrospective assessment of the disease burden resulting from invasive *Haemophilus influenzae* in infants and young children Santiago, Chile. *Pediatr Infect Dis J* 9:488-494, 1990.

234. Ketley J, Kaper JB, Herrington DA, Losonsky G, Levine MM. Diminished immunogenicity of a recombination-deficient derivative of *Vibrio cholerae* vaccine strain CVD 103. *Infect Immun* 58:1481-1484, 1990.
235. Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, Bank RS, Nardin E, DiJohn D, Nussenzweig RS, Nussenzweig V, Torres JR, Murillo J, Cortesia M, Sturchler D, Hollingdale MR, Levine MM. Human studies with a synthetic peptide sporozoite vaccine (NANP)³-TT and immunization with irradiated sporozoites. *Bull Wld Hlth Org* 68 (supplement):33-37, 1990.
236. Nardin EH, Nussenzweig RS, Altszuler R, Herrington D, Levine MM, Murphy J, Davis JR, Bathurst I, Barr P, Romero P, Zavala F. Cellular and humoral immune responses to a recombinant *P. falciparum* CS protein in sporozoite-immunized rodents and human volunteers. *Bull Wld Hlth Org* 68 (supplement):85-87, 1990.
237. Kaper JB, Levine MM. Recombinant attenuated *Vibrio cholerae* strains used as live oral vaccines. *Res Microbiol* 141:901-906, 1990.
238. Savarino SJ, Fasano A, Robertson DC, Levine MM. Enteroaggregative *Escherichia coli* elaborate a heat-stable enterotoxin demonstrable in an in vitro rabbit intestinal model. *J Clin Invest* 87:1450-1455, 1991.
239. Edelman R, Levine MM. Enteric Vaccines. *Maryland Med J* 40:199-203, 1991.
240. Levine MM. Vaccines and milk immunoglobulin concentrates for prevention of infectious diarrhea. *J Pediatr* 118 supplement:S129-S136, 1991.
241. Tacket CO, Losonsky G, Taylor DN, Baron L, Kopecko D, Cryz S, Levine MM. Lack of immune response to the Vi component of a Vi-positive variant of the *Salmonella typhi* live oral vaccine strain Ty21a in volunteer studies. *J Infect Dis* 163:901-904, 1991.
242. Cohen D, Green M, Block C, Slepon R, Ambar R, Wasserman S, Levine MM. Reduction of transmission of shigellosis by control of houseflies (*Musca domestica*). *Lancet* 337:993-997, 1991.
243. Levine O, Levine MM. Are houseflies (*Musca domestica*) mechanical vectors for transmitting *Shigella* infection? *Rev Infect Dis.* 13:688-696, 1991.
244. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically-defined double *aro* mutants of *Salmonella typhi*. *Vaccine* 9:810-816, 1991.
245. Ferreccio C, Prado V, Ojeda A, Cayazzo M, Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrhea and endemic *Shigella* infections in a poor periurban setting in Santiago, Chile. *Am J Epidemiol.* 134:614-627, 1991.
246. Black RE, Levine MM. Intestinal protein loss in shigellosis. *Nutr Res* 11:1215-1220, 1991.
247. Hall R, Losonsky G, Silveira APD, Taylor RK, Mekalanos JJ, Levine MM. Toxin coregulated pili, an essential colonization factor of *Vibrio cholerae* O1, are not immunogenic in humans. *Infect Immun.* 59:2508-2512, 1991.
248. Lagos R, Avendano A, Horwitz I, Musser JM, Hoiseth SK, Maneval DM Jr, Jones J, Levine MM, Dattas JP, Prenzel I, Enriquez N, Topfelberg S, Oliván F, Morris JG Jr. Molecular epidemiology of *Haemophilus influenzae* within families in Santiago, Chile. *J Infect Dis* 164:1149-1153, 1991.
249. Morris JG Jr, Prado V, Ferreccio C, Robins-Browne RM, Bordun A-M, Cayazzo M, Kay BA, Levine MM. *Yersinia enterocolitica* isolated from two cohorts of young children in Santiago, Chile: incidence and lack of correlation between illness and proposed virulence factors. *J Clin Microbiol* 29:2784-2788, 1991.
250. Herrington DA, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Szein M, Levine M, Nussenzweig R, Clyde D, Edelman R. Successful immunization of humans with irradiated sporozoites: humoral and cellular responses of the protected individuals. *Am J Trop Med Hyg* 45:539-547, 1991.

251. Levine MM. South America: The return of cholera. *Lancet* 338:45-46, 1991.
252. Clemens JD, Ferreccio C, Levine MM, Horwitz I, Rao M, Edwards K, Fritzell B. Impact of *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. *J Am Med Ass* 267:673-678, 1992.
253. Ferreccio C, Clemens JD, Avendano A, Horwitz I, Flores C, Avila L, Cayazzo M, Fritzell B, Cadoz M, Levine MM. The clinical and immunologic response of Chilean infants to *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with DTP at two, four and six months of age. *Pediatr Infect Dis J*. 10:764-771, 1992.
254. Davis JR, Cortese JF, Herrington DA, Murphy JR, Clyde DF, Thomas AW, Baqar S, Cochran MA, Thanassi J, Levine MM. *Plasmodium falciparum*: in vitro characterization and human infectivity of a cloned line. *Experiment Parasitol* 74:159-168, 1992.
255. Tacket CO, Hone DM, Curtiss R III, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, Levine MM. Comparison of the safety and immunogenicity of Δ aroC Δ aroD and Δ cya Δ crp *Salmonella typhi* strains in adult volunteers. *Infect Immun* 60:536-541, 1992.
256. Tacket CO, Hone DM, Losonsky G, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 *Salmonella typhi* vaccine strain. *Vaccine* 10:443-446, 1992.
257. Kotloff K, Herrington D, Hale TL, Newland JW, Van de Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM. Safety, immunogenicity, and efficacy in monkeys and humans of invasive *Escherichia coli* K-12 hybrid vaccine candidates expressing *Shigella flexneri* 2a somatic antigen. *Infect Immun* 60:2218-2224, 1992.
258. Van de Verg L, Herrington D, Boslego J, Lindberg AA, Levine MM. Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of *Shigella* in Chilean and North American populations. *J Infect Dis* 166:158-161, 1992.
259. Su-Arehawaratana PS, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttitham P, Lim Y-L, Losonsky G, Kaper JB, Wasserman SS, Cryz S, Echeverria P, Levine MM. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. *J Infect Dis* 165:1042-1048, 1992.
260. Nataro JP, Deng Y, Maneval DR, German KL, Martin WC, Levine MM. Aggregative adherence fimbriae I of enteroaggregative *Escherichia coli* mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. *Infect Immun* 60:2297-2304, 1992.
261. Levine MM, McEwen J, Losonsky G, Reymann M, Harari L, Brown JE, Taylor DN, Donohoue-Rolfe A, Cohen D, Bennish, Lim Y-L, Arnon R. Antibodies to Shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shiga dysentery. *J Clin Microbiol* 30:1636-1641, 1992.
262. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM. Evaluation in volunteers of a candidate live oral attenuated *Salmonella typhi* vaccine. *J Clin Invest* 90:412-420, 1992.
263. Kotloff KL, Hermann JE, Blacklow NR, Hudson RW, Morris JG Jr, Levine MM. Medical importance of astrovirus as a cause of diarrhea in Baltimore children. *Pediatr Infect Dis J* 11:587-589, 1992.
264. Echeverria P, Serichantalerg O, Changchawalit S, Baudry B, Levine MM, Orskov F, Orskov I. Tissue culture adherent *Escherichia coli* in infantile diarrhea. *J Infect Dis* 165:141-143.
265. Harpaz R, Edelman R, Wasserman SS, Levine MM, Davis JR, Sztein MB. Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course following challenge. *J Clin Invest* 90:515-523, 1992.

266. Kotloff KL, Wasserman SS, O'Donnell SA, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North America of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind cross-over trial. *Infect Immun* 60:4430-4432, 1992.
267. Tacket CO, Losonsky GA, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. *J Infect Dis* 166:837-841, 1992.
268. Franco A, Gonzalez C, Levine MM, Lagos R, Hall RH, Hoffman SL, Moechtar MA, Gotuzzo E, Levine MM, Hone DM, Morris JG Jr. Further evaluation of the clonal nature of molecular and clinical characteristics of strains from Indonesia and Peru. *J Clin Microbiol* 30:2187-2190, 1992.
269. Cordovez A, Prado V, Maggi L, Cordero J, Martinez J, Misraji A, Rios R, Soza G, Ojeda A, Levine MM. Enterohemorrhagic *Escherichia coli* associated with hemolytic-uremic syndrome in Chilean children. *J Clin Microbiol* 30:2153-2157, 1992.
270. Tacket CO, Losonsky G, Lubeck MD, Davis AR, Mizutani S, Horwith G, Hung P, Edelman R, Levine MM. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. *Vaccine* 10:673-676, 1992.
271. Finch MJ, Franco A, Gotuzzo E, Carrillo C, Benavente L, Wasserman SS, Levine MM, Morris JG. Plasmids in *Salmonella typhi* in Lima Peru, 1987-1988: epidemiology and lack of association with severity of illness or clinical complications. *Am J Trop Med Hyg* 47:390-396, 1992.
272. Cryz SJ Jr., Levine MM, Losonsky GA, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of *Vibrio cholerae* CVD 103-HgR live oral cholera vaccine in Swiss adults. *Infect Immun* 60:3916-3917, 1993.
273. Olanratmanee T, Levine MM, Losonsky GA, Thisyakorn U, Cryz SJ Jr. Safety and immunogenicity of *Salmonella typhi* Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children. *J Infect Dis* 166:451-452, 1992.
274. Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky GA, Totosudirjo H, Rifai AR, Clemens J, Lim YL, Burr D, Wasserman SS, Kaper J, Sorenson K, Cryz S, Levine MM. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. *Lancet* 340:689-694, 1992.
275. Makowiak PA, Wasserman SS, Levine MM. A critical appraisal of 37°C (98.6°F), the upper limit of the normal body temperature and other legacies of Carl Reinhold August Wunderlich. *JAMA* 268:1578-1580, 1992.
276. Morris, JG Jr., Tacket CO, Levine MM. Oral carrier vaccines: New tricks in an old trade. *Gastroenterology* 103:699-702, 1992
277. Herrington DA, Losonsky GA, Smith G, Volvovitz F, Cochran M, Jackson K, Hoffman SL, Gordon DM, Levine MM, Edelman RE. Safety and immunogenicity in volunteers of a recombinant *Plasmodium falciparum* circumsporozoite protein malaria vaccine produced in Lepidopteran cells. *Vaccine* 10:841-846, 1992.
278. Prado V, Ferreccio C, Levine MM, Morris JG, Marinkovic K, Cayazzo M, Reyes R. Perfil clinico y microbiologico de las infecciones entericas por *Yersinia enterocolitica* en niños de Santiago, Chile. *Rev Chil Pediatr* 63:121-127, 1992.
279. Franco A, Gonzalez C, Levine OS, Lagos R, Hall RH, Hoffman SL, Moechtar MA, Gotuzzo E, Levine MM, Hone DM, Morris JG. Further consideration of the clonal nature of *Salmonella typhi*: Evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. *J Clin Microbiol* 30:2187-2190, 1992.
280. Mackowiak PA, Wasserman SS, Levine MM. An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis. *J Infect Dis* 166:1181-1182, 1992.

281. Chatfield SN, Fairweather N, Charles I, Pickard D, Levine MM, Hone D, Posada M, Strugnell RA, Dougan G. Construction of a genetically defined *Salmonella typhi* Ty2 *aroA*, *aroC* mutant for the engineering of a candidate live oral typhoid-tetanus vaccine. *Vaccine* 10:8-11, 1992.
282. Tzipori S, Montanaro J, Robins-Browne RM, Vial P, Gibson R, Levine MM. Studies with enteroaggregative *Escherichia coli* in the gnotobiotic piglet gastroenteritis model. *Infect Immun* 60:5302-5306, 1992.
283. Contreras R, Ferreccio C, Sotomayor V, Astroza L, Berrios G, Oritz E, Palomino C, Prenzel I, Pinto ME, Levine M. Typhoid fever in school children: by what measures is the modification of the clinical course due to oral vaccination? *Rev med Chile* 120:134-141, 1992.
284. Levine MM, Kaper JB. Live oral vaccines against cholera: An update. *Vaccines* 11:207-212 1993.
285. Cohen MB, Hawkins JA, Weckbach LS, Staneck JL, Levine MM, Heck JE. Colonization by enteroaggregative *Escherichia coli* in travelers with and without diarrhea. *J Clin Microbiol* 31:351-353, 1993.
286. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary *Vibrio cholerae* specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: Changes with time and lack of correlation and protection. *Infect Immun* 61:729-733, 1993.
287. Cryz SJ Jr, Vanprapar N, Thisyakorn U, Olanratamane T, Losonsky G, Levine MM, Chearskul S. Safety and immunogenicity of *Salmonella typhi* Ty21a vaccine in young children. *Infect Immun* 61:1149-115, 1993.
288. Wolf MK, Taylor DN, Boedeker EC, Hyams KC, Maneval DR, Levine MM, Tamura K, Wilson RA, Echeverria P. Characterization of enterotoxigenic *Escherichia coli* isolated from US troops deployed to the Middle East. *J Clin Microbiol* 31:851-856, 1993.
289. Makowiak PA, Wasserman SS, Levine MM. Relationship between humoral immune responses and oral temperature during human shigellosis. *J Infect Dis* 167:1449-1452, 1993.
290. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata D, Wasserman S, Salazar E, Kaper J, Cryz S, Levine M. The safety, immunogenicity and excretion pattern of single-dose live oral cholera vaccine, CVD 103-HgR in Peruvian adults of high and low socioeconomic level. *Infect Immun* 61:3994-3997, 1993.
291. Weintraub A, Leontein K, Widmalm G, Vial PA, Levine MM, Lindberg AA. Structural studies of the O-antigenic polysaccharide of an enteroaggregative *Escherichia coli* strain. *Euro J Biochem* 213:859-864, 1993.
292. Savarino SJ, Fasano A, Watson J, Martin BM, Levine MM, Guandalini S, Guerry P. Enteroaggregative *Escherichia coli* heat-stable enterotoxin 1 represents another subfamily of *E. coli* heat-stable toxin. *PNAS* 90:3093-3097, 1993.
293. Edelman R, Russell RG, Losonsky G, Tall BD, Tacket CO, Levine MM, Lewis DH. Immunization of rabbits with enterotoxigenic *E. coli* colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). *Vaccine* 11:155-158, 1993.
294. Sonnenberg, Tacket CO, James SP, Losonsky GA, Nataro JP, Wasserman SS, Kaper JB, Levine MM. The role of the *eaeA* gene in experimental enteropathogenic *Escherichia coli* infection. *J Clin Invest* 92:1412-1417, 1993.
295. Lagos R, Avendaño A, Horwitz I, Prado V, Ferreccio C, Sotomayor V, Losonsky G, Wasserman S, Cryz S, Kaper JB, Levine M. Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated *Vibrio cholerae* 01 strain: A double blind study in Chilean adults. *Rev Méd Chile* 121:857-863, 1993.
296. Avendaño A, Ferreccio C, Lagos R, Horwitz I, Cayazzo M, Fritzell B, Meschievitz C, Levine M. *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. *Pediatr Infect Dis J* 12:638-643, 1993.

297. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarmo A, Rifai A, Wasserman SS, Losonsky GA, Kaper J, Cryz S, Levine MM. The safety, immunogenicity and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. *J Infect Dis* 168:1169-76, 1993.
298. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically-marked *Vibrio cholerae* 01 vaccine strains. *FEMS Microbiol Lett* 111:15-21, 1993.
299. Levine MM, Ferreccio C, Prado V, Cayazzo M, Abrego P, Martinez J, Maggi L, Baldini MM, Martin W, Maneval D, Kay B, Guers L, Lior H, Wasserman SS, Nataro JP. Epidemiologic studies of *Escherichia coli* diarrheal infections in a low socioeconomic level periurban community in Santiago, Chile. *Amer J Epi* 138:849-869, 1993.
300. Pongsuk S, Sarosombath S, Ekpo P, Tangtherawattana, Levine MM. Production of monoclonal antibodies to Vi polysaccharide antigen of *Salmonella typhi*. *Asian Pacific J Allergy and Immunology* 11:53-56, 1993.
301. Mahle W and Levine MM. *salmonella typhi* infection in children younger than five years of age. *Pediatr Infect Dis J* 12:627-631, 1993.
302. Kaper JB, Michalski J, Ketley JM, Levine MM. Potential for reacquisition of cholera enterotoxin genes by attenuated *Vibrio cholerae* vaccine strain CVD 103-HgR. *Infect Immun* 62:1480-1483, 1994.
303. Hone DM, Harris AM, Levine MM. Adaptive acid tolerance response by *Salmonella typhi* and candidate live oral typhoid vaccine strains. *Vaccine* 12:895-898, 1994.
304. Wasserman SS, Kotloff KL, Losonsky GA, Levine MM. Immunological response to oral cholera vaccination in a crossover study: a novel placebo effect. *Am J Epidemiol* 138: 988-993, 1993.
305. Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Fasano A, Michalski J, Kaper JB, Levine MM. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a $\Delta ctxA \Delta zot \Delta ace$ derivative of El Tor Ogawa *Vibrio cholerae*. *J Infect Dis* 168:1536-1540, 1993.
306. Giron J, Levine MM, Kaper JB. Longus: a long pilus ultrastructure produced by enterotoxigenic *Escherichia coli*. *Molec Microbiol* 12:71-82, 1994.
307. Levine MM, Noriega F. Vaccines to prevent bacterial enteric infections in children. *Pediatr Ann* 22:719-725, 1993.
308. Levine MM, Noriega F. Current status of vaccine development for enteric diseases. *Semin Pediatr Infect Dis* 5:243-250, 1994
309. Levine MM, Levine OS. Changes in human ecology and behaviour in relation to the emergence of diarrheal diseases, including cholera. *Proc Natl Acad Sci, USA* 91;2390-2394, 1994.
310. Gonzalez C, Hone D, Noriega F, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A, Nardin E, Sztein MB, Heppner DG, Fouts TR, Isibasi A, Levine MM. *Salmonella typhi* strain CVD 908 expressing the circumsporozoite protein of *Plasmodium falciparum*: strain construction, safety and immunogenicity. *J Infect Dis* 169:927-931, 1994.
311. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA, Levine MM. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of *Salmonella typhi*. *J Infect Dis* 170:1508-1517, 1994.
312. Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castañada E, Levine MM. Kinetics of the vibriocidal antibody response to live oral cholera vaccine. *Vaccine* 12:1000-1003, 1994.

313. Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM. Evaluation of the safety, immunogenicity and efficacy in healthy adults of four doses of live oral hybrid *Escherichia coli-Shigella flexneri* 2a vaccine strain EcSfta-2. *Vaccine* 13:495-502, 1995.
314. Medina EC, Widmalm G, Weintraub PA, Levine MM, Lindberg AA. Structural studies of the O-antigenic polysaccharides of *Escherichia coli* O3 and the enteroaggregative *Escherichia coli* strain 17-2. *Eur J Biochem* 224:191-196, 1994.
315. Hone DM, Harris AM, Lim V, Levine MM. Construction and characterization of isogenic O-antigen variants of *Salmonella typhi*. *Molec Microbiol* 13:525-530, 1994.
316. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. *Bull Wld Hlth Org* 72:957-971, 1994.
317. Pickard D, Li J, Roberts M, Maskell D, Hone D, Levine M, Dougan G, Chatfield S. Characterization of defined *ompR* mutants of *Salmonella typhi*: *ompR* is involved in the regulation of Vi polysaccharide expression. *Infect Immun* 62:3984-3993, 1994.
318. Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM. Construction and characterization of attenuated Δ aroA Δ virG *Shigella flexneri* 2a strain CVD 1203, a prototype live oral vaccine. *Infect Immun* 62:5168-5172, 1995.
319. Tacket CO, Losonsky G, Nataro JP, Wasserman SS, Cryz SJ, Edelman R, Levine MM. Extension of the volunteer challenge model to study South American cholera in a population of volunteers with predominantly blood group antigen O. *Trans Roy Soc Trop Med Hyg* 89:75-77, 1995.
320. Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman SS, Losonsky G, Cryz SC jr., Kaper JB, Levine MM. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. *Infect Immun* 63:707-709, 1995.
321. Levine MM, Noriega F. A review of the current status of enteric vaccines. *Papua New Guinea Medical Journal* 38:325-331, 1995.
322. Girón JA, Xu Jian-Guo, González CR, Hone DM, Kaper JB, Levine MM. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic *Escherichia coli* by \square aroC, \square aroD *Salmonella typhi* vaccine strain CVD 908. *Vaccine* 10:939-946, 1995.
323. Comstock LE, Maneval D Jr, Pinagrahi P, Joseph A, Levine MM, Kaper JB, Morris JG Jr, Johnson JA. The capsule and O antigen in *Vibrio cholerae* O139 Bengal are associated with a genetic region not present in *Vibrio cholerae* O1. *Infect Immun* 63:317-323, 1995.
324. Nataro JP, Yikang D, Cookson C, Cravioto A, Savarino SJ, Guers LD, Levine MM, Tacket CO. Heterogeneity of enteroaggregative *Escherichia coli* virulence demonstrated in volunteers. *J Infect Dis* 171:465-468, 1995.
325. Colwell RR, Brayton P, Herrington D, Tall B, Huq A, Levine MM. Viable but non-culturable *Vibrio cholerae* O1 revert to a cultivable state in the human intestine. *World J Microbiol Biotechnol*, 12:28-31, 1996.
326. Glynn JR, Hornick RB, Levine MM, Bradley DJ. Infecting dose and severity of typhoid: analysis of volunteer data and examination of the influence of the definition of illness used. *Epidemiol Infect* 115, 23-30, 1995.
327. Ojeda A, Prado V, Martinez J, Arellano C, Borczyk A, Johnson W, Lior H, Levine MM. Sorbitol-negative phenotype among enterohemorrhagic *Escherichia coli* of different serotypes and sources. *J Clin Microbiol*, 33:2199-2201, 1995.
328. Morris JG, Losonsky GE, Johnson JA, Tacket CO, Nataro JP, Panigrahi P, Levine MM. Clinical and immunologic characteristics of *Vibrio cholerae* O139 Bengal infection in North American volunteers. *J Infect Dis* 171(4): 903-908, 1995.

329. Prado V, Cordero J, Garreaud C, Olguin H, Arellano C, Nachar CL, Misraji A, Martinez J, Tous M, Rivas M, Levine MM. *Escherichia coli* enterohemorrhágica en el síndrome hemolítica urémico, en niños chilenos. Rev Med Chile 123:13-22, 1995.
330. Gómez-Duarte, OG, Galen J, Chatfield SN, Rappuoli R, Eidels L, Levine MM. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 908 vaccine strain. Vaccine 13:1596-1602, 1995.
331. Cryz SJ Jr, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (*Salmonella typhi*-Ty21a) cholera (*Vibrio cholerae* CVD 103-HgR) vaccine in healthy adults. Infect Immun 63:1336-1339, 1995.
332. Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM. Initial clinical studies of CVD 112 *Vibrio cholerae* 0139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis 172: 883-886, 1995.
333. Fasano A, Noriega FR, Maneval DR Jr, Chanasongcram S, Russell R, Guandalini S, Levine MM. *Shigella* enterotoxin 1: an enterotoxin of *Shigella flexneri* 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 95:2853-2861, 1995.
334. Noriega FR, Liao FM, Formal SB, Fasano A, Levine MM. Prevalence of *Shigella* enterotoxin among *Shigella* clinical isolates of diverse serotypes. J Infect Dis 172: 1408-1410, 1995.
335. Nataro JP, Seriwatana J, Fasano A, Maneval DR, Guers LD, Noriega F, Dubovsky F, Levine MM, Morris JG Jr. Identification and cloning of a novel plasmid-encoded enterotoxin in enteroinvasive *Escherichia coli* and *Shigella*. Infect Immun, 63:4721-4728, 1995
336. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. Cytotoxic T lymphocytes after oral immunization with attenuated strains of *Salmonella typhi* in humans. J Immunol 155:3987-3993, 1995.
337. Levine MM, Galen J, Barry E, Noriega F, Chatfield S, Dougan G, Tacket C. Attenuated *Salmonella* as live oral vaccines against typhoid fever and as live vectors. J Biotechnology 44:193-196, 1995.
338. Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Formal SB, Levine MM. A modified *Shigella* volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for *Shigella* infectivity. Vaccine 13:1488-1494, 1995.
339. Noriega FR, Losonsky G, Wang JY, Formal SB, Levine MM. Further characterization of Δ aroA, Δ virG *Shigella flexneri* 2a strain CVD 1203 as a mucosal *Shigella* vaccine and as a live vector for delivering antigens of enterotoxigenic *Escherichia coli*. Infect Immun 64:23-27, 1996.
340. Losonsky GA, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 64:10-15, 1996.
341. Acheson DWK, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin following oral immunization with Shiga-like toxin I B subunit-producing *Vibrio cholerae* CVD 103-HgR. Infect Immun 64:355-357, 1996.
342. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine OS, Levine MM. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive *Haemophilus influenzae* type b infections. Pediatr Infect Dis 15:216-222, 1996.
343. Levine MM, Kaper JB. Live oral cholera vaccine: from principle to product. Bull Inst Pasteur 93: 243-353, 1995.

344. Lagos R, Losonsky G, Abrego P, San Martin O, Prado V, Wasserman S, Levine MM. Tolerancia, inmunogenicidad, excreción y transmisión de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en niños Chilenos de 24 a 59 meses. *Bol Hosp Infant Mex* 53:214-220, 1996.
345. Girón JA, Viboud GL, Sperando V, Gomez-Duarte O, Maneval D, Albert MJ, Levine MM, Kaper JB. Prevalence and association of the longus pilus structural gene (*IngA*) with colonization factor antigens, enterotoxin types, and serotypes of enterotoxigenic *Escherichia coli*. *Infect Immun* 63:4195-4198, 1995.
346. Kaper JB, Morris JG Jr, Levine MM. Cholera. *Clin Microbiol Rev* 8:48-86, 1995.
347. Noriega FR, Losonsky G, Lauderebaugh C, Liao FM, Wang JY, Levine MM. Engineered Δ *guaB-A* Δ *virG* *Shigella flexneri* 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. *Infect Immun* 64:3055-3061, 1996.
348. Prado V, Basualdo W, Arellano C, Martinez J, Levine MM. Susceptibilidad in vitro de *Escherichia coli* enterohemorrágicos frente 11 antimicrobianos. Relación entre resistencia antibiótica y genotipos toxigénicos. *Rev Méd Chile* 123:1085-1090, 1995.
349. Levine MM. The legacy of Edward Jenner. *Brit Med J* 312:1177-1178, 1996
350. Kotloff K, Noriega F, Losonsky G, Sztein MB, Nataro JP, Levine MM. Safety, immunogenicity and transmissibility in humans of CVD 1203, a live oral *Shigella flexneri* 2a vaccine candidate attenuated by deletions in *aroA* and *virG*. *Infect Immun* 64:4542-4548, 1996.
351. Barry EM, Gomez-Duarte O, Chatfield S, Rappuoli R, Losonsky GA, Galen JE, Levine MM. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in *Salmonella typhi* vaccine strain CVD 908. *Infect Immun* 64:4172-4181, 1996.
352. ILSI Risk Science Institute Pathogen Risk Assessment Working Group (Levine, MM, member of Working Group). A Conceptual Framework to Assess the Risks of Human Disease Following Exposure to Pathogens. *Risk Analysis* 16:6 841-848, 1996.
353. Levine O, Lagos R, Losonsky GA, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine MM. No adverse impact on the immune response to pertussis antigens or clinical protection against pertussis from co-administration of *Haemophilus influenzae* type b conjugate and diphtheria-tetanus-pertussis vaccines in the same syringe. *J Infect Dis* 174:1341-1344, 1996.
354. Levine MM, Prado V, Lior H, Lagos R. Epidemiologic studies of diarrhea associated with enteropathogenic *Escherichia coli* (EPEC) in infants and children in Santiago, Chile. *Rev Microbiol Sao Paulo* 27 (supplement 1):40-44, 1996.
355. Ojeda A, Marinkovic K, Prado V, Ferreccio C, Levine MM. Rendimiento comparativo de diferentes esquemas de trabajo para aislamiento de enteropatógenos en coprocultivo. *Rev Chil Infectol* 13:137-144, 1996.
356. Galen JE, Gomez-Duarte O, Losonsky GA, Halpern J, Lauderbaugh CS, Kaintuck S, Reymann M, Levine MM. A murine model of intranasal immunization to assess the immunogenicity of attenuated *Salmonella typhi* live vector vaccines in stimulating serum antibody responses to foreign antigens. *Vaccine* 15:700-708, 1997.
357. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Galen JE, Pickard D, Dougan G, Chatfield SN, Levine MM. Safety of live oral *Salmonella typhi* vaccine strains with deletions in *htrA* and *aroC aroD* and immune response in humans. *Infect Immun* 65:452-456, 1997.
358. Levine OS, Granoff D, Fritzell B, Levine MM. Factors associated with superior antibody response to a single dose of *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. *Vaccine* 15:325-328, 1997.

359. Cookson ST, Stambouljian D, Demonte J, Quero L, Martinez de Arquiza C, Aleman A, Lepetic A, Levine MM. Repetitive seasonal cholera in Northern Argentina: a cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high risk population. *Int J Epidemiol* 26:212-219, 1997.
360. Fasano A, Noriega FR, Liao FM, Wang W, Levine MM. Effect of *Shigella* enterotoxin 1 (ShET1) on rabbit intestine *in vitro* and *in vivo*. *GUT* 40:505-511, 1997.
361. Losonsky GA, Lim Y, Motamedi P, Comstock L, Johnson JA, Tacket CO, Kaper JB, Levine MM. Vibriocidal antibody responses following *Vibrio cholerae* O139 wild-type and vaccine exposure in North American volunteers: specificity and relevance to immunity. *Clin Diag Lab Immunol* 4:264-269,1997.
362. Levine MM, Galen J, Barry E, Noriega F, Tacket C, Sztein M, Chatfield S, Dougan G, Losonsky G, Kotloff K. Attenuated *Salmonella typhi* and *Shigella* as live oral vaccines and as live vectors. *Behring Inst Mitt* 98:120-123, 1997.
363. Tacket CO, KL, Losonsky G, Nataro JP, Michalski J, Kaper JB, Edelman R, Levine MM. Volunteer studies investigating the safety and efficacy of live oral El Tor *Vibrio cholerae* O1 vaccine strain CVD 111. *Am J Trop Med Hyg* 56:533-537, 1997.
364. Levine MM, Levine OS. Disease burden, public perception, and other factors that influence new vaccine development, implementation and continued use. *Lancet* 350:1386-1392, 1997.
365. Tacket CO, Kelly SM, Schödel F, Losonsky G, Nataro JP, Edelman R, Levine MM, Curtiss R III. Safety and immunogenicity in humans of an attenuated *Salmonella typhi* vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal system. *Infect Immun* 65:3381-3385, 1997.
366. Ivanoff B, Levine MM. Typhoid fever: Continuing challenges from a resilient bacterial foe. *Bull Inst Pasteur* 95:129-142, 1997.
367. Marks RS, Bassis E, Bychenko A, Levine MM. Chemiluminescent optical fiber immunosensor for detecting cholera antitoxin. *Optical Engineering* 36:1-7, 1997.
368. Prado V, Martinez J, Arellano C, Levine MM. Variación temporal de genotipos y serogrupos de *E. coli* enterohemorrágicos aislados en niños chilenos con infecciones intestinales o síndrome hemolítico-urémico. *Rev Méd Chile* 125: 291-297, 1997.
369. Donnenberg MS, Tacket CO, Losonsky G, Frankel G, Nataro JP, Dougan G, Levine MM. Effect of prior experimental human enteropathogenic *Escherichia coli* infection on illness following homologous and heterologous rechallenge. *Infect Immun* 66:52-58, 1998.
370. Perry RT, Plowe CV, Koumaré B, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. *Bull Wld Hlth Org* 76:63-71, 1998.
371. Tacket CO, Taylor RK, Losonsky G, Lim Y, Nataro JP, Kaper JB, Levine MM. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of *Vibrio cholerae* O139 infection. *Infect Immun* 66:692-695, 1998.
372. Pang T, Levine MM, Ivanoff B, Wain J, Finaly B.B. Typhoid fever -- important issues still remain. *Trends Microbiol* 6:131-133, 1998.
373. González CR, Noriega FR, Huerta S, Santiago A, Vega M, Paniagua J, Ortiz-Navarrete V, Isibasi A, Levine MM. Immunogenicity of a *Salmonella typhi* CVD 908 candidate vaccine strain expressing the major surface protein gp63 of *Leishmania mexicana mexicana*. *Vaccine* 16:9/10 1043-1052, 1998.

374. Lagos R, Valenzuela MT, Levine OS, Lososky GA, Erazo A, Wasserman SS, Levine MM. Economisation of vaccination against *Haemophilus influenzae* type b: a randomised trial of the immunogenicity of fractional dose and two-dose regimens. *Lancet* 351:1472-76, 1998.
375. Levine MM, Lagos R, Levine OS, Heitmann I, Enriquez N, Pinto ME, Alvarez AM, Whu E, Mayorga C, Reyes A. Epidemiology of invasive pneumococcal infections in infants and young children in metropolitan Santiago, Chile, a newly industrializing country. *Pediatr Infect Dis J* 17:287-293, 1998.
376. Tacket CO, Mason HS, Lososky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. *Nature Medicine* 4:607-609, 1998.
377. Lagos R, Levine OS, Avendaño A, Horwitz I, Levine MM. The introduction of routine *Haemophilus influenzae* type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. *Pediatr Infect Dis J* 17:9 Supplement S139-S148, 1998.
378. Sack DA, Tacket CO, Cohen MB, Sack RB, Lososky GA, Shimko J, Nataro JP, Edelman R, Levine MM, Giannella RA, Schiff G, Lang D. Validation of a volunteer model of cholera with frozen bacteria as the challenge. *Infect Immun* 66:1968-1972, 1998.
379. Levine MM, Dougan G. Optimism over vaccines administered via mucosal surfaces. *Lancet* 351:1375-1376, 1998.
380. Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J. Safety and immunogenicity of an *Haemophilus influenzae* type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. *Vaccine* 16:921-927, 1998.
381. Lagos R, Kotloff K, Hoffenbach A, San martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and *Haemophilus influenzae* type b conjugate antigens in two-, four- and six-month old Chilean infants. *J Pediatr Infect Dis* 17:294-304, 1998.
382. Prado V, Pidal P, Arellano C, Lagos R, San Martin O, Levine MM. Multirresistencia antimicrobiana en cepas de *Shigella* sp en una comuna semi rural del área norte de Santiago. *Rev Méd Chile* 126:1464-1471, 1998.
383. Tang C, Moxon R, Levine MM. For discussion: live attenuated vaccines against meningococcus. *Vaccine* 17:114-117, 1999.
384. Rios M, Prado V, Arellano C, Borie M, Fica A, Levine MM. Clonal diversity of Chilean isolates of enterohemorrhagic *Escherichia coli* from patients with hemolytic-uremic syndrome, asymptomatic subjects, animal reservoirs, and food products. *J Clin Microbiol* 37:778-781, 1999.
385. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego A, Lososny G, Alegria S, Levine MM. Effect of small bowel overgrowth on the "take" of single-dose live oral cholera vaccine CVD 103-HgR. *J Infect Dis* 180:1709-1712, 1999.
386. Lagos R, San Martin O, Wasserman SS, Prado V, Lososky GA, Bustamante C, Levine MM. Palatability, reactogenicity and immunogenicity of engineered single-dose live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. *Pediatr Infect Dis J* 18:624-630, 1999.
387. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Strategy for cross-protection among *Shigella flexneri* serotypes. *Infect Immun* 67:782-788, 1999.
388. Orr N, Galen JE, Levine MM. Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM₁₉₇, and its fragments in *Salmonella typhi* vaccine strain CVD 908-*htrA*. *Infect Immun* 67:4290-4294, 1999.

389. Prado V, Lagos R, Nataro JP, Martin OS, Arellano C, Wang JY, Borczyk AA, Levine MM. A population-based study of the incidence of *Shigella* diarrhea and causative serotypes in Colina, a semi-rural poor community in Santiago, Chile. *Pediatr Infect Dis J* 18:500-5, 1999.
390. Levine MM, Ferreccio C, Abrego P, San Martin O, Ortiz E, Cryz SC. Duration of efficacy of Ty21a, attenuated *Salmonella typhi* live oral vaccine. *Vaccine* 17:2 Supplement S22-S27, 1999.
391. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. *Bull WHO* 77:651-666, 1999.
392. Levine OS, Lagos R, Muñoz A, Villaroel J, Alvarez AM, Abrego A, Levine MM. Defining the burden of pneumonia in children preventable by vaccination against *Haemophilus influenzae* type b. *Pediatr Infect Dis J*, 18:1060-1064, 1999.
393. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated Δ *guaBA* *Salmonella typhi* vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. *Clin Immun* 92:76-89, 1999.
394. Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA, Wasserman SS, Levine MM, Cryz SJ. Expanded safety and immunogenicity of a bivalent, oral attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. *Infect Immun* 67:2030-2034, 1999.
395. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Gianella RA, Schiff G, Levine MM. Randomized, double-blind, placebo-controlled multi-centered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with *Vibrio cholerae* O1 El Tor, inaba three months after vaccination. *Infect Immun* 67:6341-6345, 1999.
396. Galen JE, Nair J, Wang JY, Tanner MK, Sztein MB, Levine MM. Optimization of plasmid maintenance in the attenuated live vector vaccine *Salmonella typhi* strain CVD 908-*htrA*. *Infect Immun* 67:6424-6433, 1999.
397. Peter G, des Vignes-Kendrick M, Eickhoff TC, Fine A, Galvin V, Levine MM, Maldonado YA, Marcuse EK, Monath TP, Osborn JE, Plotkin S, Poland GA, Quinlisk MP, Smith DR, Sokol M, Soland DB, Whitley-Williams PN, Williamson DE, Breiman RF. Lessons learned from a review of the development of selected vaccines. *National Vaccine Advisory Committee. Pediatrics* 104:942-50, 1999.
398. Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Levine MM. *Shigella flexneri* 2a strain CVD 1207 with specific deletions in *virG*, *sen*, *set* and *guaBA* is highly attenuated in humans. *Infect Immun* 68:1034-39, 2000.
399. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM. Phase 2 clinical trial of attenuated *Salmonella enterica* serovar Typhi oral live vector vaccine CVD 908-*htrA* in U.S. volunteers. *Infect Immun* 68:1196-1201, 2000.
400. Pickett TE, Pasetti MF, Galen JE, Sztein MB, Levine MM. *In vivo* characterization of the murine intranasal model for assessing the immunogenicity of attenuated *Salmonella typhi* as live mucosal vaccines and as live vectors. *Infect Immun* 68:205-213, 2000.
401. Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR. Δ *guaBA* attenuated *Shigella flexneri* 2a strain CVD 1204 as a *Shigella* vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. *Vaccine* 18:2193-2202, 2000.
402. Richie E, Punjabi NH, Sidharta Y, Peetosutan K, Sukandar M, Wasserman SS, Lesmana M, Wangsasaputra F, Pandam S, Levine MM, O'Hanley P, Cryz SJ, Simanjuntak CH. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. *Vaccine* 18:2399-2410, 2000.

403. Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, Wasserman SS, Edelman R, Chatfield S, Dougan G, Levine MM. Safety and immune responses to attenuated *Salmonella enterica* serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. *Clin Immunol* 97:146-153, 2000.
404. Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BB, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM, Donnenberg MS. The role of EspB in experimental human Enteropathogenic *Escherichia coli* (EPEC) infection. *Infect Immun* 68:3689-3695, 2000.
405. Pasetti MF, Tanner MK, Pickett TE, Levine MM, Sztein M. Mechanisms and cellular events associated with the priming of mucosal and systemic immune responses to *Salmonella enterica* serovar Typhi live vector vaccines delivered intranasally in the murine model. *Vaccine* 18:3208-3213, 2000.
406. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. *J Infect Dis* 182:302-305, 2000.
407. Cooper PJ, Chico H ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, Aguilar M, Guevara A, Guderian RH, Levine MM, Griffin GE, Nutman TB. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. *J Infect Dis* 182:1199-1206, 2000.
408. Wu S, Beier M, Sztein M, Galen JE, Pickett T, Holder AA, Gómez-Duarte O, Levine MM. Construction and immunogenicity in mice of attenuated *Salmonella typhi* expressing *Plasmodium falciparum* merozoite surface protein (MSP-1) fused to tetanus toxin fragment C. *J Biotechnol.* 83:125-135, 2000.
409. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated *Salmonella enterica* serovar Typhi oral vaccine strain CVD 909. *Infect Immun* 68:4647-4652, 2000.
410. Levine MM. Immunization against bacterial diseases of the intestine. *J Pediatr Gastroenterol Nutr* 31:366-355, 2000.
411. Koprowski H II, Levine MM, Anderson RA, Losonsky G, Pizza M, Barry EM. Attenuated *Shigella flexneri* 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic *Escherichia coli*. *Infect Immun* 68:4884-92, 2000.
412. Plaisance KI, Kudravalli S, Wasserman SS, Levine MM, Mackowiak PA. Effect of antipyretic therapy on the duration of illness in experimental influenza A, *Shigella sonnei*, and *Rickettsia rickettsii* infections. *Pharmacotherapy.* 20:1417-22, 2000.
413. Gómez-Duarte O, Pasetti M, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, secretion and immunogenicity of the *Plasmodium falciparum* SSP-2 protein in *Salmonella* vaccine strains by a type I secretion system. *Infect Immun* 69:1192-1198, 2001.
414. Orr N, Galen JE, Levine MM. Novel use of anaerobically induced promoter, *dmsA*, for controlled expression of Fragment C of tetanus toxin in live attenuated *Salmonella enterica* serovar Typhi strain CVD 908-*htrA*. *Vaccine* 19:1694-1700, 2001.
415. Altboum Z, Barry EM, Losonsky G, Galen JE, Levine MM. Attenuated *Shigella flexneri* 2a Δ *guaBA* strain CVD 1204 expressing ETEC CS2 and CS3 fimbriae as a live mucosal vaccine against *Shigella* and enterotoxigenic *Escherichia coli* infection. *Infect Immun* 69:3150-8, 2001.
416. Wang JY, Pasetti MF, Noriega FR, Anderson RS, Wasserman SS, Galen JE, Sztein MB, Levine MM. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated Δ *guaBA* *Salmonella enterica* serovar Typhi strain CVD 915. *Infect Immun* 69:4734-4741, 2001.
417. Galen JE, Levine MM. Can a "flawless" live vector vaccine strain be engineered? *Trends Microbiol* 9:372-376, 2001.

418. Campbell JD, Levine MM. Vaccines against enteric bacterial pathogens. *Asian J Paediatric Practice* 5:19-37, 2001.
419. Levine MM, Tacket CO, Sztein MB. Host-*Salmonella* interaction: clinical trials. *Microbes Infect* 3:1271-79, 2001.
420. Levine MM, Campbell J and Kotloff K. Overview of vaccines and immunization. *Brit Medical Bulletin*, 62:1-13, 2002.
421. Stephens I, Levine MM. Management of typhoid fever in children. *Pediatr Infect Dis J*. 21:157-8, 2002.
422. Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.. Phase I evaluation of γ virG *Shigella sonnei* live, attenuated, oral vaccine strain WRSS1 in healthy adults. *Infect Immun* 70:2016-21, 2002.
423. Kidgell C, Pickard D, Wain J, James K, Diem Nga LT, Diep TS, Levine MM, O'Gaora P, Prentice MB, Parkhill J, Day N, Farrar J, Dougan G. Characterisation and distribution of a cryptic *Salmonella typhi* plasmid pHCM2. *Plasmid*. 47:159-71, 2002.
424. Campbell JD, Lagos R, Levine MM, Losonsky GA. Standard and alternative regimens of *Haemophilus influenzae* type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. *Pediatr Infect Dis J* 21:822-826, 2002.
425. Lagos R, Muñoz A, Valenzuela MT, Heitmann I, Levine MM. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. *Pediatr Infect Dis J* 21:1115-1123, 2002.
426. Pasetti, M, Levine MM, Sztein MB. Animal models paving the way for clinical trials of attenuated *Salmonella enterica* serovar Typhi live oral vaccines and live vectors. *Vaccine*. 21:401-18, 2003.
427. Levine MM. Can needle-free administration of vaccines become the norm in global immunization? *Nature Med* 9:99-103, 2003.
428. Barry EM, Altboum Z, Losonsky G, Levine MM. Immune responses elicited against multiple enterotoxigenic *Escherichia coli* fimbriae and mutant LT expressed in attenuated *Shigella* vaccine strains. *Vaccine* 21:333-340, 2003.
429. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno, SM, Polo JM, Robinson H, Sztein MB, Levine MM. Attenuated *Salmonella enterica* serovar Typhi and *Shigella flexneri* 2A strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. *J Virol* 77:5209-5217, 2003.
430. Altboum Z, Levine MM, Galen JE, Barry EM. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic *Escherichia coli* when it is expressed in a *Shigella* live-vector strain. *Infect Immun* 71:1352-1360, 2003.
431. Salerno-Goncalves R, Wyant TL, Pasetti MF, Fernandez-Vina M, Tacket CO, Levine MM, Sztein MB. Concomitant Induction of CD4(+) and CD8(+) T Cell Responses in Volunteers Immunized with *Salmonella enterica* Serovar Typhi Strain CVD 908-htrA. *J Immunol* 170:2734-2741, 2003.
432. Lagos R*, Muñoz A, Dumas R, Pichon S, Zambrano B, Levine MM, Vidor E. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. *Vaccine* 21:3730-3733, 2003.
433. Levine MM. Use of vaccines for the prevention of typhoid fever. *Indian Pediatr* 40:1029-1034, 2003.
434. Lee Y, Sun YH, Ison C, Levine MM, Tang C. Vaccination with attenuated *Neisseria meningitidis* strains protects against challenge with live Meningococci. *Infect Immun* 72:345-351, 2004.

435. Tacket CO, Pasetti MF, Sztein, MB, Livio S, Levine MM. Immune responses to an oral Typhoid vaccine strain modified to constitutively express Vi capsular polysaccharide. *J Infect Dis*, 190:565-570, 2004.
436. Vindurampulle CJ, Cuberos LF, Barry EM, Pasetti MF, Levine MM. Recombinant *Salmonella enterica* serovar Typhi in a prime-boost strategy. *Vaccine* 22(27-28):3744-3750, 2004.
437. Mallet E, Belohradsky BH, Lagos R, Gothefors L, Camier P, Carrière J-P, Kanra G, Hoffenbach A, Langue J, Undreiner F, Roussel F, Reinert P, Flodmark C-E, Stojanov S, Liese J, Levine MM, Muñoz A, Schödel F, Luc Hessel, Hexavalent Vaccine Trial Study Group. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, *Haemophilus influenzae* type b and hepatitis B: review of immunogenicity and safety. *Vaccine* 22:1343-1357, 2004.
438. Levine MM, Sztein, MB. Vaccine development strategies for improving immunization: the role of modern immunology. *Nature Immunol* 5:460-4, 2004.
439. Campbell JD, Sow S, Levine MM, Kotloff KL. The causes of hospital admission and death among children in Bamako, Mali. *J Trop Pediatr* 50:158-63, 2004.
440. Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, Diallo S, Hormazabal JC, Murray P, Levine MM. Invasive Pneumococcal Infections Among Hospitalized Children in Bamako, Mali. *J Pediatr Infect Dis* 23:642-649, 2004.
441. Capozzo AV, Cuberos L, Levine MM, Pasetti MF. Mucosally delivered *Salmonella* live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. *Infect Immun* 72:4637-4646, 2004.
442. Wyburn NR, Clark A, Roberts RE, Jamieson SJ, Tzokov S, Bullough PA, Stillman TJ, Artymiuk PJ, Galen JE, Zhao L, Levine MM, Green J. Properties of haemolysin E (HlyE) from a pathogenic *Escherichia coli* avian isolate and studies of HlyE export. *Microbiology*150:1495-1505, 2004.
443. Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM. Deletion in the *Shigella* enterotoxin genes further attenuates *Shigella flexneri* 2a bearing guanine auxotrophy in a Phase 1 trial of CVD 1204 and CVD 1208. *J Infect Dis* 190:1745-1754, 2004.
444. Galen JE, Zhao L, Chinchilla M, Wang JY, Pasetti MF, Green J, Levine MM. Adaptation of the endogenous *Salmonella enterica* serovar Typhi *plyA*-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live vector vaccine strain CVD 908-*htrA*. *Infect Immun* 72:7096-7106, 2004.
445. Tapia, MD, Sow SO, Medina-Moreno S, Pasetti M, Kotloff KL, Levine MM. A serosurvey to identify the "window of vulnerability" to wild type measles among infants in rural Mali. *Am J Trop Med Hyg*, 73:26-31, 2005.
446. Sow SO, Diallo S, Campbell JD, Tapia M, Keita T, Keita MM, Murray P, Kotloff KL, Levine MM. Burden of Invasive disease caused by *Haemophilus influenzae* type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. *Pediatr Infect Dis J*, 24:533-7, 2005.
447. Lagos R, Hoffenbach, Scemama, Dupuy, Schodel F, Hessel L, and Levine MM. Lot-to-lot consistency of a combined hexavalent diphtheria-tetanus-acellular-pertussis, hepatitis B, inactivated polio and Haemophilus B conjugate vaccine to healthy Chilean infants at 2, 4 and 6 months of age. *Human Vaccines*, 1:112-117, 2005.
448. Vidal MO, Kruger E, Durán C, Lagos R, Levine M, Prado V, Toro C, Vidal RA. A single multiplex PCR assay to identify simultaneously the six categories of diarrheagenic *Escherichia coli* associated to enteric infections. *J Clin Micro*, 43:5362-5365, 2005.
449. Song MK, Vindurampulle CJ, Capozzo AVE, Ulmer J, Polo JM, Pasetti MF, Barry EM, Levine MM. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding

- measles virus hemagglutinin and/or fusion proteins. *J of Virology* 79:9854-9861, 2005.
450. Fulla N, Prado V, Duran C, Lagos R, Levine MM. Surveillance for antimicrobial resistance profiles among *Shigella* species isolate from a semirural community in the northern administrative area of Santiago, Chile. *Am J Trop Med Hyg* 72:851-4, 2005.
451. Levine MM, Lepage P. Prevention of typhoid fever. *Adv Exp Med Biol*, 568:161-73, 2005
452. Levine MM, Gallo RC. A Tribute to Maurice Ralph Hilleman. *Human Vaccines*, 1:93-130, 2005.
453. Levine MM. Enteric infections and the vaccines to counter them: Future directions. *Vaccine*, 24:3865-73, 2006.
454. Capozzo AV, Ramirez K, Polo JM, Ulmer J, Barry EM, Levine MM, Pasetti MF. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-Like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. *J Immunol* 176:5671-81, 2006.
455. Barry E, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent *Shigella*-ETEC candidate vaccine strains in a guinea pig model. *Vaccine* 24:3727-34, 2006.
456. Roca A, Sigauque B, Quinto L, Maldonado I, Valles X, Espasa M, Abacassamo F, Scarlal J, Macete E, Nhacolo A, Levine M, Alonso P. Invasive pneumococcal disease in children <5 years of age in rural Mozambique. *Trop Med Int Health* 11:1422-31, 2006.
457. Valles X, Flannery B, Roca A, Mandomando I, Sigauque B, Sanz S, Schuchat A, Levine M, Soriano-Gabarro M, Alonso P. Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of *Streptococcus pneumoniae* among children in rural Mozambique. *Trop Med Int Health* 11:358-356, 2006.
458. Lagos RM, Muñoz, AE, Levine MM. Prevalence of pneumococcal bacteremia among children < 36 months of age presenting with moderate fever to Pediatric Emergency Rooms of the Metropolitan Region (Santiago), Chile. *Human Vaccines* 2:129-133, 2006
459. Levine MM. Mass vaccination to control epidemic and endemic typhoid fever. *Curr Top Microbiol Immunol* 304:231-246, 2006
460. Tapia MD, Pasetti MF, Cuberos L, Sow SO, Doumbia MN, Bagayogo M, Kotloff ML, Levine MM. Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys. *Pediatr Infect Dis J* 25:819-825, 2006.
461. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB. Cell-mediated immune responses in humans after immunization with one and two doses of oral live attenuated typhoid vaccine CVD 909. *Vaccine* 25:1416-25, 2007.
462. Simon JK, Pasetti MF, Viret JF, Mischler R, Munoz A, Lagos R, Levine MM, Campbell JD. A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults. *Human Vaccines* 3:54-58, 2007.
463. Chinchilla M, Pasetti MF, Medina-Moreno S, Wang JY, Gomez-Duarte OG, Stout R, Levine MM, Galen JE. Enhanced immunity to *Plasmodium falciparum* circumsporozoite protein using *Salmonella* Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. *Infect Immun* 75:3769-79, 2007.
464. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of *Shigella* Vaccines; Two Steps Forward and One Step Back on a Long, Hard Road. *Nature Reviews Microbiology*, 5:540-553, 2007; (doi:10.1038/nrmicro1662).
465. Tacket CO, Levine MM. CVD 908, CVD 908-hTrA, and CVD 909 live oral typhoid vaccines: a logical progression. *Clin Infect Dis* 45 Suppl 1:S20-S23, 2007.

466. Mandomando I, Sigaúque B, Vallès X, Espasa M, Sanz S, Sacarial J, Macete E, Abacassamo F, Ruiz J, Gascon J, Kotloff KL, Levine MM, Alonso PL. Epidemiology and clinical presentation of shigellosis in children less than five years of age in rural Mozambique. *Pediatr Infect Dis J* 26:1059-61, 2007.
467. Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, Polack FP, Ward BJ, Burt D, Chabot S, Ulmer J, Barry EM, Levine MM. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. *Clin Pharmacol Ther* 82:672-85, 2007.
468. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by *Salmonella enterica* Serovar Paratyphi B. *Clin Infect Dis* Jul 15;45 Suppl 1:S24-8, 2007.
469. Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM. Safety and immunogenicity of CVD 1208S, a live, oral Δ *guaBA* Δ *sen* Δ *set* *Shigella flexneri* 2a vaccine grown on animal-free media. *Human Vaccines* 3:6, 268-275, 2007.
470. Sigaúque B, Roca A, Sanz S, Oliveiras I, Martinez M, Mandomando I, Vallès X, Espasa M, Abacassamo F, Sacarial J, Macete E, Nhacolo A, Aponte J, Levine MM, Alonso PL. Acute bacterial meningitis among children, in Manhica, a rural area in Southern Mozambique. *Acta Trop* 105:1, 21-7, 2008.
471. Levy H, Diallo S, Tennant SM, Livio S, Sow SO, Tapia M, Fields PI, Mikoleit M, Tamboura B, Kotloff KL, Lagos R, Nataro JP, Galen JE, Levine MM. PCR method to identify *Salmonella enterica* Serovars Typhi, Paratyphi A, and Paratyphi B among *Salmonella* isolates from the blood of patients with clinical enteric fever. *J Clin Micro* 46:1861-1866, 2008.
472. Petri, WA, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. *J Clin Invest* 118:1277-1290, 2008.
473. Cross, AS, Chen W, Levine MM. A case for immunization against nosocomial infections. *J Leukoc Biol* 83:483-488, 2008.
474. Roca A, Abacassamo F, Morais L, Vallès X, Espasa M, Sigaúque B, Sacarial J, Macete E, Nhacolo A, Mandomando I, Levine MM, Alonso PL. Invasive *Haemophilus influenzae* disease in children less than 5 years of age in Manhica, a rural area of southern Mozambique. *Trop Med Int Hlth*, 13:818-26, 2008
475. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM and Sztein MB. Generation of specific effector and memory T cells with gut and secondary lymphoid tissues homing potential by oral attenuated CVD 909 typhoid vaccine in humans. *Mucosal Immun* 1:389-398, 2008.
476. Mandomando IM, Naniche D, Pasetti MF, Vallés X, Cuberos L, Nhacolo A, Kotloff KL, Martins H, Levine MM, Alonso P. Measles-specific neutralizing antibodies in rural Mozambique: Seroprevalence and presence in breast milk. *Am J Trop Med Hyg*, 79:787-792, 2008.
477. Fang CM, Wang JY, Chinchilla M, Levine MM, Blackwelder WC, Galen JE. Use of *mchl* encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors. *Infect Immun* 76:4422-4430, 2008.
478. Lagos R, Muñoz A, San Martin O, Maldonado A, Hormazabal JC, Blackwelder WC, Levine MM. Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile. 1994-2007. *J Infect Dis* 198:1809-1817, 2008.
479. Sigaúque B, Roca A, Mandomando I, Morais L, Quintó L, Sacarlal J, Macete E, Nhamposa T Machevo S, Aide P, Bassat Q, Bardaji A, Nhalungo D, Soriano-Gabarró M, Flannery B, Menendez C, Levine MM, Alonso PL. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. *Pediatr Infect Dis J*. 28:108-113, 2009.

480. Galen JE, Chinchilla M, Pasetti MF, Wang JY, Zhao L, Arciniega-Martinez I, Silverman, DJ, Levine MM. Mucosal immunization with attenuated *Salmonella enterica* serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. *JID*, 199:326-335, 2009
481. Baker KK, Levine MM, Morison J, Philips A, Barry EM. CfaE tip mutations in ETEC CFA/I fimbriae define critical human intestinal binding sites. *Cell Microbiol* 11(5):742-54, 2009
482. Pasetti M, Ramirez K, Resendiz-Albor A, Ulmer J, Barry EM, Levine MM. Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity. *J Virol* 83:2789-2794, 2009.
483. Simon JK, Wahid R, Maciel M Jr, Picking WL, Kotloff KL, Levine MM, Sztein MB. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated *Shigella flexneri* 2a vaccine candidates. *Vaccine* 27:565-572, 2009.
484. Lagos R, Muñoz A, Levine MM, Watson W, Chang I, Paradiso P. Immunology of combining CRM(197) conjugates for *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* in Chilean infants. *Vaccine* 27:2299-2305, 2009.
485. Sow SO, Tapia MD, Diallo S, Keita MM, Sylla M, Onwuchekwa U, Pasetti MF, Kotloff KL, Levine MM. *Haemophilus influenzae* Type B conjugate vaccine introduction in Mali: Impact on disease burden and serologic correlate of protection. *Am J Trop Med Hyg*, 80:1033-1038, 2009.
486. Levine MM and Robins-Browne RM. Vaccines, global health and social equity. *Immun Cell Biol* 87:274-278, 2009.
487. Galen JE, Pasetti MF, Tennant S, Oliveira-Ruiz P, Sztein MB, Levine MM. *Salmonella enterica* serovar Typhi Live Vector Vaccines Finally Come of Age. *Immun Cell Biol*, 87:400-12, 2009.
488. Santiago AE, Cole LE, Franco A, Vogel SN, Levine MM, Barry EM. Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. *Vaccine*, 27:2426-36, 2009.
489. Levine MM. Typhoid vaccines ready for implementation (editorial). *NEJM*, 361:403-405, 2009
490. Mandomando I, Macete E, Sigaúque B, Morais L, Quintó L, Sacarlal J, Espasa M, Vallès X, Bassat Q, Aide P, Nhampossa T, Machevo S, Ruiz J, Nhacolo A, Menéndez C, Kotloff KL, Roca A, Levine MM, Alonso PL. Invasive non-typhoidal *Salmonella* in Mozambican children. *Trop Med & Int Hlth*, 14:1467-1474, 2009
491. Vidal RM, Valenzuela P, Baker K, Lagos R, Esparza M, Livio S, Farfán M, Nataro JP, Levine MM, Prado V. Characterization of the most prevalent colonization factor antigens present in Chilean clinical enterotoxigenic *Escherichia coli* strains using a new multiplex polymerase chain reaction. *Diagn Microbiol Infect Dis* 65:217-23, 2009.
492. Lagos R, Muñoz A, Espinoza A, Dowes A, Ruttiman R, Colindres R, Levine MM. Direct medical costs of invasive pneumococcal disease and radiologically-diagnosed pneumonia among Chilean children. *Rev Panam Salud Publica* 26:101-111, 2009 (Spanish)
493. Galen JE, Wang JY, Chinchilla M, Vindurampulle C, Vogel JE, Levy H, Blackwelder WC, Pasetti MF, Levine MM. A new generation of stable, non-antibiotic, low copy number plasmids improve immune responses to foreign antigens in *Salmonella enterica* serovar Typhi live vectors. *IAI* 78:337-47, 2010.
494. Tennant SM, Diallo S, Levy H, Livio S, Sow SO, Tapia M, Fields PI, Mikoleit M, Tamboura B, Kotloff KL, Nataro JP, Galen JE, Levine MM. Identification by PCR of non-typhoidal *Salmonella enterica* serovars associated with invasive infections among febrile patients in Mali. *PLoS-Negl Trop Dis* 4(3):e621 2010

495. Shipley ST, Panda A, Khan AQ, Kriel EH, Maciel M, Livio S, Nataro JP, Levine MM, Sztein MB, DeTolla LJ. A challenge model for *Shigella dysenteriae* 1 in Cynomolgus monkeys (*Macaca fascicularis*). *Comparative Medicine* 60:54-61, 2010.
496. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansa NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomized, double-blind, placebo-controlled trial. *Lancet* 376:606-614, 2010.
497. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. *BMC Biology* 8:129, 2010.
498. Poland GA, Levine MM, Clemens JD. Developing the next generation of vaccinologists. *Vaccine* 82:2887-2888, 2010.
499. Levine MM, Farag T. Invasive *Salmonella* infections and HIV in Northern Tanzania. *Clin Infect Dis*, 52:349-351, 2011.
500. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. *Vaccine volume of Immunological Reviews* 239:125-148, 2011.
501. Wahid R, Pasetti MF, Maciel M Jr, Simon JK, Tacket CO, Levine MM, Sztein MB. Oral priming with *Salmonella* Typhi vaccine strain CVD 909 followed by parenteral boost with the *S. Typhi* Vi capsular polysaccharide vaccine induces CD27(+)IgD(-) *S. Typhi*-specific IgA and IgG B memory cells in humans. *Clin Immunol* 138:187-200, 2010
502. Alonso PL, Arevalo M, Binka F, Brown G, Chitnis C, Collins F, Doumbo O, Greenwood B, Hall L, Levine MM, Mendis K, Plowe C, Rodriguez MH, Sinden R, Slutsker L, Tanner M. A research agenda to underpin malaria eradication. *PLoS Medicine*, 8:e1000406, 2011.
503. Breman JG, de Quadros C A, Dowdle WR, Foege WH, Henderson DA, John T Jacob, Levine MM. The role of research in viral disease eradication and elimination programs: lessons for malaria eradication. *PLoS Medicine* 8:e1000405, 2011.
504. Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R, Levine MM, Pasetti MF. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. *Clin Vaccine Immunol* 18:355-61, 2011.
505. Tennant SM, Zhang Y, Galen JE, Geddes CD, Levine MM. Ultra-Fast and Sensitive Detection of non-typhoidal *Salmonella* using microwave-accelerated metal-enhanced fluorescence ("MAMEF"). *PLoS One* 6:e18700, 2011
506. Simon JK, Maciel M Jr, Weld ED, Wahid R, Pasetti MF, Picking WL, Kotloff KL, Levine MM, Sztein MB. Antigen-specific IgA B memory cell responses to *Shigella* antigens elicited in volunteers immunized with live attenuated *Shigella flexneri* 2a oral vaccine candidates. *Clin Immunol* 139:185-92, 2011
507. Simon R, Tennant SM, Galen JE, Levine MM. Mouse models to assess the efficacy of non-typhoidal *Salmonella* vaccines: Revisiting the role of host innate susceptibility and routes of challenge. *Vaccine* 29:5094-5106, 2011.
508. Mandomando I, Naniche D, Pasetti MF, Cuberos L, Sanz S, Vallès X, Sigauque B, Macete E, Nhalungo D, Kotloff KL, Levine MM, Alonso PL. Assessment of the epidemiology and burden of measles in Southern Mozambique. *Am J Trop Med Hyg* 85:146-151, 2011.
509. Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, Gat O, Levine MM. Engineering and pre-clinical evaluation of attenuated non-typhoidal *Salmonella* strains serving as live oral vaccines and as reagent strains. *Infect Immun* 79:4175-4185, 2011.
510. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, Pasetti MF, Galen JE, Levine MM.

Salmonella Enteritidis Core-O Polysaccharide (COPS) conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with *Salmonella* Enteritidis. *Infect Immun* 79:4240-4249, 2011.

511. Del Canto F, Valenzuela P, Cantero L, Bronstein J, Blanco JE, Blanco J, Prado V, Levine M, Nataro J, Sommerfelt H, Vidal R. Distribution of classical and non-classical virulence genes in enterotoxigenic *Escherichia coli* isolates from Chilean children and tRNA gene screening for putative insertion sites for genomic Islands. *J Clin Microbiol* 49:3198-203, 2011.
-
513. Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered needle-free to healthy young adults by LectraJet® M3 RA disposable-syringe jet injector. *Vaccine* Nov 28;29:9544-50. Epub 2011 Oct 8.
514. Gat O, Galen JE, Tennant SM, Simon R, Blackwelder W, Silverman D, Pasetti MF, Levine MM. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated *Salmonella* Paratyphi A vaccines. *PLoS Neglected Tropical Diseases* 2011 Nov;5(11):e1373. Epub 2011 Nov 1.
515. Wu T, Grassel C, Levine MM, Barry EM. Live attenuated *Shigella dysenteriae* type 1 vaccine strains over-expressing Shiga toxin B subunit. *Infect Immun* Dec;79(12):4912-22. Epub 2011 Oct 3.
516. Boisen N, Scheutz F, Rasko DA, Redman JC, Persson S, Simon J, Kotloff KL, Levine MM, Tamboura B, Panchalingam S, Krogfelt KA, Nataro JP. Genomic characterization of enteroaggregative *Escherichia coli* from children in Mali. *J Infect Dis* 205:431-444, 2011.
517. Levine MM. "Ideal vaccines" for resource poor settings. *Vaccine* Dec 30; 29 Suppl 4:D116-25, 2011.
518. Sabui S, Dutta S, Debnath A, Ghosh A, Hamabata T, Rajendran K, Ramamurthy T, Nataro J, Sur D, Levine M, Chatterjee N. Real time PCR-based mismatch amplification mutation assay for the specific detection of CS6-expressing allelic variants of enterotoxigenic *Escherichia coli* and its application in assessing diarrheal cases and asymptomatic controls". *J Clin Microbiol* Epub Apr;50(4):1308-12. Epub 2012 Jan 4.
519. Hutter J, Pasetti MF, Sanogo D, Tapia MD, Sow SO, Levine MM. Naturally-Acquired and Conjugate Vaccine-induced antibody to *Haemophilus influenzae* type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali. *Am J Trop Med Hyg* 86:1026-31, 2012.
520. Simon R, Levine MM. Glycoconjugate vaccine strategies for protection against invasive *Salmonella* infections. *Hum Vaccin Immunother*. Apr 1;8(4), 2012. [Epub ahead of print]
521. Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. *Vaccine*, Apr 27;30 Suppl 1:A79-85, 2012.
522. Del Canto F, Botkin D, Valenzuela P, Popov V, Ruiz-Pérez F, Nataro J, Levine M, Stine O, Pop M, Torres A, Vidal R. Identification of the Coli Surface Antigen 23 (CS23), a Novel Adhesin of Enterotoxigenic *Escherichia coli*. *IAI* 80(8): 2791-801, 2012.
523. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral Typhoid vaccine Ty21a induces cross-reactive humoral immune responses against *Salmonella enterica* Serovar Paratyphi A and S. Paratyphi B in humans. *Clin Vaccine Immunol* 19:825-34, 2012.
524. Pasetti MF, Levine MM. Insights from natural infection-derived immunity to cholera instruct vaccine efforts. *Clin Vaccine Immunol* 19(11):1707-11, 2012.

525. Orenstein LAV, Orenstein EW, Teguede I, Kodio M, Tapia M, Sow So, Levine MM. Background rates of adverse pregnancy outcomes for assessing the safety of maternal vaccine trials in Sub-Saharan Africa. PLOS ONE7(10):e46638. Epub Octo.4. 2012
526. Levine MM, Kotloff KL, Nataro JP, Muhsen K. The Global Enteric Multicenter Study (GEMS): Impetus, Rationale and Genesis. Clin Infect Dis 2012 Dec;55 Suppl 4:S215-24. doi: 10.1093/cid/cis761.
527. Farag T, Nasrin D, Wu Y, Muhsen K, Blackwelder WC, Nataro JP, Kotloff KL, Levine MM. Some Epidemiologic, Clinical, Microbiologic and Organizational Assumptions that Influenced the Design and Performance of GEMS-1. Clin Infect Dis 2012 Dec;55 Suppl 4:S225-31. doi: 10.1093/cid/cis787.
528. Kotloff KL, Blackwelder WC, Nasrin D, Nataro JP, Farag TH, van Eijk A, Adegbola RA, Alonso PL, Breiman RF, Faruque ASG, Saha D, Sow SO, Sur D, Zaidi AKM, Biswas K, Panchalingam S, Clemens JD, Cohen D, Glass RI, Mintz ED, Sommerfelt H, Levine MM. The Global Enterics Multicenter Study (GEMS) of Diarrheal Disease in Infants and Young Children in Developing Countries: Epidemiologic and Clinical Methods of the Case-Control Study. Clin Infect Dis 2012 Dec;55 Suppl 4:S232-45. doi: 10.1093/cid/cis753.
529. Blackwelder WC, Biswas K, Wu Y, Kotloff KL, Farag TH, Nasrin D, Graubard BI, Sommerfelt H, Levine MM. Statistical Methods in the Global Enteric Multicenter Study. Clin Infect Dis 2012 Dec;55 Suppl 4:S246-53. doi: 10.1093/cid/cis788.
530. Biswas K, Carty T, Horney R, Nasrin D, Farag T, Kotloff KL, Levine MM. Data Management and Other Logistical Challenges for the GEMS – The Data Coordinating Center Perspective. Clin Infect Dis 2012 Dec;55 Suppl 4:S254-61. doi: 10.1093/cid/cis755.
531. Sommerfelt H, Steinsland H, van der Merve L, Blackwelder WC, Nasrin D, Farag TH, Kotloff KL, Levine MM, Gjessing HK. Case-Control Studies with Follow-Up –Constructing the Source Population to Estimate Effects of Risk Factors on Development, Disease and Survival. Clin Infect Dis 2012 Dec;55 Suppl 4:S262-70. doi: 10.1093/cid/cis802.
532. Levine MM, Muhsen K. A Systematic Review and Meta-Analysis of the Association Between *Giardia lamblia* and Endemic Pediatric Diarrhea in Developing Countries. Clin Infect Dis 2012 Dec;55 Suppl 4:S271-93. doi: 10.1093/cid/cis762.
533. Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng B, Oundo J, Ramamurthy T, Tamboura B, Zaidi AKM, Petri W, Houpt E, Murray P, Prado V, Vidal R, Steele D, Strockbine N, Sansonetti P, Glass R, Robins-Browne RM, Tauschek M, Svennerholm A-M, Kotloff KL, Levine MM, Nataro JP. Diagnostic Microbiology Methods in the GEMS-1 Case/Control Study. Clin Infect Dis 2012 Dec;55 Suppl 4:S294-302. doi: 10.1093/cid/cis754
534. Levine MM, Robins-Browne RM. Factors that Explain Excretion of Enteric Pathogens by Persons Without Diarrhea. Clin Infect Dis 2012 Dec;55 Suppl 4:S303-11. doi: 10.1093/cid/cis789
535. Robins-Browne RM, Levine MM. Laboratory Diagnostic Challenges in Case-Control Studies of Diarrhea in Developing Countries. Clin Infect Dis 2012; 2012 Dec;55 Suppl 4:S312-6. doi: 10.1093/cid/cis756.
536. Rheingans R, Kukla M, Adegbola R, Saha D, Breiman RF, Sow SO, Nasrin D, Farag T, Kotloff KL, Levine MM. Exploring Household Economic Impacts of Childhood Diarrheal Illnesses in Three African Settings. Clin Infect Dis 2012 Dec;55 Suppl 4:S317-26. doi: 10.1093/cid/cis763.
537. Rheingans R, Kukla M, Faruque ASG, Sur D, Zaidi AKM, Nasrin D, Farag T, Levine MM, Kotloff KL. Determinants of Household Costs Associated with Childhood Diarrhea in Three South Asian Settings. Clin Infect Dis 2012 Dec;55 Suppl 4:S327-35. doi: 10.1093/cid/cis764.
538. Okoro CK, Kingsley RA, Connor TR, harris SR, Parry CM, Al-Mshhadani MN, Kariuki S, Msefula CL, Gordon MA,

- de Pinna E, Wain J, Heyderman RS, Obarao S, Alonso PL, Mandomando I, Macelennan CA, Tapia MD, Levine MM, Tennant SM, Parkhill J, Dougan G. Intracontinental spread of human invasive *Salmonella* Typhimurium pathovariants in sub-Saharan Africa. *Nat Genet* Sept 30. Doi: 10.1038/ng.2423 2012.
539. Pollard AJ, Savulescu J, Oxford J, Hill AV, Levine MM, Lewis DJ, Read RC, Graham DY, Sun W, Openshaw P, Gordin SB. *Lancet Infect Dis* 2012 Dec;12(12):903-5. doi: 10.1016/S1473-3099(12)70292-X.
540. Mullick S, Mukherjee A, Ghosh S, Pazhani GP, Sur D, Manna B, Nataro JP, Levine MM, Ramamurthy T, Chawla-Sarkar M. Genomic analysis of human rotavirus strains G6P[14] and G11P[25] isolated from Kolkata in 2009 reveals interspecies transmission and complex reassortment events. *Infect Genet Evol* 2013; 14:15-21.
541. Fiorentino M, Lammers KM, Stzein MB, Levine MM. *In vitro* intestinal mucosal epithelial responses to wild-type *Salmonella* Typhi and attenuated vaccines. *Front Immunol* 2013; 4:17 doi: 10.3389/fimmu.2013.00017 Epub, %2013 Feb 12.:17.
542. Barry EM, Pasetti MF, Sztein MB, Fasano A, Koyloff KL and Levine MM. Progress and pitfalls in *Shigella* vaccine research. *Nat Rev Gastroenterol Hepatol* 2013; 10:245-255. doi: 10.1038/nrgastro.2013.12
543. Simon R, Wang JY, Boyd MA, Tulapurkar ME, Ramachandran G, Tennant SM, Pasetti M, Galen JE, Levine MM. Sustained protection in mice immunized with fractional doses of *Salmonella* Enteritidis core and o polysaccharide-flagellin glycoconjugates. *PLoS ONE*. 2013; 8:e64680.
544. Lindsay B, Ochieng JB, Ikumapayi UN, Toure A, Ahmed D, Li S, Panchalingam S, Levine MM, Kotloff K, Rasko DA, Morris CR, Juma J, Fields BS, Dione M, Malle D, Becker SM, Houpt ER, Nataro JP, Sommerfelt H, Pop M, Oundo J, Antonio M, Hossain A, Tamboura B, Stine OC. Quantitative PCR for Detection of *Shigella* Improves Ascertainment of *Shigella* Burden in Children with Moderate-to-Severe Diarrhea in Low-Income Countries. *J Clin Microbiol*. 2013; 51:1740-6.
545. Saha D, Akinsola A, Sharples K, Adeyemi MO, Antonio M, Imran S, Jasseh M, Hossain MJ, Nasrin D, Kotloff KL, Levine MM, Hill PC. Health Care Utilization and Attitudes Survey: Understanding Diarrheal Disease in Rural Gambia. *Am J Trop Med Hyg*. 2013.
546. Nhampossa T, Mandomando I, Acacio S, Nhalungo D, Saco C, Nhacolo A, Macete E, Nhabanga A, Quinto L, Kotloff K, Levine MM, Nasrin D, Farag T, Bassat Q, Alonso P. Healthcare Use and Attitudes Survey in Cases of Moderate-to-Severe Diarrhea among Children Ages 0-59 Months in the District of Manhica, Southern Mozambique. *Am J Trop Med Hyg* 2013.
547. Quadri F, Nasrin D, Khan A, Bokhari T, Sunder TS, Nisar MI, Bhatti Z, Kotloff K, Levine MM, Zaidi AK. Healthcare Use Patterns for Diarrhea in Children in Low-Income Periurban Communities of Karachi, Pakistan. *Am J Trop Med Hyg* 2013.
548. Omere R, O'Reilly CE, Williamson J, Moke F, Were V, Farag TH, van Eijk AM, Kotloff KL, Levine MM, Obor D, Odhiambo F, Vulule J, Laserson KF, Mintz ED, Breiman RF. Health-Seeking Behavior During Childhood Diarrheal Illness: Results of Healthcare Use and Attitude Surveys of Caretakers in Western Kenya, 2007-2010. *Am J Trop Med Hyg* 2013.
549. Levine MM, Kotloff KL, Breiman RF, Zaidi AK. Preface. *Am J Trop Med Hyg* 2013.
550. Farag TH, Kotloff KL, Levine MM, Onwuchekwa U, van Eijk AM, Doh S, Sow SO. Seeking Care for Pediatric Diarrheal Illness from Traditional Healers in Bamako, Mali. *Am J Trop Med Hyg* 2013.
551. Manna B, Nasrin D, Kanungo S, Roy S, Ramamurthy T, Kotloff KL, Levine MM, Sur D. Determinants of Health Care Seeking for Diarrheal Illness in Young Children in Urban Slums of Kolkata, India. *Am J Trop Med Hyg* 2013.
552. Das SK, Nasrin D, Ahmed S, Wu Y, Ferdous F, Dil FF, Hossain KS, Malek MA, el AS, Levine MM, Kotloff KL, Faruque AS. Health Care-Seeking Behavior for Childhood Diarrhea in Mirzapur, Rural Bangladesh. *Am J Trop Med Hyg* 2013.

553. Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque AS, Zaidi AK, Biswas K, van Eijk AM, Levine MM, Kotloff KL. Healthcare-Seeking for Childhood Diarrhea in Developing Countries: Evidence from Seven Sites in Africa and Asia. *Am J Trop Med Hyg* 2013. PMID: 23629939
554. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omere R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acácio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet*. 2013 May 13. doi:pii: S0140-6736(13)60844-2. 10.1016/S0140-6736(13)60844-2. [Epub ahead of print]
555. Farag TH, Faruque AS, Wu Y, Das SK, Hossain A, Ahmed S, Ahmed D, Nasrin D, Kotloff KL, Panchilangam S, Nataro JP, Cohen D, Blackwelder WC, Levine MM. Housefly population density correlates with shigellosis among children in Mirzapur, Bangladesh: a time series analysis. *PLoS Neglected Tropical Diseases* 2013; Jun 20;7(6):e2280. PMID: 23818998.
556. Simon R, Wang JY, Boyd MA, Tulapurkar ME, Ramachandran G, Tennant SM, Pasetti M, Galen JE, Levine MM. Sustained protection in mice immunized with fractional doses of *Salmonella* Enteritidis core and O polysaccharide-flagellin glycoconjugates. *PLoS One*. 2013 May 31;8(5):e64680. doi: 10.1371/journal.pone.0064680. PMID: 23741368.
557. Bhutta ZA, Zipursky A, Wazny K, Levine MM, Black RE, Bassani DG, Shantosham M, Freedman SB, Grange A, Kosek M, Keenan W, Petri W, Campbell H, Rudan I. Setting priorities for development of emerging interventions against childhood diarrhoea. *J Glob Health* 3:10302, 2013.
558. Lindsay B, Pop M, Antonio M, Walker AW, Mai V, Ahmed D, Oundo J, Tamboura B, Panchalingam S, Levine MM, Kotloff K, Li S, Magder LS, Paulson JN, Liu B, Ikumapayi U, Ebruke C, Dione M, Adeyemi M, Rance R, Stares MD, Ukhanova M, Barnes B, Lewis I, Ahmed F, Alam MT, Amin R, Siddiqui S, Ochieng JB, Ouma E, Juma J, Mailu E, Omere R, O'Reilly CE, Hannis J, Manalili S, Deleon J, Yasuda I, Blyn L, Ranken R, Li F, Housley R, Ecker DJ, Hossain MA, Breiman RF, Morris JG, McDaniel TK, Parkhill J, Saha D, Sampath R, Stine OC, Nataro JP. Survey of culture, goldengate assay, universal biosensor assay, and 16S rRNA Gene sequencing as alternative methods of bacterial pathogen detection. *J Clin Microbiol* 51:3263-9, 2013.
559. Ault A, Tennant SM, Gorres JP, Eckhaus M, Sandler NG, Roque A, Livio S, Bao S, Foulds KE, Kao SF, Roederer M, Schmidlein P, Boyd MA, Pasetti MF, Douek DC, Estes JD, Nabel GJ, Levine MM, Rao SS. Safety and tolerability of a live oral *Salmonella* Typhimurium vaccine candidate in SIV-infected nonhuman primates. *Vaccine*. 31:5879-88, 2013.
560. Muhsen K, Cohen D, Levine MM. Can *Giardia lamblia* infection lower the risk of acute diarrhea among preschool children? *J Trop Pediatr* 2013.
561. Kwambana BA, Ikumapayi UN, Sallah N, Dione M, Jarju S, Panchalingham S, Jafali J, Lamin M, Betts M, Adeyemi M, Akinsola A, Bittaye O, Jasseh M, Kotloff KL, Levine MM, Nataro JP, Corrah T, Hossain MJ, Saha D, Antonio M. High Genotypic Diversity among Rotavirus Strains Infecting Gambian Children. *Pediatr.Infect.Dis.J.* 2014; 33 Suppl 1:S69-75. doi: 10.1097/INF.000000000000087.:S69-S75.
562. Muhsen K, Pasetti MF, Reymann MK, Graham DY, Levine MM. *Helicobacter pylori* Infection Affects Immune Responses Following Vaccination of Typhoid-Naive US Adults With Attenuated *Salmonella* Typhi Oral Vaccine CVD 908-htrA. *J Infect Dis* 2013.
563. Chen WH, Greenberg RN, Pasetti MF, Livio S, Lock M, Gurwith M, Levine MM. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR prepared from new master and working cell banks. *Clin Vaccine Immunol* 21:66-73, 2014.
564. Fiorentino M, Levine MM, Stzein MB, Fasano, A. Effect of wild type *Shigella* species and *Shigella* vaccine

- candidates on small intestinal barrier function, antigen trafficking and cytokine release. PLoS One. 2014 Jan 9;9(1):e85211. doi: 10.1371/journal.pone.0085211.
565. Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral *Salmonella* Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with *S. Paratyphi A* and *S. Paratyphi B*. Clin Vaccine Immunol. 21:427-434, 2014.
566. Muhsen K, Lagos R, Reymann MK, Graham DY, Pasetti MF, Levine MM. Age-dependent association among *Helicobacter pylori*, serum pepsinogen levels, and immune response of children to live oral cholera vaccine CVD 103-HgR. PLoS One. 2014 Jan 15;9(1):e83999. doi: 10.1371/journal.pone.0083999. eCollection 2014 Jan 15.
567. Waddington CS, Darton TC, Woodward WE, Angus B, Levine MM, Pollard AJ. Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies. J Infect. 2014 Jan 31. pii: S0163-4453(14)00012-7. doi: 10.1016/j.jinf.2014.01.006.
568. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, Thompson BA, Kerridge SA, Kingsley RA, Zhou L, Holt KE, Yu LM, Lockhart S, Farrar JJ, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ. An outpatient, ambulant design, controlled human infection model using escalating doses of *Salmonella* Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis 58:1230-1240 doi: 10.1093/cid/ciu078 (PMID24519873).
569. Boyd MA, Tennant SM, Saague VA, Simon R, Muhsen K, Ramachandran G, Cross AS, Galen JE, Pasetti MF, Levine MM. Serum bactericidal assays to evaluate typhoidal and non-typhoidal *Salmonella* vaccines. Clin Vaccine Immunol 2014; in press & Epub ahead of print (PMID 24623469).
570. Baker KK, Dil Farzana F, Ferdous F, Ahmed S, Kumar Das S, Faruque AS, Nasrin D, Kotloff KK, Nataro JP, Kolappaswamy K, Levine M. Association between moderate-to-severe diarrhea in the Global Enteric Multicenter Study (GEMS) and types of handwashing materials used by caretakers in Mirzapur, Bangladesh. Am J Trop med Hyg 2014; 91:181-189 (PMID 24778193).
571. Pop M, Walker AW, Paulson J, Lindsay B, Antonio M, Hossain M, Oundo J, Tamboura B, Mai V, Astrovskaya I, Bravo H, Rance R, Stares M, Levine MM, Panchalingam S, Kotloff K, Ikumapayi UN, Ebruke C, Adeyemi M, Ahmed D, Ahmed F, Alam M, Amin R, Siddiqui S, Ochieng JB, Ouma E, Juma J, Mailu E, Omere R, Morris J, Breiman RF, Saha D, Parkhill J, Nataro JP, Stine O. Diarrhea in young children from low income countries leads to large-scale alterations in intestinal microbiota composition. Genome Biol. 2014 Jun 27;15(6):R76. doi: 10.1186/gb-2014-15-6-r76 (PMID 24995464).
572. Livio S, Strockbine N, Panchalingam S, Tennant SM, Barry EM, Marohn ME, Antonio M, Hossain A, Mandomando I, Ochieng JB, Oundo JO, Qureshi S, Ramamurthy T, Tamboura B, Adegbola RA, Hossain MJ, Saha D, Sen S, Faruque AS, Alonso PL, Breiman RF, Zaidi AK, Sur D, Sow SO, Berkeley LY, O'Reilly C, Mintz ED, Biswas K, Cohen D, Farag TH, Nasrin D, Wu Y, Blackwelder WC, Kotloff KL, Nataro JP, Levine MM. *Shigella* isolates from the Global Enteric Multicenter Study (GEMS) inform vaccine development. Clin Infect Dis 2014 Oct;59(7):933-41 (PMID 24958238; PMIC 4166982).
573. Panda A, Tatarov I, Masek BJ, Hardick J, Crusan A, Wakefield T, Carroll K, Yang S, Hsieh YH, Lipsky MM, McLeod CG, Levine MM, Rothman RE, Gaydos CA, DeTolla LJ. A rabbit model of non-typhoidal *Salmonella* bacteremia. Comp Immunol Microbiol Infect Dis 2014 July 3 pii: S0147-9571(14)00024-1. Doi: 10.1016/j.cimid.2014.05.004 [Epub ahead of print] (PMID:25033732).
574. Simon R, Curtis B, Deumic V, Nicki J, Tennant SM, Pasetti MF, Lees A, Wills PW, Chacon M, Levine MM. A scalable method for biochemical purification of *Salmonella* flagellin. Protein Expr Purif July 19;pii: S10406-5928(14)00163-6.doi: 10.1016/j.jpep.2014.07.005 [Epub ahead of print (PMID:25050462).
575. Thompson CN, Kama M, Acharya S, Bera U, Clemens J, Crump JA, Dawainavesi A, Dougan G, Edmunds WJ, Fox K, Jenkins K, Khan MI, Koroivuetu J, Levine MM, Martin LB, Nilles E, Pitzer VE, Singh S, Raiwalu RV, Baker S, Mulholland K. Typhoid fever in Fiji: a reversible plaque? Trop Med Int Health. 2014 Jul 25. doi: 10.1111/tmi.12367. [Epub ahead of print] (PMID: 25066005)

576. Toapanta FR, Simon JK, Barry EM, Pasetti MF, Levine MM, Kotloff KL, Sztein MB. Gut-Homing conventional plasmablasts and CD27(-) plasmablasts elicited after a short time of exposure to an oral live-attenuated *Shigella* vaccine candidate in humans. *Front Immunol.* 2014 Aug 20;5:374. doi: 10.3389/fimmu.2014.00374. eCollection 2014. (PMID: 25191323)
577. Levine MM, Tapia M, Hill AV, Sow SO. How the current West African Ebola virus disease epidemic is Altering views on the need for vaccines and is galvanizing a global effort to field-test leading candidate vaccines. *J Infect Dis* DOI: V10.1093/infdis/jiu513.
578. Mullick S, Mukherjee A, Ghosh S, Pazhani GP, Sur D, Manna B, Nataro JP, Levine MM, Ramamurthy T, Chawla-Sarkar M. Community based case-control study of rotavirus gastroenteritis among young children during 2008-2010 reveals vast genetic diversity and increased prevalence of G9 strains in Kolkata. *PLoS One.* 2014 Nov 17;9(11):e112970. doi: 10.1371/journal.pone.0112970. eCollection 2014. PMID: 25401757.
579. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, Wilkie M, Venkatraman N, Poulton I, Lella N, Roberts R, Sierra-Davidson K, Krähling V, Berrie E, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgiori A, Di Marco S, Cortese R, Becker S, Graham BS, Koup RA, Levine MM, Moorthy V, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.. Safety and immunogenicity of a monovalent chimpanzee adenovirus vaccine candidate targeted at Ebola outbreak control in West Africa. *N Eng J Med* 2015; Jan 28, epub ahead of print (PMID: 25629663).
580. Boyd MA, Tennant SM, Melendez JH, Toema D, Galen JE, Geddes CD, Levine MM. Adaptation of red blood cell lysis represents a fundamental breakthrough that improves the sensitivity of *Salmonella* detection in blood. *J Appl Microbiol* 2015; Jan 29. doi: 10.1111/jam.12769. [Epub ahead of print].
581. Lindsay B, Oundo J, Hossain MA, Antonio M, Tamboura B, Walker AW, Paulson JN, Parkhill J, Omore R, Faruque AS, Das SK, Ikumapayi UN, Adeyemi M, Sanogo D, Saha D, Sow S, Farag TH, Nasrin D, Li S, Panchalingam S, Levine MM, Kotloff K, Magder LS, Hungerford L, Sommerfelt H, Pop M, Nataro JP, Stine OC. Microbiota that affect risk for shigellosis in children in low-income countries. *Emerg Infect Dis.* 2015 Feb;21(2):242-50. doi: 10.3201/eid2101.140795. (PMID 25625766).
582. Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Safety and immunogenicity of a Vi polysaccharide-Tetanus Toxoid conjugate vaccine (Tybbar-TCV™) in healthy infants, children and adults in typhoid endemic areas: a multi-center, two-cohort (open-label/double-blind, randomized, controlled), phase III study. *Clin Infect Dis.* 2015 Apr 13. pii: civ295. [Epub ahead of print]. (PMID 25870324).
583. Donnenberg MS, Hazen TH, Farag TH, Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng JB, Ramamurthy T, Tamboura B, Zaidi A, Levine MM, Kotloff K, Rasko DA, Nataro JP. Bacterial factors associated with lethal outcome of enteropathogenic *Escherichia coli* infection: genomic case-control studies. *PLoS Negl Trop Dis* 2015; May 15;9(5):e0003791. doi: 10.1371/journal.pntd.0003791. eCollection 2015 May. PMID: 25978422.
584. Nhampossa T, Mandomando I, Acacio S, Quintó L, Vubil D, Ruiz J, Nhalungo D, Sacoor C, Nhabanga A, Nhacolo A, Aide P, Machevo S, Sigaúque B, Nhama A, Kotloff K, Farag T, Nasrin D, Bassat Q, Macete E, Levine MM, Alonso P. Diarrheal disease in rural Mozambique: burden, risk factors and etiology of diarrheal disease among children aged 0-59 months seeking care at health facilities. *PLoS One.* 2015; May 14;10(5):e0119824. doi: 10.1371/journal.pone.0119824. eCollection 2015. PMID: 25973880
585. Tennant SM and Levine MM. Live attenuated vaccines for invasive *Salmonella* infections. *Vaccine.* 2015 Apr 19. pii: S0264-410X(15)00482-X. doi: 10.1016/j.vaccine.2015.04.029. PMID: 25902362.
586. Wahid R, Fresnay S, Levine MM, Sztein MB. Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against *Salmonella enterica* serovar Typhi, *S. Paratyphi A*, and *S. Paratyphi B* in humans. *Mucosal Immunol.* 2015 Apr 15. doi: 10.1038/mi.2015.24. [Epub ahead of print]. (PMID 25872480).

587. Travassos MA, Beyene B, Adam Z, Campbell JD, Mulholland N, Diarra SS, Kassa T, Oot L, Sequeira J, Reymann M, Blackwelder WC, Pasetti MF, Sow SO, Steinglass R, Kebede A, Levine MM. Strategies for coordination of a serosurvey with an immunization coverage survey. *Am J Trop Med Hyg* 2015; 93:416-424. (PMID 26055737).
588. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen JA. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. *Lancet* 2015; 386:857-66. doi: 10.1016/S0140-6736(15)61117-5. Epub 2015 Aug 3. (PMID 26248676).
589. Lindsay B, Saha D, Sanogo D, Das SK, Farag TH, Nasrin D, Li S, Panchalingam S, Levine MM, Kotloff K, Nataro JP, Magder L, Hungerford L, Oundo J, Hossain MA, Adeyemi M, Stine OC, Faruque AS. Association between *Shigella* infection and diarrhea varies based on location and age of children. *Am J Trop Med Hyg* 2015; Aug 31. pii: 14-0319. [Epub ahead of print]. (PMID 26324734).
590. Darton TC, Blohmke CJ, Moorthy VS, Altmann DM, Hayden FG, Clutterbuck EA, Levine MM, Hill AV, Pollard AJ. Design, recruitment, and microbiological considerations in human challenge studies. *Lancet Infect Dis* 2015; Jul;15(7):840-51. doi: 10.1016/S1473-3099(15)00068-7. Epub 2015 May 27. Review. (PMID 26026195).
591. Toapanta FR, Bernal PJ, Fresnay S, Darton TC, Jones C, Waddington CS, Blohmke CJ, Dougan G, Angus B, Levine MM, Pollard AJ, Sztein MB. Oral wild-type *Salmonella* Typhi challenge induces activation of circulating monocytes and dendritic cells in individuals who develop typhoid disease. *PLoS Negl Trop Dis* 2015; Jun 11;9(6):e0003837. doi: 10.1371/journal.pntd.0003837. eCollection 2015 Jun. (PMID 26065687).
592. Tennant SM, Schmidlein P, Simon R, Pasetti MF, Galen JE, Levine MM. Refined live attenuated *Salmonella* Typhimurium and Enteritidis vaccines mediate homologous and heterologous serogroup protection in mice. *Infect Immun* 2015; pii: IAI.00924-15. [Epub ahead of print] (PMID 26351285).
593. McArthur MA, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, Blohmke CJ, Dougan G, Angus B, Levine MM, Pollard AJ, Sztein MB. Activation of *Salmonella* Typhi-specific regulatory T cells in typhoid disease in a wild-type *S. Typhi* challenge model. *PLoS Pathog*. 2015 May 22;11(5):e1004914. doi: 10.1371/journal.ppat.1004914. eCollection 2015 May. (PMID 26001081).
594. Omer SB, Richards JL, Madhi SA, Tapia MD, Steinhoff MC, Aqil AR, Wairagkar N; BMGF Supported Maternal Influenza Immunization Trials Investigators Group. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: Methods and expectations. *Vaccine*. 2015 Jul 31;33(32):3801-12. doi: 10.1016/j.vaccine.2015.05.077. Epub 2015 Jun 19. Review. (PMID 26095508).
595. Tennant SM, Toema D, Qamar F, Iqbal N, Boyd MA, Marshall JM, Blackwelder WC, Wu Y, Quadri F, Khan A, Aziz F, Ahmad K, Kalam A, Asif E, Qureshi S, Khan E, Zaidi AK, Levine MM. Detection of Typhoidal and Paratyphoidal *Salmonella* in Blood by Real-time Polymerase Chain Reaction. *Clin Infect Dis*. 2015 Nov 1;61 Suppl 4:S241-50. doi: 10.1093/cid/civ726. (PMID 26449938).
596. Tapia MD, Tennant SM, Bornstein K, Onwuchekwa U, Tamboura B, Maiga A, Sylla MB, Sissoko S, Kourouma N, Toure A, Malle D, Livio S, Sow SO, Levine MM. Invasive Nontyphoidal *Salmonella* Infections Among Children in Mali, 2002-2014: Microbiological and Epidemiologic Features Guide Vaccine Development. *Clin Infect Dis*. 2015 Nov 1;61 Suppl 4:S332-8. doi: 10.1093/cid/civ729. (PMID 26449949; PMC 45969334).
597. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AV, Ballou WR, Sullivan N, Graham B, Levine MM. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis*. 2016 Jan;16(1):31-42. doi: 10.1016/S1473-3099(15)00362-X.. (PMID 26546548; PMC 4700389).

598. Hazen TH, Donnenberg MS, Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng JB, Ramamurthy T, Tamboura B, Qureshi S, Quadri F, Zaidi A, Kotloff KL, Levine MM, Barry EM, Kaper JB, Rasko DA, Nataro JP. Genomic diversity of EPEC associated with clinical presentations of differing severity. *Nat Microbiol*. 2016 Jan 18;1:15014. doi: 10.1038/nmicrobiol.2015.14. PMID: 27571975; PMC 5067155
599. Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant SM, Levine MM. Single-Dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection with *Vibrio cholerae* O1 El Tor. *Clinical Infect Dis*, 2016 Jun 1;62(11):1329-35 (PMID 27001804; PMCID PMC 4872293).
600. Travassos MA, Beyene B, Adam Zenaw, Campbell JD, Mulholland N, Diarra SS, Kassa T, Oot L, Sequeira J, Reymann M, Blackwelder WC, Wu Y, Ruslanova I, Goswami J, Sow SO, Pasetti MF, Steinglass R, Kebede A, Levine MM. Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia. *PLoS One*, 2016, Mar 2;11(3):e0149970. doi: 10.1371/journal.pone.0149970. eCollection 2016. (PMID 26934372; PMC 4774907).
601. Nygren BL, O'Reilly CE, Rajasingham A, Omoro R, Ombok M, Awuor AO, Jaron P, Moke F, Vulule J, Laserson K, Farag TH, Nasrin D, Nataro JP, Kotloff KL, Levine MM, Derado G, Ayers TL, Lash RR, Breiman RF, Mintz ED. The Relationship Between Distance to Water Source and Moderate-to-Severe Diarrhea in the Global Enterics Multi-Center Study in Kenya, 2008-2011. *Am J Trop Med Hyg* Feb 29. pii: 15-0393. [Epub ahead of print]. (PMID 26928833; PMC 4856616).
602. Ramachandran G, Tennant SM, Boyd MA, Wang JY, Tulapurkar ME, Pasetti MF, Levine MM, Simon R. Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal *Salmonella*. *PLoS One*. 2016 Mar 21;11(3):e0151875. doi: 10.1371/journal.pone.0151875. eCollection 2016. PMID 26998925; PMC 4801366.
603. Fresnay S, McArthur MA, Magder L, Darton TC, Jones C, Waddington CS, Blohmke CJ, Angus B, Levine MM, Pollard AJ, Sztein MB. *Salmonella* Typhi-specific multifunctional CD8+T cells play a dominant role in protection from typhoid fever in humans. *J Transl Med* 2016 Mar 1;14(1):62. doi: 10.1186/s12967-016-0819-7. (PMID: 26928826; PMCID: 4772330)
604. Ramachandran G, Boyd MA, MacSwords J, Higginson EE, Simon R, Galen JE, Pasetti MF, Levine MM, Tennant SM. An opsonophagocytic assay to evaluate immunogenicity of non-typhoidal *Salmonella* Vaccines. *Clin Vaccine Immunol*. 2016 Jun 6;23(6):520-3. doi: 10.1128/CVI.00106-16, (PMID 27030587; PMCID: PMC4895007)
605. DeLaine BC, Wu T, Grassel CL, Shimanovich A, Pasetti MF, Levine MM, Barry EM. Characterization of a multicomponent live, attenuated *Shigella flexneri* vaccine. *Pathog Dis*. 2016 July;74(5) pii: ftw034. PMID 27106253; PMC 4895007.
606. Baker KK, O'Reilly CE, Levine MM, Kotloff KL, Nataro JP, Ayers TL, Farag TH, Nasrin D, Blackwelder WC, Wu Y, Alonso PL, Breiman RF, Omoro R, Faruque AS, Das SK, Ahmed S, Saha D, Sow SO, Sur D, Zaidi AK, Quadri F, Mintz ED. Sanitation and hygiene-specific risk factors for moderate-to-severe diarrhea in young children in the Global Enteric Multicenter Study, 2007-2011: case-control study. *PLoS Medicine* 2016; *PLoS Med*. 2016 May 3;13(5):e1002010. doi: 10.1371/journal.pmed.1002010. eCollection 2016 May. (PMID: 27138888) PMCID: PMC4854459.
607. Tapia, MD, Sow, S, Tamboura, B, Teguede I, Pasetti MF, Kodio M, Onwuchekwa U, Tennant SM, Blackwelder WC, Coulibaly F, Traore A, Keita AM, Haidara FC, Diallo F, Doumbia M, Sanogo D, DeMatt, E, Schluterman NH, Buchwald A, Kotloff KL, Chen WH, Orenstein EW, Orenstein LAV, Villanueva J, Bresee J, Treanor JJ, Levine MM. A prospective, active-controlled, observer-blind, randomized Phase 4 trial of the efficacy, safety and immunogenicity of trivalent inactivated influenza vaccine administered to third trimester pregnant women in Mali for the prevention of influenza in their infants up to 6 months of age. *Lancet Infect Dis* 2016; pii: S1473-3099(16)30054-8. doi: 10.1016/S1473-3099(16)30054-8. [Epub ahead of print]. (PMID 27261067).

608. Levine MM and Pasetti MF. Serologic monitoring is key to sustain progress of the maternal and neonatal tetanus elimination initiative. *Clin. Vaccine Immunol.* 2016 Jul 5;23(7):532-4. doi: 10.1128/CVI.00259-16. Print 2016 July (PMID: 27226278 PMCID: PMC4933770)
609. Blohmke CJ, Darton TC, Jones C, Suarez NM, Waddington CS, Angus B, Zhou L, Hill J, Clare S, Kane L, Mukhopadhyay S, Schreiber F, Duque-Correa MA, Wright JC, Roumeliotis TI, Yu L, Choudhary JS, Mejias A, Ramilo O, Shanyinde M, Sztein MB, Kingsley RA, Lockhart S, Levine MM, Lynn DJ, Dougan G, Pollard AJ. Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. *J Exp Med.* 2016 May 30;213(6):1061-77. doi: 10.1084/jem.20151025. Epub 2016 May 23. (PMID 27217537, PMCID: PMC4886356).
610. Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, Panchalingam S, Sur D, Zaidi AK, Faruque AS, Saha D, Adegbola R, Alonso PL, Breiman RF, Bassat Q, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ahmed S, Qureshi S, Quadri F, Hossain A, Das SK, Antonio M, Hossain MJ, Mandomando I, Nhampossa T, Acácio S, Omoro R, Oundo JO, Ochieng JB, Mintz ED, O'Reilly CE, Berkeley LY, Livio S, Tennant SM, Sommerfelt H, Nataro JP, Ziv-Baran T, Robins-Browne RM, Mishcherkin V, Zhang J, Liu J, Houtpt ER, Kotloff KL, Levine MM. The burden of *Cryptosporidium* diarrheal disease among children < 24 months of age in moderate/high mortality regions of sub-Saharan Africa and South Asia, utilizing data from the Global Enteric Multicenter Study (GEMS). *PLoS Negl Trop Dis.* 2016 May 24;10(5):e0004729. doi: 10.1371/journal.pntd.0004729. eCollection 2016 May. (PMID 27219054, PMCID: PMC4878811).
611. Tapia MD, Sow SO, Tamboura B, Tégueté I, Pasetti MF, Kodio M, Onwuchekwa U, Tennant SM, Blackwelder WC, Coulibaly F, Traoré A, Keita AM, Haidara FC, Diallo F, Doumbia M, Sanogo D, DeMatt E, Schluterman NH, Buchwald A, Kotloff KL, Chen WH, Orenstein EW, Orenstein LA, Villanueva J, Bresee J, Treanor J, Levine MM. Maternal immunization with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomized phase 4 trial. *Lancet Infect Dis.* 2016 Sept.16(0):1026-35. doi: 10.1016/S1473-3099(16)30054-8. [Epub 20156 May31] (PMID: 2726106; PMCID: PMC4985566)
612. Toapanta FR, Bernal PJ, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, Blohmke CJ, Angus B, Levine MM, Pollard AJ, Sztein MB. Oral challenge with wild-type *Salmonella* Typhi induces distinct changes in B cell subsets in individuals who develop typhoid disease. *PLoS Negl Trop Dis.* 2016 Jun 14;10(6):e0004766. doi: 10.1371/journal.pntd.0004766. eCollection 2016 Jun. (27300136). (PMID: 27300136, PMCID: PMC4907489)
613. Omoro R, Tate JE, O'Reilly CE, Ayers T, Williamson J, Moke F, Schilling KA, Awuor AO, Jaron P, Ochieng JB, Oundo J, Parashar UD, Parsons MB, Bopp CC, Nasrin D, Farag TH, Kotloff KL, Nataro JP, Panchalingam S, Levine MM, Laserson KF, Nuorti JP, Mintz ED, Breiman RF. Epidemiology, Seasonality and Factors Associated with Rotavirus Infection among Children with Moderate-to-Severe Diarrhea in Rural Western Kenya, 2008-2012: The Global Enteric Multicenter Study (GEMS). *PLoS One.* 2016 Aug 5;11(8):e0160060. doi: 10.1371/journal.pone.0160060. eCollection 2016. PMID: 27494517; PMCID: PMC4975461
614. Qamar FN, Nisar MI, Quadri F, Shakoor S, Sow SO, Nasrin D, Blackwelder WC, Wu Y, Farag T, Panchalingam S, Sur D, Qureshi S, Faruque AS, Saha D, Alonso PL, Breiman RF, Bassat Q, Tamboura B, Ramamurthy T, Kanungo S, Ahmed S, Hossain A, Das SK, Antonio M, Hossain MJ, Mandomando I, Mintz ED, Tennant SM, Kotloff KL, Levine MM, Zaidi AK. Aeromonas-associated diarrhea in children under 5 years: The GEMS Experience. *Am J Trop Med Hyg.* 2016 Oct 5;95(4):774-780 PMID: 27527635, PMCID: 5062620
615. Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BAV, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. *PLoS Negl Trop Dis* 2016 Aug 17;10(8):e0004926. doi: 10.1371/journal.pntd.0004926. PMID: 27533046; PMCID: PMC4988630
616. Feasey NA, Hadfield J, Keddy KH, Dallman TJ, Jacobs J, Deng X, Wigley P, Barquist L, Langridge GC,

- Feltwell T, Harris SR, Mather AE, Fookes M, Aslett M, Msefula C, Kariuki S, Maclennan CA, Onsare RS, Weill FX, Le Hello S, Smith AM, McClelland M, Desai P, Parry CM, Cheesbrough J, French N, Campos J, Chabalgoity JA, Betancor L, Hopkins KL, Nair S, Humphrey TJ, Lunguya O, Cogan TA, Tapia MD, Sow SO, Tennant SM, Bornstein K, Levine MM, Lacharme-Lora L, Everett DB, Kingsley RA, Parkhill J, Heyderman RS, Dougan G, Gordon MA, Thomson NR. Distinct Salmonella Enteritidis lineages associated with enterocolitis in high-income settings and invasive disease in low-income settings. *Nat Genet.* 2016 Oct 48(10):1211-7 doi: 10.1038/ng.3644. PMID: 27548315; PMCID: PMC5047355
617. Wahid R, Fresnay S, Levine MM, Sztein MB. Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a. *Clin Immunol.* 2016 Sep 12. pii: S1521-6616(16)30376-X. doi: 10.1016/j.clim.2016.09.006. [Epub ahead of print] PMID: 27634430; PMC 5322816
618. Higginson EE, Galen JE, Levine MM, Tennant SM. Microgravity as a biological tool to examine host-pathogen interactions and to guide development of therapeutics and preventatives that target pathogenic bacteria. *Pathog Dis.* 2016 Nov;74(8). PMID: 27630185
619. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, Operario DJ, Uddin J, Ahmed S, Alonso PL, Antonio M, Becker SM, Blackwelder WC, Breiman RF, Faruque AS, Fields B, Gratz J, Haque R, Hossain A, Hossain MJ, Jarju S, Qamar F, Iqbal NT, Kwambana B, Mandomando I, McMurry TL, Ochieng C, Ochieng JB, Ochieng M, Onyango C, Panchalingam S, Kalam A, Aziz F, Qureshi S, Ramamurthy T, Roberts JH, Saha D, Sow SO, Stroup SE, Sur D, Tamboura B, Taniuchi M, Tennant SM, Toema D, Wu Y, Zaidi A, Nataro JP, Kotloff KL, Levine MM, Houpt ER. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. *Lancet.* 2016 Sep 24;388(10051):1291-1301. doi: 10.1016/S0140-6736(16)31529-X. PMID: 27673470
620. Koshiol J, Wozniak A, Cook P, Adaniel C, Acevedo J, Azócar L, Hsing AW, Roa JC, Pasetti MF, Miquel JF, Levine MM, Ferreccio C; Gallbladder Cancer Chile Working Group.. Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. *Cancer Med.* 2016 Oct 11. doi: 10.1002/cam4.915. PMID: 27726295; PMC 5119987
621. Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB. The live attenuated cholera vaccine, CVD 103-HgR, primes responses to the toxin-coregulated pilus antigen TcpA in subjects challenged with wild type Vibrio cholera. *Clin Vaccine Immunol.* 2016 Nov 9. pii: CVI.00470-16. PMID: 27847368; PMCID 5119987
622. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Drugeuz B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watte SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Maugé T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). *Lancet.* 2016 Dec 23. pii: S0140-6736(16)32621-6. doi: 10.1016/S0140-6736(16)32621-6. PMID: 28017403; PMC 5364328
623. Ifeonu OO, Simon R, Tennant SM, Sheoran AS, Daly MC, Felix V, Kissinger JC, Widmer G, Levine MM, Tzipori S, Silva JC. Cryptosporidium hominis gene catalog: a resource for the selection of novel Cryptosporidium vaccine candidates. *Database (Oxford).* 2016 Oct 19;2016. pii: baw137. doi: 10.1093/database/baw137. PMID: 28095366; PMC 5070614
624. McArthur MA, Chen WH, Magder L, Levine MM, Sztein MB. Impact of CD4+ T cell responses on clinical outcome following oral administration of Wild-Type Enterotoxigenic Escherichia coli in humans. *PLoS Negl Trop Dis.* 2017 Jan 19;11(1):e0005291. doi: 10.1371/journal.pntd.0005291. PMID: 28103236; PMC 5283752
625. Del Canto F, O'Ryan M, Pardo M, Torres A, Gutiérrez D, Cádiz L, Valdés R, Mansilla A, Martínez R, Hernández D, Caro B, Levine MM, Rasko DA, Hill CM, Pop M, Stine OC, Vidal R. Chaperone-Usher Pili Loci of Colonization

Factor-Negative Human Enterotoxigenic *Escherichia coli*. Front Cell Infect Microbiol. 2017 Jan 6;6:200. doi: 10.3389/fcimb.2016.00200. PMID: 28111618; PMC: 5216030

626. Dobinson HC, Gibani MM, Jones C, Thomaidis-Brears HB, Voysey M, Darton TC, Waddington CS, Campbell D, Milligan I, Zhou L, Shrestha S, Kerridge SA, Peters A, Stevens Z, Podda A, Martin LB, D'Alessio F, Thanh DP, Basnyat B, Baker S, Angus B, Levine MM, Blohmke CJ, Pollard AJ. Evaluation of the clinical and microbiological response to Salmonella Paratyphi A infection in the first paratyphoid human challenge model. Clin Infect Dis. 2017 Feb 4. doi: 10.1093/cid/cix042. [Epub ahead of print] PMID: 28158395
627. Orenstein EW, Orenstein LA, Diarra K, Djiteye M, Sidibé D, Haidara FC, Doumbia MF, Diallo F, Coulibaly F, Keita AM, Onwuchekwa U, Teguate I, Tapia MD, Sow SO, Levine MM, Rheingans R. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS One. 2017 Feb 7;12(2):e0171499. doi: 10.1371/journal.pone.0171499. PMID: 28170416; PMC: 5295679
628. Bornstein K, Hungerford L, Hartley D, Sorkin JD, Tapia MD, Sow SO, Onwuchekwa U, Simon R, Tennant SM, Levine MM. Modeling the Potential for Vaccination to Diminish the Burden of Invasive Non-typhoidal Salmonella Disease in Young Children in Mali, West Africa. PLoS Negl Trop Dis. 2017 Feb 9;11(2):e0005283. doi: 10.1371/journal.pntd.0005283. PMID: 28182657; PMCID: 5300129
629. Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev of Vaccines. 2017 Mar 16;3, 197-213, DOI: 10.1080/14760584.2017.1291348 PMID: 28165831
630. Fresnay S, McArthur MA, Magder LS, Darton TC, Jones C, Waddington CS, Blohmke CJ, Angus B, Levine MM, Pollard AJ, Szein MB. Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. 2017 Mar 2;8:208. doi: 10.3389/fimmu.2017.00208. PMID: 28303138; PMC 5332428
631. Feasey NA, Hadfield J, Keddy KH, Dallman TJ, Jacobs J, Deng X, Wigley P, Barquist Barquist L, Langridge GC, Feltwell T, Harris SR, Mather AE, Fookes M, Aslett M, Msefula C, Kariuki S, Maclennan CA, Onsare RS, Weill FX, Le Hello S, Smith AM, McClelland M, Desai P, Parry CM, Cheesbrough J, French N, Campos J, Chabalgoity JA, Betancor L, Hopkins KL, Nair S, Humphrey TJ, Lunguya O, Cogan TA, Tapia MD, Sow SO, Tennant SM, Bornstein K, Levine MM, Lacharme-Lora L, Everett DB, Kingsley RA, Parkhill J, Heyderman RS, Dougan G, Gordon MA, Thomson NR. Erratum: Distinct Salmonella Enteritidis lineages associated with enterocolitis in high-income settings and invasive disease in low-income settings. Nat Genet. 2017 Mar 30;49(4):651. doi: 10.1038/ng0417-651c. PMID: 28358127;
632. Salerno-Goncalves R, Luo D, Fresnay S, Magder L, Darton TC, Jones C, Waddington CS, Blohmke CJ, Angus B, Levine MM, Pollard AJ, Szein MB. Challenge of Humans with Wild-type *Salmonella enterica* Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. Front Immunol. 2017 April, doi.org/10.3389/fimmu.2017.003981. PMID: 28428786; PMCID: PMC5382150
633. Baliban SM, Yang M, Ramachandran G, Curtis B, Shridhar S, Laufer RS, Wang JY, Van Druff J, Higginson EE, Hegerle N, Varney KM, Galen JE, Tennant SM, Lees A, MacKerell AD Jr, Levine MM, Simon R. Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa. PLoS Negl Trop Dis. 2017 Apr 7;11(4):e0005493. doi: 10.1371/journal.pntd.0005493. eCollection 2017 Apr. PMID: 28388624; PMCID: PMC5397072
634. Salerno-Goncalves R, Luo D, Fresnay S, Magder L, Darton TC, Jones C, Waddington CS, Blohmke CJ, Angus B, Levine MM, Pollard AJ, Szein MB. Challenge of Humans with Wild-type *Salmonella enterica* Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. Front Immunol. 2017 Apr 6;8:398. doi: 10.3389/fimmu.2017.00398. eCollection 2017. PMID: 28428786; PMCID: PMC5382150
635. Schilling KA, Omere R, Derado G, Ayers T, Ochieng J, Farag TH, Nasrin D, Panchalingam S, Nataro JP, Kotloff KL, Levine MM, Oundo J, Parsons MB, Bopp C, Laserson K, Stauber CE, Rothenberg R, Breiman RF, O'Reilly CE, Mintz ED. Factors Associated with the Duration of Moderate-to-Severe Diarrhea among Children in Rural

Western Kenya Enrolled in the Global Enteric Multicenter Study, 2008-2012. *Am J Trop Med Hyg.* 2017 Jul;97(1):248-258. doi: 10.4269/ajtmh.16-0898. PMID: 28719331 PMCID: PMC5508904

636. Kotloff KL, Platts-Mills JA, Nasrin D, Roose A, Blackwelder WC, Levine MM. Summary of workshop "global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques". *Vaccine.* 2017 Jul 29. pii: S0264-410X(17)30944-1. doi: 10.1016/j.vaccine.2017.07.036. [Epub ahead of print]. PMID: 28765005
637. Conan A, O'Reilly CE, Ogola E, Ochieng JB, Blackstock AJ, Omoro R, Ochieng L, Moke F, Parsons MB, Xiao L, Roellig D, Farag TH, Nataro JP, Kotloff KL, Levine MM, Mintz ED, Breiman RF, Cleaveland S, Knobel DL. Animal-related factors associated with moderate-to-severe diarrhea in children younger than five years in western Kenya: A matched case-control study. *PLoS Negl Trop Dis.* 2017 Aug 4;11(8):e0005795. doi: 10.1371/journal.pntd.0005795. eCollection 2017 Aug. PMID: 28783751 PMCID: PMC5559092
638. Meiring JE, Gibani M; TyVAC Consortium Meeting Group: Basnyat B, Bentsi-Enchill A4, Clemens J, Darton TC, Date K, Dougan G, Garrett D, Gessner BD, Gordon MA, Heyderman RS, Hombach J, Kotloff KL, Levine MM, Luby SP, Mohan VK, Marfin AA, Mulholland K, Neuzil K, Pitzer VE, Pollard AJ, Qadri F, Salisbury D, Zaidi A. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK. *Vaccine.* 2017 Sep 12;35(38):5081-5088. doi: 10.1016/j.vaccine.2017.08.001. Epub 2017 Aug 10. PMID: 28802757
639. Arevalillo JM, Sztein MB, Kotloff KL, Levine MM, Simon JK. Identification of immune correlates of protection in Shigella infection by application of machine learning. PMID: 28802838 PMCID: PMC5641263.
640. Cross A, Levine MM. Patterns of bacteraemia aetiology. *Lancet Infect Dis.* 2017 Oct;17(10):1005-1006. doi: 10.1016/S1473-3099(17)30491-7. Epub 2017 Aug 14. PMID: 28818542
641. Feasey NA, Levine MM. Typhoid vaccine development with a human challenge model. *Lancet.* 2017 Sep 28. pii: S0140-6736(17)32407-8. doi: 10.1016/S0140-6736(17)32407-8. [Epub ahead of print. PMID: 28965714
642. Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM. A randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single $\geq 2 \times 10^8$ colony forming units [cfu] standard-dose versus a $\geq 2 \times 10^9$ cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open label immunologic comparator. *Clin Vaccine Immunol.* 2017 Dec 24(12) pii: CVI.00265-17. doi: 10.1128/CVI.00265-17. [Epub ahead of print]. PMID: 29021299
643. Ingle DJ, Valcanis M, Kuzevski A, Tauschek M, Inouye M, Stinear T, Levine MM, Robins-Browne RM, Holt KE. Corrigendum: In silico serotyping of E. coli from short read data identifies limited novel O-loci but extensive diversity of O:H serotype combinations within and between pathogenic lineages. *Microb Genom.* 2017 Aug 1;3(7):e000109. doi: 10.1099/mgen.0.000109. eCollection 2017 Jul. PMID: 29026653; PMCID: PMC5605953
644. Kukla M, McKay N, Rheingans R, Harman J, Schumacher J, Kotloff KL, Levine MM, Breiman R, Farag T, Walker D, Nasrin D, Omoro R, O'Reilly C, Mintz E. The effect of costs on Kenyan households' demand for medical care: why time and distance matter. *Health Policy Plan.* 2017 Oct 5. doi: 10.1093/heapol/czx120. [Epub ahead of print] PMID: 29036378
645. Liu J, Almeida M, Kabir F, Shakoor S, Qureshi S, Zaidi A, Li S, Tamboura B, Sow SO, Mandomando I, Alonso PL, Ramamurthy T, Sur D, Kotloff K, Nataro J, Levine MM, Stine OC, Houpt E. Detection of Shigella in direct stool specimens using a metagenomic approach. *J Clin Microbiol.* 2017 Nov 8. pii: JCM.01374-17. doi: 10.1128/JCM.01374-17. [Epub ahead of print]

Books and Book Chapters:

1. DuPont HL, Levine MM, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Oral Attenuated Vaccines in the Control of Shigellosis. Internatio/nal Conference of the Application of Vaccines Against Viral, Rickettsial, and Bacterial Diseases of Man, December 14-18, 1970. Pan American Health Organization/World Health Organization. Scientific Publication #226, Washington, D.C., pp. 364-367, 1971.
2. Levine MM, DuPont HL, Hornick RB, Gangarosa EJ, Formal SB, Snyder MJ, Libonati JP, Vacuna de Shigella dysenteriae-1 (Shiga) in "Symposium on Shiga Dysentery in Central America." Pan American Health Organization Scientific Publication #283, Washington, D.C., 1974.
3. Levine MM. Epidemiologic and Sereoepidemiologic Methods in Evaluation of the Endemicity of Typhoid Fever in Peru (Dissertation for D.T.P.H.) Copyright University of London, 1974.
4. Levine MM, Craig JP, Pierce NF, Waterman D, Caplan ES, Libonati JP. The Immune Response to Parenteral and Oral Cholera Toxoid in Volunteers. Proceedings of the 12th Joint Conference, U.S.-Japan Cooperative Medical Science Program Cholera Panel. Sapporo, Japan, October 6-8, 1976.
5. Levine MM. Bacillary Dysentery. In: Conn H (ed.), Current Diagnosis. Philadelphia: WB Saunders, Co., 1976.
6. Levine MM, Rennels MB, Bacillary Dysentery. In: Conn, H., (ed.), *Current Therapy*, 31st Ed. Philadelphia: W.B. Saunders and Co., 1979.
7. Levine MM. Immunity to Cholera as Evaluated in Volunteers. In Nobel Symposium on Cholera and Related Diarrhoeas, 43rd Stockholm, 1978. Cholera and Related Diarrhoeas: Molecular Aspects of a Global Health Problem. Editors O Ouchterlony and J Holmgren. S Karger, Basel, 1980.
8. Levine MM, Hornick RB. Immunology of Enteric Pathogens - Salmonella, Shigella and *E. coli*. In: Nahmias A, and O'Reilly R, (Eds.), Immunology of Human Infections, Volume 11. Plenum, New York: pp. 249-290, 1981.
9. Levine MM. Shigellosis. In: Top FH, Jr, and Wehrle PF, (Eds.), Communicable and Infectious Diseases, 9th Edition. St. Louis: Mosby Co., pp. 569-576, 1981.
10. Levine MM and Cisneros L. Typhoid Fever. In: Conn FH, (Ed.), Current Therapy. Philadelphia: W.B. Saunders Co., 1981
11. Clements ML, Levine MM, *Vibrio cholerae*, *Escherichia coli*, and Related Diarrheal Infections. In: Stanford JP, and Luby JP, (Eds.), The Science and Practice of Clinical Medicine. York: Grune and Stratton, pp.282-287, 1981
12. Levine MM. Adhesion of Enterotoxigenic *Escherichia coli* in Man and Animals. In: Taylor-Robinson D, (ed.), Adhesion and Pathogenicity. Ciba Symposium: pp.142-154, 1981.
13. Clements ML, Levine MM, Black RE, Treatment of Enteric Infections and Combinations. In: Hitchings GH, (ed.), Handbook of Experimental Pharmacology. Vol. on "Sulfonamides, Trimethoprim and Combinations." Springer-Verlag, New York: Chap. 17, pp.357-378, 1982.
14. Levine MM, Clements ML, Black RE, Hughes TP, Cleaves TF, Oral Rehydration with Simple Sugar/Salt Solutions as an Alternative in Rural Areas when Glucose/Electrolyte Solutions are Unavailable. In: Holme T, Holmgren J Eds., Acute Enteric Infections in Children: New Prospects for Treatment and Prevention. Elsevier, Amsterdam: pp.325-331, 1981.
15. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA, Volunteer Studies in Development of Vaccines Against Cholera and Enterotoxigenic *Escherichia coli*: A Review. In: Holme T, Holmgren J, Eds., Acute

- Enteric Infections in Children: New Prospects for Treatment and Prevention. Elsevier, Amsterdam: pp.443-459, 1981.
16. Levine MM. Myth and Reality in the Management of Diarrhea. In: Simpson TW, Strickland GT, Mercer MA, Eds., New Developments in Tropical Medicine II. National Council for International Health, Washington, D.C., 1983.
 17. Levine MM. Cholera. In: Gellis SS, Kagan GM, Eds., Current Pediatric Therapy, 11th edition. Saunders, Philadelphia: pp. 609-611, 1984.
 18. Levine MM. Vaccine Against *Escherichia coli* Infections. In: Germanier R, Ed., Bacterial Vaccines, Chapter 7. New York: Academic Press, pp. 187- 235, 1984.
 19. Formal SB, Levine MM, Shigellosis. In: Germanier R, Ed., Bacterial Vaccines, Chapter 6. Orlando: Academic Press, pp. 167-186, 1984.
 20. Levine MM, Black R, Clements ML, Pathogenesis of Enteric Infections Caused by *Vibrio*. In: Colwell R, Ed., Vibrios in the Environment, Chapter 7. New York: Academic Press, pp. 109-122, 1984.
 21. Levine MM. Immunization Against Infectious Diarrhoeas. Chapter 12, In: Gracey M, Ed., Diarrhoeal Disease and Malnutrition: A Clinical Update. London: Churchill Livingstone, pp 183-200, 1985.
 22. Kaper JB, Levine MM, Lockman HA, Baldini MM, Black RE, Clements ML, Morris JG, Development and Testing of Recombinant Live Oral Cholera Vaccine. Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial and Viral Diseases. Cold Spring Harbor Laboratories, pp. 107- 111, 1985.
 23. Morris JG, Michalski J, Wright AC, Kaper JB, Kaviti JN, Kinoti S, Mohamed AJ, Turkish J, Mhalu FS, Levine MM, Molecular Epidemiology of Antibiotic- Resistant Cholera in East Africa. In: S. Kuwahara, and N.F. Pierce (eds.), Advances in Research on Cholera and Related Diarrhea. Vol. 4, Tokyo: KTK Scientific Publishers, 1988, 17-22.
 24. Levine MM, Kaper JB, Black RE, Clements ML, Morris JG, Landmarks on the Road Toward a Live Oral Attenuated Cholera Vaccine. In: Proceedings of the 20th U.S.-Japan Joint Conference on Cholera, 1984. Martinus-Nijhoff Publishers, in press.
 25. Levine MM, Black RE, Clements ML, Young CR, Cheney CP, Schad P, Collins H, Boedeker EC, Prevention of Enterotoxigenic *Escherichia coli* Diarrheal Infection in Man by Vaccines that Stimulate Antiadhesion (Anti-Pili) Immunity. In: Boedecker EC (ed.), Attachment of Organisms to the Gut Mucosa. Boca Raton: CRC Press, pp. 223-244, 1984.
 26. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Rooney J, Chilean Typhoid Committee, The Efficacy of Attenuated *Salmonella typhi* Oral Vaccine Strain Ty21a Evaluated in Controlled Field Trials. In: J Holmgren, A Lindberg, R Mollby, Proceedings of the Nobel Conference on Recent Advances in Vaccines and Drugs against Diarrhoeal Diseases, Stockholm, June 3-6, 1985. Student Literatur, Gothenberg, pp. 90-101, 1986.
 27. Levine MM, Morris JG, Losonsky G, Boedeker E, Rowe B, Fimbriae (pili) Adhesins as Vaccines. In: Lark D, Normak S, Brent-Uhlin E, Eds., Protein-Carbohydrate Interactions in Biological Systems. London: Academic Press, pp. 143-145, 1986.
 28. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Sears S, Morris JG, Cisneros L, Germanier R, Chilean Typhoid Commission, Interventions to Control Endemic Typhoid Fever: Field Studies in Santiago, Chile. In: Control and Eradication of Infectious Diseases. An International Symposium. PAHO Copublication Series No. 1, Pan American Health Organization, Washington, D.C., 1986, pp.37-53.
 29. Levine MM, Kaper JB, Morris JG, Herrington D, Losonsky G, Tall B, Hall R, Reactogenicity, Colonizing Capacity, and Immunogenicity of Further Attenuated, Genetically-Engineered *Vibrio cholerae* 01 Vaccine Strains. In: Proceedings of the 21st U.S.-Japan Joint Conference on Cholera, 1985. Martinus-Nijhoff Publishers, in press.

30. Levine MM, Tramont EC, Vaccines Against Enteric Infections. In: Branski D, Pinari G, Rozen P, Walker-Smith J, Eds., Pediatric Gastroenterology: Aspects of Immunology and Infections. Karger, Basel, pp. 355-369, 1986.
31. Holmgren J, Svennerholm A-M, Clemens J, Sack D, Black R, Levine M. An Oral B Subunit-Whole Cell Vaccine Against Cholera: From Concept to Successful Field Trial. In: Meslecky J., ed. Proceedings of the International Congress on Mucosal Immunology, Niagara Falls, 1986.
32. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Rooney J, Field Trials of Efficacy of Attenuated *Salmonella typhi* Oral Vaccine Strain Ty21a. In: Robbins JB, Ed., Proceedings of International Symposium on Bacterial Vaccines, Bethesda, 1984. New York, Praeger Press, pp. 79-89, 1987.
33. Levine MM. Typhoid Fever Vaccines. In: Vaccines. Plotkin SA, Mortimer A, Jr., eds. Philadelphia, W.B. Saunders Company, pp. 333-361, 1988.
34. Kapikan AZ, Flores J, Hoshino Y, Midthun D, Green KY, Gorziglia M, Chanock RM, Potash L, Perez-Schael I, Gonzalez M, Vesikari T, Gothefors L, Wadell G, Glass RI, Levine MM, Rennels MB, Losonsky GA, Christy C, Dolin R, Anderson EL, Belshe RB, Wright PF, Santosham M, Halsey NA, Clements ML, Sears SD, Steinhoff MC, Black RE. Rationale for the development of rotavirus vaccine for infants and young children. In: Talwar, ed. Progress in Vaccinology. Springer-Verlag, 1989:150-180.
35. Levine MM. Development of vaccines against bacteria. In: Enteric Infection. Farthing MJG, Keusch GT, eds. Chapman and Hall, London 1989, pp. 495-508.
36. Levine MM, Woodrow GC (eds). New Generation Vaccines, 1st ed., New York: Marcel Dekker, Inc., 979 pages, 1990.
37. Levine MM. Vaccines and Vaccination in the Historical Perspective. In: New Generation Vaccines: The Molecular Approach. Woodrow GC, Levine MM, eds. New York, Marcel Dekker, Inc. 1990, pp 3-19.
38. Levine MM, Hone D, Stocker B, Cadoz M. New and Improved Vaccines to Prevent Typhoid Fever. In: New Generation Vaccines: The Molecular Approach. Woodrow GC, Levine MM, eds. New York, Marcel Dekker, Inc., 1990, pp 269-288.
39. Levine MM Vaccines against enterotoxigenic *Escherichia coli* infections. Vaccines based predominantly on antibacterial immunity. In: The Molecular Approach. Woodrow GC, Levine MM, eds. New York, Marcel Dekker, Inc., 1990, pp 649-660.
40. Levine MM. Typhoid fever and enteric fever. In: Current therapy in infectious diseases 3. Kass E, Platt R, eds. BC Decker, Inc, Philadelphia, 1990, pp. 143-145.
41. Levine MM, Edelman R. Future vaccines against enteric pathogens. In: Immunization of Adults I: Infectious Disease Clinics of North America. Schaffner W, ed. Saunders Co, Philadelphia, 1990, pp. 105-1217.
42. Levine MM. Vaccines against enteric infections. In: Diarrheal Diseases, Field M, ed. Elsevier, New York, 1991, Chapter 20, pp 455-484.
43. Kaper JB, Levine MM. Cholera. In: Vaccines and Immunotherapy. Cryz SJ, ed. Pergamon Press, Inc., New York, 1991, Chapter 6, pp. 73-85.
44. Levine MM. Typhoid fever. In: Vaccines and Immunotherapy. Cryz SJ, ed. Pergamon Press, Inc., New York, 1991, Chapter 5, pp. 59-73.
45. Levine MM. Shigellosis. In: Hunter's Tropical Medicine, 7th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1991, Chapter 37, pp.340-344.
46. Levine MM. Diarrhea caused by *Escherichia coli*. In: Hunter's Tropical Medicine, 7th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1991, Chapter 41.1, pp. 377-381.

47. Savarino S, Levine MM. Specific and non-specific treatment of diarrhea. In: Infectious Diseases. Gorbach SL, Bartlett JG, Blacklow NR, eds. WB Saunders, Philadelphia, 1992, Chapter 86, pp 638-646.
48. Levine MM, Pierce NF. Immunity and vaccine development. In: Greenough WB III & Barua D, eds. Cholera. Plenum Press, New York, 1992, Chapter 14, pp. 285-327.
49. Levine MM, Noriega F. Vaccines to prevent enteric infections. *Bailliere's Clinical Gastroenterology* 7:501-17, 1993.
50. Levine MM, Hone DM, Tacket CO, Sztein MB, Losonsky GA, Nataro JP, Gonzalez C, Dougan G, Chatfield S, Cryz S, Curtiss R, Kelley S. Attenuated *Salmonella typhi* as live oral vaccines to prevent typhoid fever and as carrier vaccines to express foreign antigens. In: Cabello F, Hormaeche C, Mastroeni P, Bonina L, eds. *Biology of Salmonella*, Plenum Press, New York, 1993, p. 343.
51. Levine MM, K. Shigellosis. In: *Current Pediatric Therapy*, 14th edition, Burg FD, Ingelfinger JR, Wald ER, eds., W.B. Saunders Co., Philadelphia, pp.574-575, 1993.
52. Levine MM. Typhoid fever. In: *Current Pediatric Therapy*, 14th edition, Burg FD, Ingelfinger JR, Wald ER, eds., W.B. Saunders Co., Philadelphia, pp.575-576, 1993.
53. Nataro JP, Levine MM. *Escherichia coli* infections of humans. In: Gyles C, ed. *Escherichia coli* in Animals. CAB International, Wallingford. Chapter 13, pp. 285-335, 1994.
54. Hone DM, Tacket CO, Levine MM, Hasday J, Harris AM. Induction of tumor necrosis factor secretion from U937 macrophage-like cells after infection with *Salmonella typhi*. *Vaccines 93*, Cold Spring Harbor Laboratory Press, 1993.
55. Levine MM, Giron J, Noriega F. Fimbrial vaccines. In: *Fimbriae: Adhesion, Biogenics, Genetics and Vaccines*. Klemm P, ed., CRC Press, Boca Raton, Chapter 18, pp 255-276, 1994.
56. Levine MM, Tacket CO. Recombinant live cholera vaccines. in: *Vibrio cholerae* and Cholera. Wachsmuth IK, Blake P, Olsvik S, eds. *Am Soc Microbiol*, Washington, D.C., Chapter 26, pp395-413, 1994.
57. Levine MM. Typhoid Fever Vaccines. In: *Vaccines*. Plotkin SA, Mortimer A, Jr., eds. Philadelphia, W.B. Saunders Company, Chapter 21, pp. 597-633, 1994.
58. Levine MM, Nataro JP. Intestinal infections. In: *Mucosal Immunology, Vol.2 Mucosal Diseases*. Ogra P, Mestecky J, Lamm M, Strober W, Bienenstock J, McGhee JR, eds.. Academic Press, San Diego, Chapter 41, pp 505-512, 1994.
59. Levine MM, Savarino S. The treatment of acute diarrhea. Chapter 21. In: Owen R, Surawicz C, eds., W.B. Saunders, Philadelphia, pp 519-536, 1995.
60. Fouts TR, Tacket CO, Levine MM, Lewis GK, Hone DM. Expression of human immunodeficiency virus envelope protein, recombinant gp120, in an attenuated *salmonella typhi* vector vaccine. Chapter 44. In: *Recombinant and synthetic vaccines*. Talwar GP, Rao KVS, Chauhan VS, eds. Narosa Publishing House, New Delhi, pp. 352-356, 1994.
61. Levine MM. Development of bacterial vaccines. In: *Infections of the gastrointestinal tract*. Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Raven Press, New York, 1995, pp 1441-1470.
62. Levine MM, Tacket CO. Live oral vaccines against cholera. In: Ala'Aldeen D, Hormaeche C, eds. *Molecular and clinical aspects of bacterial vaccine development*. John Wiley & Sons, Chichester, 1995, pp. 233-258.
63. Levine MM. Vaccines against typhoid fever. In: Ala'Aldeen D, Hormaeche C, eds. *Molecular and clinical aspects of bacterial vaccine development*. John Wiley & Sons, Chichester, 1995, pp.155-178.

64. Levine MM, Levine OS. Changes in human ecology and behaviour in relation to the emergence of diarrheal diseases, including cholera. In: Infectious diseases in an age of change. Roizman B, ed. National Academy Press, Washington, D.C., 1995, pp. 31-42.
65. Levine MM. Non-target effects of live vaccines: myth, reality and demagoguery. In: Non-target effects of live vaccines. Developments in Biological Standardization vol. 84;33-38, 1995, Karger, Basel.
66. Levine MM, Kaper JB. Cholera: pathogenesis and vaccine development. In: Drasar B, Forrest B, eds., Cholera and the Ecology of Cholera. Chapman and Hall, 1996. Chapter 5, pp. 125-186.
67. Levine MM, Noriega F. Vaccines against diarrheal disease, dysentery and enteric fever. In: Gracey M and Walker-Smith JA, Diarrheal Disease. Nestlé Nutrition Workshop Series volume 38, Lippincott-Raven, Philadelphia, 1997, pp. 139-151
68. Levine MM, Woodrow GC, Kaper JB, and Cobon GS (eds). New Generation Vaccines 2nd ed. New York: Marcel Dekker, Inc., 1214 pages, 1997
69. Kotloff KK, Levine MM. *Shigella* infections. In: LaMont JT, ed., Gastrointestinal Infections. Diagnosis and Management. Chapter 9, Marcel Dekker, New York, 1997, pp. 265-291.
70. Mintz ED, Tauxe RV, Levine MM. The global resurgence of cholera, Chapter 3, in: Communicable Disease: Epidemiology and Control. Noah N and O'Mahony M, eds., John Wiley & Sons, Chichester, 1998, pp.63-104.
71. Savarino S, Levine MM. Specific and non-specific treatment of diarrhea. In: Infectious Diseases. Gorbach SL, Bartlett JG, Blacklow NR, eds. WB Saunders, Philadelphia, 1998, Chapter 83, pp 781-788.
72. Levine MM. Typhoid Fever Vaccines. In: Vaccines. Plotkin SA, Orenstein W, eds. Philadelphia, W.B. Saunders Company, 1999, Chapter 33, pp 781-814.
73. Levine MM. Immunoprophylaxis of Shiga toxin-producing *Escherichia coli* infection and disease: strengths and weaknesses of various strategies. In: *Escherichia coli* O157:H7 and other Shiga toxin-producing *E. coli* strains. Kaper JB and O'Brien AD, eds. ASM Press, Washington, DC, 1998, Chapter 40, pp.405-408.
74. Levine MM. Typhoid Fever. In: Bacterial infections of humans: epidemiology and control, Evans AS, Brachman PS, eds. Plenum Medical, New York, 1998. Chapter 42, pp 839-858.
75. Levine MM and Vial P. Typhoid Fever. In: Current Pediatric Therapy, 16th edition, Burg FD, Ingelfinger JR, Wald ER, Polin RA, eds., W.B. Saunders Co., Philadelphia, pp. 100-101, 1998.
76. Nataro JP and Levine MM. Enteric bacterial vaccines: *Salmonella*, *Shigella*, cholera, *Escherichia coli*. In: Mucosal Immunology, 2nd ed. Ogra P, Mestecky J, Lamm M, Strober W, Bienenstock J, McGhee JR, eds.. Academic Press, San Diego, Chapter 53, pp 851-866, 1999.
77. Levine MM, Barry E, Nataro JP, Kaper JB. The molecular epidemiology of 19th century cholera. In: Digging for Pathogens. Ancient Emerging Diseases B Their Evolutionary, Anthropological and Archaeological Context. Greenblatt C, ed. Balaban Publishers, Rehovot, Chapter 13, pp 265-276, 1998.
78. Levine MM. Shigellosis. In: Hunter's Tropical Medicine, 8th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1999, Chapter 40, pp. 319-323.
79. Levine MM. Diarrhea caused by *Escherichia coli*. In: Hunter's Tropical Medicine, 8th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1999, Chapter 42, pp. 334-338.
80. Levine MM, Gotuzzo E. Cholera. In: Tropical Infectious Diseases. Principles, Pathogens and Practice. Guerrant RL, Walker DH, Weller PF, eds. Churchill Livingstone, Philadelphia, 1999. Volume I, Chapter 26, pp. 326-335.

81. Levine MM, Sztein MB. *Shigella, Salmonella typhi, Escherichia coli*. In: Effects of Microbes of the Immune System. Cunningham MW, Fujinami RS, eds. Lippincott-Raven Publishers, Philadelphia. Chapter 12, 2000, pp. 171-194.
82. Levine MM, Galen JE, Barry E, Tacket CO, Kotloff K, Gomez-Duarte O, Pasetti MF, Sztein MB. Live vectors: have they delivered? In "Fighting Infection". Blackwell Science, London, 2000, pp. 72-86.
83. Levine MM, Levine OS. Disease burden, public perception and other factors that influence new vaccine development, implementation and continued use. In: Progress in Vaccinology. Richard Moxon, ed., Euromed Communications, Ltd., Surrey, UK, 2000, Chapter 3, pp. 27-45.
84. Levine MM, Svennerholm AM. Enteric Vaccines: Present and Future. In: The Textbook of Travel Medicine and Health, 2nd ed. DuPont HL, Steffen R., eds. B.C. Decker, Inc., Hamilton, Ontario, 2001. Chapter 22.3, pp. 252-263.
85. LevineMM, Gotuzzo E. Cholera. In: Essentials of Tropical Infectious Diseases. Guerrant RL, Walker DH, Weller PF, eds. Churchill Livingstone, Philadelphia, Pennsylvania, 2001. Chapter 19, pp. 163-167.
86. Levine MM. Bacterial Enteric Vaccines. In: Infections of the gastrointestinal Tract, 2nd ed. Blaser MB, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL. Eds. Lippincott, Williams & Wilkins, Philadelphia 2002. Chapter 80, pp. 1251-1271.
87. Levine MM, Galen JE, Barry E, Pasetti MF, Tacket, CO, Sztein MB. Attenuated *Salmonella* and *Shigella* Live Vectors. In: Vaccine Delivery Strategies. Dietrich G, Goebel W eds. Horizon Scientific Press, Norfolk, UK 2002. Chapter 8, pp 185-210.
88. Levine MM, Donnenberg MS. *Escherichia coli* vaccines. In: New Bacterial Vaccines. Ellis RW, Brodeur BR eds. Landes Bioscience, Georgetown, Texas 2003. Chapter 8, pp 110-127.
89. Levine MM, Kaper JB, Rappuoli R, Liu M, Good M (eds). New Generation Vaccines, 3rd ed., New York: Marcel Dekker, Inc., 1117 pages, 2004.
90. Campbell JD, Kotloff KL, Levine MM. Specific and non-specific treatment of diarrhea. In: Infectious Diseases, 3rd ed. Gorbach SL, Bartlett JG, Blacklow NR, eds. Lippincott Williams & Wilkins, Philadelphia 2004. Chapter 78, pp. 702-710.
91. Levine MM. Vaccines and Vaccination in Historical Perspective. In: New Generation Vaccines, 3rd Ed. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF eds. Marcel Dekker, Inc., New York 2004. Chapter 1, pp. 1-10.
92. Galen JE, Pasetti MF, Sztein MB, Barry EM, Levine MM. Attenuated *Salmonella* and *Shigella* as Live Vectors Carrying Either Prokaryotic or Eukaryotic Expression Systems. In: New Generation Vaccines, 3rd Ed. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF eds. Marcel Dekker, Inc., New York 2004. Chapter 30, pp. 353-365.
93. Levine MM, Campbell JD. Mucosal Immunization and Needle-Free Injection Devices. In: New Generation Vaccines, 3rd Ed. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF eds. Marcel Dekker, Inc., New York 2004. Chapter 33, pp. 393-399.
94. Levine MM, Galen J, Tacket CO, Barry EM, Pasetti MF, Sztein MB. Attenuated Strains of *Salmonella enterica* serovar Typhi as Live Oral Vaccines Against Typhoid Fever. In: New Generation Vaccines, 3rd Ed. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF eds. Marcel Dekker, Inc., New York 2004. Chapter 41, pp. 479-486.
95. Barry EM, Levine MM. Multivalent *Shigella*/Enterotoxigenic *Escherichia coli* Vaccine. In: New Generation Vaccines, 3rd Ed. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF eds. Marcel Dekker, Inc., New York 2004. Chapter 61, pp. 751-754.
96. Campbell JD, Levine MM. Typhoid and Cholera Vaccines. In: Travelers' Vaccines. Jong EC and Zuckerman JN eds. BC Decker, Inc., London 2004. Chapter 7, pp. 162-184.

97. Nataro JP, Levine MM. New Vaccine Technologies. In: Topley and Wilson's Microbiology and Microbial Infections: Immunology Volume. Kaufmann SH & Steward M, eds. Edward Arnold, Ltd, London 2005. Chapter 41, pp 837-852,
98. Levine MM, Lepage P. In: Hot Topics in Infection and Immunity in Children II. Pollard AJ and Finn A eds. Springer Science+Business Media 2005, New York 2005. Chapter 11, pp 161-173.
99. Levine MM. Mass Vaccination to Control Epidemic and Endemic Typhoid Fever. In: Mass Vaccination: Global Aspects – Progress and Obstacles. Plotkin SA ed. Springer-Verlag Berlin Heidelberg 2006. CTMI Vol. 304, pp 231-246
100. Graves P and Levine MM . Battling Malaria. Strengthening the US Military Malaria Vaccine Program. The National Academies Press, Washington, DC, 2006.
101. Levine MM and Svennerholm A-M. Immunoprophylaxis and Immunologic Control. In: Travelers' Diarrhea 2nd Ed. Ericsson CD, DuPont HL and Steffen R eds. BC Decker, Hamilton, Ontario 2008. Chapter 23, pp 215-232.
102. Levine MM. Typhoid fever vaccines. In: Vaccines, 5th edition. Plotkin SA, Orenstein WA and Offit PA eds. Saunders – Elsevier, United Kingdom 2008. Chapter 34, pp 887-914.
103. Levine MM. Typhoid Fever. In: Bacterial Infections of Humans: epidemiology and control, 4th ed. Brachman PS, and Abrutyn E eds. Springer Science+Business Media, New York, 2009. Chapter 43, pp 913-937.
104. Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R (eds). New Generation Vaccines, 4th ed., New York: Informa Healthcare USA, Inc., 1011, 2010.
105. Levine MM, Lagos R, Esparza J. Vaccines and Vaccination in Historical Perspective. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 1, pp. 1-11.
106. Levine MM, Lagos R, Esparza J. Vaccines and Vaccination in Historical Perspective. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 1, pp. 1-11.
107. Galen JE, Pasetti, MF, Tennant S, Sztejn MB, Levine MM Engineering of Attenuated *Salmonella enterica* Serovars for Use as Live Vector Vaccines. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 36, pp. 375-385.
108. Simon JK, Levine MM, Weniger BG, Restrepo AMH Mucosal Immunization and Needle-Free Injectin Devices. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 39, pp. 405-414.
109. Levine MM, Galen JE, Pasetti JF, Sztejn MB. Attenuated Strains of *Salmonella enterica* Serovars Typhi and Paratyphi as Live Oral Vaccines Against Enteric Fever. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 48, pp. 497-505.
110. Pasetti MF, Ramirez K, Kotloff KL, Barry EM, Levine MM. Novel Strategies for Immunizing Infants in Developing Countries who are too Young to Receive the Currently Licensed Meases Vaccines. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 54, pp. 579-584
111. Kotloff KL, Barry EM, Levine MM, Hale TL, Sansonetti P. Overview of live and Subcellular Vaccine Strategies Against *Shigella*. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 64, pp. 700-713.

112. Barry EM and Levine MM. Multivalent *Shigella* Enterotoxigenic *Escherichia coli* Vaccine. In: New Generation Vaccines, 4th Ed. Levine MM, Dougan G, Good MF, Liu MA, Nabel G, Nataro, JP, Rappuoli R, eds. Informa Healthcare USA, Inc., New York 2010. Chapter 66, pp. 723-727.
113. Levine MM, Tapi M, Zaidi A. Typhoid and Paratyphoid (Enteric) Fever. In: Tropical Infectious Diseases, 3rd Ed. Guerrant RL, Walker DH, Weller PF eds. US Elsevier, New York 2011. Chapter 16, pp. 121-127
114. Levine MM, Saha D, Faruque ASG, Sow SO. Cholera Infections. In: Tropical Infectious Diseases, 3rd Ed. Guerrant RL, Walker DH, Weller PF eds. US Elsevier, New York 2011. Chapter 20, pp. 150-156.
115. Levine MM. Typhoid fever vaccines. In: Vaccines, 6th edition. Plotkin SA, Orenstein WA and Offit PA eds. Saunders – Elsevier, United Kingdom 2013. Chapter 36, pp 812-836.
116. Levine MM and Chen WH. How are Vaccines Assessed in Clinical Trials? In: The Vaccine Book, 2nd edition. Lambert P-H and Bloom B. Elsevier, Philadelphia 2016. Chapter 6
117. Levine MM. Typhoid fever vaccines. In: Vaccines, 7th edition. Plotkin SA, Orenstein WA, Offit PA and Edwards KA, eds. Saunders – Elsevier, United Kingdom 2016. Chapter 37, in press.

Abstracts and Presentations at National and International Meetings (Partial Listing)

1. Levine MM, DuPont HL, Hornick RB. Immunity in shigellosis. Clinical Research, XVIII:689, 1970 (abstract).
2. Levine MM, DuPont HL, Libonati JP, Gangarosa EJ, Snyder MJ, Hornick RB. An immunologic approach to the control of epidemic shiga dysentery. Clinical Research XIX:461, 1971 (abstract).
3. Levine MM, Gangarosa EJ. Oral attenuated streptomycin-dependent (SmD) shigella vaccines: *In vivo* stability and transmissibility. Ped. Res. 7:736, 1973 (abstract).
4. Levine MM, Hattwick M, Risi J. Poliovirus in the Caribbean. Ped. Res. 7:736, 1973 (abstract).
5. Levine MM and Hornick RB. Lactulose therapy in shigella carrier state and acute dysentery. 14th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Sept. 1974 (abstract).
6. Levine MM, Hornick RB, Snyder MH, DuPont HL, Woodward WE, Gilman RH. Streptomycin-dependent oral typhoid vaccine. Abstract of paper presented at 15th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26, 1975. Washington DC (abstract #371).
7. Levine MM, Gilman RH, Grados O, Solis R. Diagnostic value of Widal test in areas endemic for typhoid fever. Abstract of paper presented at 15th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, September 24, 1975 (abstract #132).
8. Levine MM, Caplan ES, Cash RA, Snyder MJ. Diarrhea due to *Escherichia coli* that produce only heat-stable enterotoxin. Presented at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, October 27-29, 1976.
9. Levine MM. Legal and ethical problems in epidemiologic research -- informed consent (abstract) Am. J. Epidemiol. 104:350, 1976.
10. Levine MM, Nalin DR, Hoover DL, Bergquist EHJ, and Hornick RB. Immunity to enterotoxigenic *Escherichia coli*. Presented at 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York City, October 14, 1977.

11. Levine MM, Nalin DR, Craig JP, Hoover D, Bergquist EJ, Waterman D, Holley HP, Jr, Libonati JP, Hornick RB, Pierce NF. Immunity to Cholera. 13th Joint Conference on Cholera U.S.-Japan Cooperative Medical Science Program. Atlanta, September, 1977.
12. Levine MM. Immunity to Cholera in Man. Royal Society of Tropical Medicine and Hygiene Symposium on Cholera. London, England, May 4, 1978.
13. Levine MM. Immunity to Cholera as Evaluated in Volunteers. Nobel Symposium on Cholera. Sweden, August, 1978.
14. Levine MM. Oral Rehydration of Infant Diarrhea. Presented at Diarrhea Research Symposium at the Caribbean Epidemiology Center. October 18, 1978.
15. Levine MM, Daya V. Hemagglutination, Pili and Diarrheagenic Potential of *Escherichia coli* Strains in Man. 18th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, October, 1978.
16. Levine MM. Infant Diarrhea in the Less-Developed World: Epidemiology and Control. Am Publ Hlth Assoc Annual Meeting, New York, Nov. 8, 1979.
17. Levine MM. Adhesion of Enterotoxigenic *Escherichia coli* in Humans and Animals. Presented at Ciba Foundation Symposium on Adhesion and Microorganism Pathogenicity. London, May, 1980.
18. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA. Volunteer Studies in Development of Vaccines against Cholera and Enterotoxigenic *Escherichia coli*: A Review. Presented at Nobel Conference 3: Acute Enteric Infections in Children. New Prospects for Treatment and Prevention. Stockholm, Sweden, September 22-26, 1980.
19. Levine MM, Clements ML, Black RE, Hughes TP, Cleaves Tome F. Oral Rehydration with Simple Sugar/Salt Solutions as an Alternative in Rural Areas when Glucose/Electrolyte Solutions are Unavailable. Presented at Nobel Conference 3: Acute Enteric Infections in Children. New Prospects for Treatment and Prevention. Stockholm, Sweden, September 22-26, 1980.
20. Levine MM, Black RE, Clements ML, Young CR, Finkelstein RA, Honda T, Murphy JR. Clinical and Immunologic Response in Man Following Ingestion of Naturally-Occurring and Laboratory-Derived Attenuated *Vibrio cholerae*. Presented at the 16th Joint Conference U.S.-Japan Cooperative Medical Science Program Cholera Panel. Gifu, Japan, October 6-8, 1980.
21. Levine MM. Immunity to Enterotoxigenic *Escherichia coli* in Man Stimulated by Prior Infection or Purified Pili Vaccine. Presented at the Workshop on Bacterial Attachment. Stockholm, Sweden, January 23, 1981.
22. Levine MM. Shigella Infections and Vaccines: Experiences from Volunteer and Controlled Field Studies. International Conference on Shigellosis. Cox's Bazaar, Bangladesh, June 18, 1981.
23. Levine MM, Black RE, Clements ML, Young CR, Honda T, Finkelstein R. Texas Star-SR: Attenuated *Vibrio cholerae* Oral Vaccine Candidate. Presented at the 17th Joint Conference on Cholera, U.S.-Japan Cooperative Medical Science Program. Baltimore, October 26-28, 1981.
24. Levine MM, Black RE, Clements ML, Young CR, Lanata C, Sears S, Honda T, Finkelstein R. Texas Star-SR: Attenuated *Vibrio cholerae* oral vaccine candidate. Symposium on Enteric Infections in Man and Animals: Standardization of Immunological Procedures. Dublin, Sept. 6-8, 1982.
25. Levine MM, Black RE, Clements ML, Young CR, Boedeker EC, Cheney C, Brinton CC, Jr. Immunoprophylaxis of Enterotoxigenic *Escherichia coli* Infections in Man by Vaccines that Stimulate Anti-Pili Immunity. Symposium on Enteric Infections in Man and Animals: Standardization of Immunological Procedures. Dublin, Sept. 6-8, 1982.

26. Levine MM, Black RE, Clements ML, Kaper JB. Present Status of Cholera Vaccines. Biochemical Society, Cambridge, England, June 29 - July 1, 1983.
27. Levine MM, Kaper JB, Black RE, Clements ML, Morris JG. New Insights into the Pathogenesis of Cholera and its Prevention. 19th Joint Conference on Cholera. U.S.-Japan Cooperative Medical Science Program, Bethesda, Md. October 17-19, 1983.
28. Levine MM, Black RE, Clements M, Boedeker E, Young C, Rowe B. Stimulation of Intestinal Secretory IgA Antibody to Colonization Factor Fimbriae of Enterotoxigenic *Escherichia coli* by Both Killed Antigen and Live Oral Vaccines. Intestinal Immunity Workshop. XI. International Congress of Tropical Medicine and Malaria. Calgary, Alberta, September 16-22, 1984.
29. Levine MM. Landmarks on the Road Toward a Live Oral Attenuated Cholera Vaccine. Robert Koch Memorial Symposium on Cholera. Kashiwara City, Japan, November 5, 1984.
30. Levine MM. Epidemiologic Patterns of Endemic Typhoid Fever and Usefulness of Seroepidemiology. International Workshop on Typhoid Fever, Washington, DC November 29 and 30, 1984.
31. Levine MM. New Approaches to Immunization Against Cholera. Symposium on Cholera. Am. Soc. Trop. Med. and Hygiene, 33rd Annual Meeting. Baltimore, December 2-6, 1984.
32. Levine MM. Antibiotic Treatment for Infectious Diarrheas. NIH National Consensus Conference on Travelers' Diarrhea. Bethesda, January 24-26, 1985.
33. Levine MM. Dehydration, Metabolic and Nutritional Consequences of Infant Diarrhea and Oral Rehydration. Internation Seminar on Infectious Diarrhoea in the Young. Strategies for Control in Humans and Animals. Geelong, Australia, February 10-15, 1985.
34. Levine MM. Vaccines against Bacterial Enteric Infections of Man. Strategies for Control in Humans and Animals. Geelong, Australia, February 10-15, 1985.
35. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, Chilean Typhoid Committee. The Efficacy of Attenuated *Salmonella typhi* oral vaccine strain Ty21a evaluated in controlled field trials. Development of Vaccines and Drugs against Diarrhea. 11th Nobel Conference, Stockholm, June 3-6, 1985.
36. Levine MM, Losonsky G, Herrington D, Kaper JB, Tacket CO, Rennels MB, Morris JG. Pediatric Diarrhea: The Challenge of Prevention. Thrasher International Conference on Pediatric Enteric Infections. Salt Lake City, June 13-15, 1985.
37. Levine MM, Morris JG, Losonsky G, Boedeker E, Rowe B. Fimbriae (Pili) Adhesins as Vaccines. Federation of European Microbiology Societies Symposium on Molecular Biology of Pathogenic Microorganisms. Lulea, Sweden, June 17-20, 1985.
38. Levine MM. Pathogenesis of Bacterial Enteric Infection. Keynote Speaker, Third International Workshop on Campylobacter Infections. Ottawa, July 8-10, 1985.
39. Levine MM. Stimulation of Mucosal Immunity against Enterotoxigenic *Escherichia coli*. Conference on Immunity and Infection at Mucosal Surfaces. Hamilton, Montant, August 26-28, 1985.
40. Levine MM. The Pathogenesis of Bacterial Diarrheas: A Basis for Rational Therapy. Canadian Society of Clinical Investigation. Vancouver, Canada, September 12, 1985.
41. Levine MM, Herrington D. The Current Status of Phase I and II Clinical Trials of the Anti-Sporozoite *Plasmodium falciparum* Vaccines. Agency for International Development Americas Conference on Malaria Vaccines. Ft. Lauderdale, October 9-12, 1985.

42. Levine MM. Status of Vaccines against Enteric Infections. Typhoid Vaccines. Interscience Conference on Antimicrobial Agents and Chemotherapy. Minneapolis, September 29 - October 2, 1985.
43. Levine MM, Kaper JB, Morris JG, Herrington D, Losonsky G, Tall B, Hall R. Reactogenicity, Colonizing Capacity and Immunogenicity of Further Attenuated, Genetically-Engineered *Vibrio cholerae* 01 Vaccine Strains. 21st U.S.-Japan Joint Conference on Cholera. Bethesda, October 21-23, 1985.
44. Levine MM. *Escherichia coli* qui Caused les Maladies Diarrheiques. Congres Africain de Maladies Infectieuses. Kigali, Rwanda, January 21-23, 1986.
45. Levine MM. Patogenia e Inmunidad de las Infecciones Intestinales. International Seminar on Diarrheal Diseases and Oral Rehydration. Mexico City, April 2-4, 1986.
46. Levine MM. New Vaccines under Development. Federation of Societies for Experimental Biology. St. Louis, April 13, 1986.
47. Levine MM. Immunity to Shigellosis. World Health Organization Meeting on Development of Vaccines against Shigellosis. Calcutta, May 19-22, 1986.
48. Levine MM. *Salmonella typhi* Vaccine. International Symposium on Vaccine Development and Utilization. Sponsored by the U.S. Agency for International Development and the Pan American Health Organization. Washington, D.C., June 9 and 10, 1986.
49. Levine MM. Vaccines against Bacterial Enteric Infections. International Congress of Pediatrics, Honolulu, July 9, 1986.
50. Levine MM. New Approaches to Antibacterial Vaccines. Vaccines against Enteric Infections. IXth International Congress of Infections and Parasitic Diseases. Munich, July 20-26, 1986.
51. Levine MM. Keynote Speaker, 24th Annual Meeting of the Infectious Diseases Society of America. *Escherichia coli* that cause Diarrhea. New Orleans, October 3, 1986.
52. Levine MM. Clinical and field trials to assess the efficacy of vaccines against bacterial enteric infections. Sclavo International Symposium. November 17-19, 1986.
53. Levine MM, Jian-Guo J, Kaper JB, Lior H, Prado V, Tall B, Nataro J, Karch H, Wachsmuth K. International Symposium and Workshop on Verocytotoxin-Producing Infections. A DNA Probe to Identify Enterohemorrhagic *Escherichia coli* of O157:H7 and other Serotypes that Cause Hemorrhagic Colitis and Hemolytic Uremic Syndrome. Toronto, July 12-15, 1987.
54. Levine MM. Vaccines against typhoid fever. The Annual Howard Florey Memorial Lecture, University of Adelaide, September, 1987.
55. Levine MM. Prospects for a Vaccine against AIDS. Annual meeting of the Chilean Infectious Diseases Society, October, 1987.
56. Levine MM. Identification of diarrheagenic *Escherichia coli* by DNA probes. Fifth International Symposium on Rapid methods and Automation in Microbiology and Immunology. Florence, Italy, November 6, 1987.
57. Levine MM. Diarrheal diseases in young children in the developing world: magnitude of the problem and prospects for prevention by vaccines and other interventions. Sackler Visiting Scholar Lecture, Sackler Institute of Advanced Studies, Tel Aviv University Medical School, November 8, 1987.
58. Levine MM. Update on vaccines against bacterial infections in pediatrics. International Congress of Pediatrics, Bangkok, Thailand, November 11, 1987.

59. Levine MM. Progress in vaccines against typhoid fever. International Conference on Advanced Knowledge on Vaccines for Tropical Diseases of Public Health Importance. Bangkok, Thailand, February 1, 1988.
60. Levine MM. New developments in vaccines against typhoid fever. Tel Hashomer Hospital, Tel Aviv, Israel, November 26, 1987.
61. Levine MM. The pathogenesis and epidemiology of *Escherichia coli* that cause diarrhea. Colloquium Lecture, Tel Aviv University School of Medicine, December 9, 1987.
62. Levine MM. New developments in vaccines against cholera. International Conference on Advanced Knowledge on Vaccines for Tropical Diseases of Public Health Importance. Bangkok, Thailand, February 2, 1988.
63. Levine MM. Progress in vaccines against typhoid fever. International Conference on Advanced Knowledge on Vaccines for Tropical Diseases of Public Health Importance. Bangkok, Thailand, February 2, 1988.
64. Levine MM. The application of biotechnology to vaccine development. Keynote talk at the Annual Meeting of the Israeli Society of Microbiology, Tel Aviv, Israel, February 8, 1988.
65. Levine MM. The role of clinical trials in vaccine development. Joint Israel Defence Forces - United States Army Conference on Vaccines of Military Importance. Kfar Maccabiah, Ramat Gan, Israel, March 21-23, 1988.
66. Levine MM. New diagnostic tools in gastrointestinal microbiology. International Meeting on Recent Progress in Pediatric Gastroenterology and Nutrition. Naples, June 2-3, 1988.
67. Levine MM. Pathogenesis of diarrhoeal diseases caused by *Escherichia coli*. International Symposium on Infections in Developing Countries. Johannesburg, South Africa, August 31, 1988.
68. Levine MM. New developments in malaria vaccines. International Symposium on Infections in Developing Countries. Johannesburg, South Africa, September 1, 1988.
69. Levine MM. *Escherichia coli* que causan la diarrhea: patogenia y propiedades de virulencia. Keynote speaker, Annual meeting of the Argentinian Society of Microbiology, Mar de Plata, Argentina, November 21-22, 1988.
70. Levine MM. Prospects for oral enteric vaccines. XIII International Symposium on Intestinal Microecology. Sardinia, Italy, September 11-14, 1988.
71. Levine MM. Oral vaccines against typhoid fever: results of recent controlled field trials. Symposium on oral vaccines, American Society for Microbiology Annual Meeting, Miami Beach, May 9, 1988.
72. Levine MM. The pathogenic mechanisms in *Escherichia coli* diarrhea. Dallas Infectious Diseases Dinner Seminar, Dallas, Texas, January, 1989.
73. Levine MM. Typhoid vaccines. Armed Forces Epidemiological Board, Washington, D.C., February 16, 1989.
74. Levine MM. Enteraggregative *Escherichia coli*. A new diarrheal agent. Federation of European Microbiological Societies Workshop on Microbial Surface Components and Toxins in Relation to Pathogenesis. Ramat Rachel, Israel, May 15-19, 1989.
75. Levine MM. The epidemiology of diarrhea due to *Escherichia coli* in children less than five years of age. Second Annual Joint Israel Defence Force - U.S. Army Medical Research and Development Command Conference on Vaccines. Tel Hashomer Hospital, Tel Aviv, May 30-31, 1989.
76. Levine MM. Attenuated *Salmonella typhi* live oral vaccine strains expressing foreign antigens: a summary of clinical experience. World Health Organization Meeting on the Potential Use of Live Vectors for Vaccines: the Biological Requirements and the Medical Constraints. Geneva, Switzerland June 19-22, 1989.

77. Levine MM. Shigellosis. 26th Annual Semana Pediatrica, Hospital Nacional de Ninos. San Jose, Costa Rica, September 18-22, 1989.
78. Levine MM. Attenuated *Salmonella* as carrier vaccine strains for the expression of foreign antigens. U.S. - India Joint Vaccine Working Group Meeting. New Delhi, India, October 23-26, 1989.
79. Levine MM. Progress in the development of live oral vaccines to prevent cholera. International Center for Diarrhoeal Diseases Research, Bangladesh. Dhaka, Bangladesh, October 28, 1989.
80. Levine MM. *Salmonella* vectors for immunization. Seminar given at the Walter and Eliza Hall Institute for Immunology, Melbourne, Australia, November 8, 1989.
81. Levine MM. The Center for Vaccine Development. Invited lecture given at the Commonwealth Serum Laboratories, Melbourne, Australia, November 10, 1989.
82. Levine MM. Vaccines against enteric infections. Annual Meeting of the Australian Society for Infectious Diseases, Melbourne, Australia, November 13, 1989.
83. Levine MM. The pathogenesis of bacterial enteric infections. 2nd Annual Course in Infectious, Parasitic and Tropical Diseases, Armed Forces Institute of Pathology. Bethesda, Maryland November 30, 1989.
84. Levine MM. Field trials of efficacy of live oral typhoid vaccine, Ty21a. American Epidemiological Society, Baltimore, March 1990.
85. Levine MM. Prevention of enteric infections using vaccines and oral immunoglobulin preparations. International Symposium on the Management of Acute Diarrhea. Stuart, Florida, May 17-19, 1990.
86. Levine MM. The design of clinical trials. First European Course on Hospitalology. Annecy, France, June 1, 1990.
87. Levine MM. Clinical and field trials with attenuated *Salmonella typhi* as live oral vaccines and as "carrier" vaccines. International Symposium on Oral Immunization using Recombinant Bacteria. Munich, June 4-8, 1990.
88. Levine MM. A large-scale field trial comparing the efficacy of Ty21a, live oral typhoid vaccine in liquid versus enteric-coated capsule formulations. Annual Joint Meeting on Vaccines of the U.S. Army Medical Research and Development Command and the Israel Defence Force. Gaithersburg, Maryland June 18-20, 1990.
89. Levine MM. *Salmonella* vaccines. International symposium on New Antimicrobial Strategies, Broomfield Hall, England, July 1-3, 1990.
90. Levine MM. Vaccines against typhoid fever. Department of Chemical Immunology Seminar, the Weizmann Institute of Science, Rehovoth, Israel, July 13, 1990.
91. Levine MM. Attenuated *Salmonella typhi* as a live oral vaccine and as a carrier to express foreign antigens. Life Science Transfer Technology Seminar, Kyoto, September 19, 1990.
92. Levine MM. *Escherichia coli* that cause diarrhea in the tropics. International Union of Microbiological Societies, Osaka, Japan, September, 19, 1990.
93. Levine MM, Fasano A, Savarino S, Robertson D, Maneval D. Enterotoxins elaborated by enteroinvasive and enteroaggregative *Escherichia coli*. 26th Joint Conference of the U.S.- Japan Cooperative Medical Science Program on Cholera and Related Diarrheal Diseases. Kyoto, September 24-26, 1990.
94. Levine MM. Typhoid vaccines. Council on Industrial Health. Johns Hopkins University, Baltimore, MD, October 3, 1990.

95. Levine MM. The new generation of typhoid vaccines: prospects for the protection of international travelers and children in endemic areas. Centers for Infectious Diseases Grand Rounds. Centers for Diseases Control, Atlanta, Georgia, October 10, 1990.
96. Levine MM. Vaccines against diarrheal infections. Symposium on diarrheal diseases at the Annual Meeting of the American Society of Tropical Medicine and Hygiene. New Orleans, November 6, 1990.
97. Levine MM. *Salmonella typhi* and foreign epitopes. Philippe Laudat International Conference on Immune Responses to Proteins with Recombinant Epitopes: Perspectives for Vaccines. Bischenberg, France, November 12-15, 1990.
98. Levine MM. Avances en el desarrollo de vacunas contra la fiebre tifoidea. 5th Congreso Panamericano de Infectología, Lima, Peru, April 7-10, 1991.
99. Levine MM. Cholera: epidemiología y control de la enfermedad. 5th Congreso Panamericano de Infectología, Lima, Peru, April 7-10, 1991.
100. Microbiología, inmunología y patogenia del colera. Congreso Paraguayo de Pediatría, October 11, 1991, Asuncion, Paraguay.
101. Fisiología de la rehidratación oral. Congreso Paraguayo de Pediatría, October 11, 1991, Asuncion, Paraguay.
102. Vacunas del futuro. Sociedad Colombiana de Medicina Tropical y Parasitología, Bogotá, Colombia, October 13, 19, 1991.
103. La epidemiología global del colera. Sociedad Colombiana de Medicina Tropical y Parasitología, Bogotá, Colombia, October 13, 1991.
104. *Escherichia coli* that cause diarrhea. Annual Meeting of the Brazilian Pediatric Society, Porto Alegre, Brazil, October 17, 1991.
105. Vaccines against *Haemophilus influenzae* type b. Annual Meeting of the Brazilian Pediatric Society, Porto Alegre, Brazil, October 17, 1991.
106. New vaccines against typhoid fever and cholera. Congreso Latinoamericano de Infectología Pediátrica, Santiago, Chile October 23, 1991.
107. Perspectives on diarrhea caused by *Escherichia coli*. Congreso Latinoamericano de Infectología Pediátrica, Santiago, Chile October 23, 1991.
108. Cholera - Worldwide epidemiology and prevention. Annual Meeting of the Israel Society for Microbiology, Beer Sheva, Israel February 11, 1992.
109. Current trends in *S. typhi* vaccines. Society for General Microbiology, 122nd Meeting, University of Wales College of Cardiff March 23-26, 1992.
110. Cholera. Biomedical Research Advancement: Saturday Scholars (BRASS) Program, National Institutes of Health, April 4, 1992.
111. A progress report on the safety, immunogenicity and efficacy of CVD 103-HgR, a one dose, genetically engineered live oral cholera vaccine. First International Symposium on Cholera in the Americas, Mexico City, April 20-21, 1992.
112. The problem of cholera in the world. International Symposium on Cholera in Latin America, Buenos Aires, Argentina, April 29, 1992.
113. Vaccine development. International Symposium on Cholera in Latin America, Buenos Aires, Argentina, April 29, 1992.

114. Cholera: Keynote address for the Cholera session. Vaccines for Enteric Diseases, Cambridge, England, April 13-15, 1992.
115. Attenuated *Salmonella typhi* as live oral vaccines to prevent typhoid fever and as carrier vaccines to express foreign antigens. NATO Advanced Research Workshop on the Biology of *Salmonella*, Portorosa, Italy, May 10-15, 1992.
116. Production, laboratory evaluation, and clinical trial of vaccines against cholera. International Symposium on Cholera in the American Continents, Sao Paulo, Brazil, May 21-23, 1992.
117. Old and new cholera vaccines: A 100 year perspective. The American Society for Microbiology 1992 General Meeting, New Orleans, Louisiana, May 27, 1992.
118. A new generation of cholera vaccines. The Bazeley Oration, The Australian Society for Microbiology 1992 Annual Meeting, Sydney, Australia, July 16, 1992.
119. Cholera. Brazilian Society of Immunology Annual Meeting, August 26, 1992.
120. Enteric Fever: *Salmonella typhi*. Eastern Pennsylvania Branch, American Society for Microbiology, Philadelphia, PA, November 12, 1992.
121. Attenuated *Salmonella typhi* live vector vaccines expressing foreign antigens: Versatility to meet public health demands. University of California at San Francisco. February 9, 1993.
122. Attenuated *Salmonella typhi* live vector vaccines expressing foreign antigens. The Mount Sinai Medical Center, New York, February 23, 1993.
123. The recent cholera epidemic in Latin America. Baltimore Tropical Medicine Dinner Club. Baltimore, Maryland. March 17, 1993.
124. Vaccines to prevent enteric infections in travelers. Presented at the 3rd Conference on International Travel Medicine, Paris, France, April 26, 1993.
125. CVD 103-HgR, live oral cholera vaccine. Presented at the International Workshop on New Approaches to Bacterial Vaccines. Munich, Germany, April 28-29, 1993.
126. Vacuna oral contra el colera. Congreso de la Sociedad Panameiricana de Infectologia, Viña del Mar, Chile, May 27, 1993.
127. Vacunas contra enfermedades entericas. Congreso de la Sociedad Panameiricana de Infectologia, Viña del Mar, Chile, May 27, 1993.
128. Vaccines against cholera and enterotoxigenic *E. coli*. The 18th International Congress of Chemotherapy. Stockholm, Sweden. June 27-July 2, 1993.
129. Modern approaches to the development of vaccines against bacterial enteric infections. Canadian Society of Microbiology/Society for Industrial Microbiology Annual Meeting. Symposium on Vaccination Strategies for Bacterial Pathogens, keynote address. Toronto, Ontario, August 3, 1993.
130. *Shigella*, *Salmonella* and other enteric vaccines. Ross Conference on Strategies for Pediatric Vaccines: conventional and molecular approaches. San Diego, CA, September 19-22, 1993.
131. The emergence of diarrheal diseases including cholera. Colloquium on Changes in Human Ecology and Behavior: Infectious Diseases. National Academy of Sciences, Washington, D.C., September 27-28, 1993.
132. Cholera Vaccines and Typhoid Vaccines. Invited talks given at the Mexican Infectious Diseases Society XVIII Annual Meeting, Mexico City, November 21-24, 1993.

133. Recent Advances in Vaccine Development. Invited talk delivered at the XI Biennial Conference of the Pakistan Pediatric Association, Lahore, Pakistan, February 2-5, 1994.
134. Experiences with *Haemophilus influenzae* type b capsular polysaccharide-tetanus protein conjugate vaccine in Chilean infants. Special lecture of the Korean pediatric Society, Seoul, Korea, March 30, 1994.
135. Bacterial enteric vaccines. Mucosal Immunology Symposium, FASEB, Anaheim, CA, April 28, 1994.
136. Cholera Vaccines. Invited lecture presented at the 2nd Simposio Internacional de Infectologia Pediatrica, Cordoba, Argentina, May 9, 1994.
137. Mucosal immunization -- The perspective of the vaccinologist versus the immunologist. Invited talk at the inaugural meeting of the International Society for Vaccines. Las Vegas, May 22-23, 1994.
138. Live oral cholera vaccines - A status report. 7th Asian Conference on Diarrheal Diseases. Dhaka, Bangladesh, September 17, 1994.
139. Attenuated strains of *Vibrio cholerae*, *Salmonellatyphi* and *Shigella* as live oral vaccines and as live vectors. Keystone Conference on Mucosal Immunization. January, 1995.
140. The epidemiology of typhoid fever. WHO meeting on Vaccines against Bacterial Infections, Madrid, March 1-2, 1995.
141. Large-scale post-licensure effectiveness trial of PRP-T conjugate vaccine in preventing invasive *Haemophilus influenzae* type b infections in Chilean infants. Annual Meeting of the American Epidemiological Society, Tampa, Florida March 23, 1995.
142. Attenuated *Salmonella* as live oral vaccines against typhoid fever and as live vectors. New Approaches to Vaccine Development, Vienna April 12, 1995.
143. Enteric vaccines -- the next five years. Keynote talk at the 8th International Workshop on *Campylobacters*, *Helicobacters* and Related Organisms. Winchester, United Kingdom, July 12, 1995,.
144. Characteristics of newly licensed typhoid vaccines (Ty21a, Vi polysaccharide), candidate Vi conjugate vaccines and new generation attenuated vaccine strains. U.S.-India Vaccine Program, New Delhi, July 17, 1995.
145. Immunizations for diarrheal diseases. International Congress of Chemotherapy, Montreal, July 20, 1996.
146. The epidemiology of enteropathogenic *Escherichia coli* (EPEC) infections in Chile. International Symposium on EPEC, Sao Paulo, Brazil, August 28, 1995.
147. Prospects for a vaccine against EPEC. International Symposium on EPEC, Sao Paulo, Brazil, August 28, 1995.
148. Engineered live oral cholera vaccines. State of the Art Minilecture, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995
149. Development of a live oral cholera vaccine; a paradigm. NIH Meeting on Planning and Implementing Clinical Trials for Parasitic Diseases, Bethesda, MD, September 19, 1995,.
150. Live attenuated vaccines against bacterial enteric infections. Year of Louis Pasteur Symposium, Paris, September 26, 1995.
151. Vaccines against diarrheal disease, dysentery and enteric fever. Presented at Nestlé Nutrition Workshop Series 38:Diarrheal Diseases. Islamabad, Pakistan, October 23, 1995.
152. New developments in cholera vaccines. Congress of the African Society of Microbiology. Bamako, Africa.

February 2, 1996.

153. A consideration of the host factors that modulate susceptibility to cholera and the immune response to engineered live oral cholera vaccines. ICTDR Meeting, Bethesda, MD, April 23, 1996.
152. Mucosal routes of vaccination. Edward Jenner Bi-centennial Celebration, Royal College of Physicians, London. May 15, 1996.
153. Attenuated *Salmonella typhi* and *Shigella flexneri* as live vector vaccines: Expression of foreign antigens and elicitation of relevant immune responses. Munich, Germany. May 28, 1996.
154. New vaccines against cholera and typhoid fever. International Society for Infectious Diseases, Hong Kong, June 12, 1996.
155. Engineered *Vibrio cholerae* and *Shigella* strains as live oral vaccines and as live vectors to deliver foreign antigens by mucosal immunization. 10th International Biotechnology Symposium. Sydney, Australia. August 26, 1996.
156. The vaccine development paradigm: Illustrative examples in the development of vaccines against tropical diseases. American Society of Tropical Medicine and Hygiene, Baltimore, MD, December 2, 1996.
157. Development of enteric vaccines. Asia Pan Pacific Society for Paediatric Gastroenterology and Nutrition, Jakarta, Indonesia, December 16, 1996.
158. Quantitating invasive Hib disease in Santiago, Chile. Revelation of an important public health problem. First International Symposium on Hib in Asia, Bali, Indonesia, December 17, 1996.
159. Cholera vaccine for travelers: Indications and options. Presented at the Fifth International Conference on Travel Medicine, Geneva, SW, March 24, 1997.
160. Bacterial live vector vaccines. Presented at 2nd National Symposium on Basic Aspects of Vaccines, Walter Reed Army Institute of Research, Bethesda, MD, April 30, 1997.
161. *Salmonella* vaccines as carriers of foreign antigens. American Gastroenterological Association. Washington, DC. May 13, 1997.
162. The molecular epidemiology of 19th century cholera: What was the serogroup and biotype of *Vibrio cholerae* responsible for the early cholera pandemics? First International Symposium The Archaeology of Emerging Diseases, Tel Aviv, Israel, May 20, 1997.
163. Artificial challenge studies. Presented at International Association of Biologic Standardization Meeting on Clinical Trials in Paris, France, May 28, 1997.
164. Phase 1 and 2 clinical trials of candidate malaria vaccines. Presented at the Second Global Meeting on Parasitic Diseases with a focus on Malaria, Hyderabad, India. August 18, 1997.
165. New strategies of bacterial vaccines against enteric infections. Presented at the Deutschen Gesellschaft für Hygiene und Mikrobiologie in Jena Germany. October 7, 1997.
166. Developments in prevention: The way forward. Presented at the Strategies for Vaccine Protection in Developing Countries, Universidad Nacional Autonoma de Mexico, Mexico City. October 17, 1997.
167. Emerging infections: fundamental concepts and models to explain a phenomenon of global importance. Presented at the Congreso Chileno de Infectología, Valdivia, Chile, December 2, 1997.
168. Mucosal vaccines. Presented at the Congreso Chileno de Infectología, Valdivia, Chile, December 3, 1997.

169. Recent research on vaccines and prevention of typhoid fever. Presented at the Third Asia-Pacific Symposium on typhoid fever and other salmonellosis, Denpasar, Bali, Indonesia December 8-10, 1997.
170. New typhoid vaccine development. Presented at Workshop on Typhoid Fever, National Institute of Health, Seoul, Korea, December 16, 1997.
171. *Salmonella* as a live vector. Presented at the WHO/NIAID Workshop on Vaccines administered via Mucosal Surfaces, February 9-11, 1998.
172. Vaccines delivered via mucosal surface. Presented at the International Workshop on Vaccine Development, Rio de Janeiro, April 14-16, 1998.
173. Mucosal Immunization. Presented at the 8th International Congress on Infectious Diseases meeting, Boston, May 15-18, 1998
174. Prospects for improving disease control through simplifying vaccination: Oral/mucosal vaccines and combinations. Presented at the Consultative Group Meeting of the Children's Vaccine Initiative in Geneva, Switzerland, November 9-10, 1998.
175. Live oral vaccines against enteric pathogens. Presented at the Centennial celebration of the Swiss Serum and Vaccine Institute, Berne, Switzerland, November 6, 1998.
176. Rotavirus Vaccines. Presented at the Infectious Diseases in Children conference, New York, November 21-22, 1998.
177. Status of typhoid vaccines. Presented at the V International Congress of Tropical Pediatrics, Jaipur, India, February 10-15, 1999.
178. Oral and Nasal Immunization. Presented at A New Approaches to Bacterial Vaccine Development, Munich, Germany, May 19-22, 1999.
179. Update on Edible Vaccines. Presented at meeting on An Overview on Vaccine Research in WHO and UNAIDS, Montreux, Switzerland, June 16-18, 1999.
180. Vacunas contra Enfermedades Entericas. Presented at the 8th Congreso de la Sociedad Latinoamericana de Infectología Pediátrica. Asunción, Paraguay, August 8-11, 1999.
181. Enfermedades Emergentes. Presented at the 8th Congreso de la Sociedad Latinoamericana de Infectología Pediátrica. Asunción, Paraguay, August 8-11, 1999.
182. Development of new vaccines against diarrheal pathogens -- a hope for developing countries? Presented at the International Congress on Cooperative Research with Developing Countries. Basel, Switzerland, August 19-21, 1999.
183. How to test vaccines in the field -- Are there alternatives? Presented at the International Congress on Cooperative Research with Developing Countries. Basel, Switzerland, August 19-21, 1999.
184. Organizing Vaccine Trials. Presented at the 1st Global Conference on Vaccines and Immunisation into the next millennium. Manchester, UK, September 6-9, 1999.
185. Evaluaciones de la eficacia y la efectividad (impacto epidemiológico) de las vacunas. Second Congress of the Sociedad Española de Medicina Tropical y Salud Internacional. Sitges (Barcelona), January 27-29, 2000.
186. Current status of new generation vaccines: Live oral; Live oral Shigella vaccines; and Live oral Cholera vaccines (CVD candidates). Three talks presented at the DOMI Program Meeting, WHO headquarters, Geneva, Switzerland. February 7-8, 2000.

187. Live oral vaccines to prevent enteric infections in travelers. Presented at the Oral Vaccination Symposium at I. Matzkel "Droreth" Ltd., Tel Aviv, Israel. March 23, 2000.
188. Live attenuated vectors: have they delivered? Presented at the Millennium Joint Meeting of the Society for General Bacteriology and the Society for Applied Microbiology, April 10-14, 2000.
189. Global efforts in vaccination. From the laboratory to the field. Presented at the Wellcome Trust conference on Bacteriology in the Tropics. Cambridgeshire, UK, May 14-17, 2000.
190. The global burden of diarrheal diseases: A perspective. Presented at the XV International Congress for Tropical medicine and Malaria. Cartagena, Bogota, Colombia, August 20-25, 2000.
191. Progress in non-parenteral delivery of vaccines. Infectious Disease Society of America. New Orleans, LA, September 7-10, 2000.
192. Ethical Considerations in Mass Vaccination Campaigns. Presented at the Berzelius Symposium, Vaccines are beneficial! What are the risks? Stockholm, February 8-10, 2001.
193. Vaccines against enteric infections: Public health rationale, vaccinology strategies, successes, disappointments and surprises. Presented at the Institute Butantan Symposium on vaccines against enteric infections. Sao Paulo, Brazil, February 19-22, 2001.
194. Realizing the promise of new vaccine technologies: Pitfalls, perseverance, disappointments and successes. Presented at the World Vaccine Congress. Montreal, Canada, April 3-5, 2001.
195. Vaccine triumphs and tribulations in the USA and globally. Presented at the Practical Day of Pediatrics, University of Alabama-Birmingham, May 16-17, 2001.
196. "Oral Vaccines", and, "Attenuated *Salmonella typhi* and *Shigella* as live vectors to deliver foreign protein antigens or DNA vaccines to the mammalian immune system". Both lectures presented at the American Society for Microbiology. Orlando, Florida, May 20-24, 2001.
197. Review of issues too be considered in Phase 3 trials: Lessons from various clinical trials. Presented at the Second Advanced Vaccinology Course. Merieux Foundation, Annecy, France, May 23, 2001.
198. Issues in clinical trials. Presented at the Global Vaccine Research Forum. Montreux, Switzerland, June 10-12, 2001.
199. Cholera Vaccines – Overview. Presented at the Vaccines for Enteric Diseases VED 2001. Tampere, Finland, September 12-14, 2001.
200. Widespread Vaccination Against Gastrointestinal Pathogens in DCC - Is it Worthwhile? Pediatric Infectious Disease Conference. Monterey, California, October 28-30, 2001.
201. Vaccines against bioterror agents: Overcoming the challenges to development, testing, stockpiling and implementation. Presented at the University of Maryland, Baltimore, Health Policy Seminar, November 16, 2001.
202. Overview of the Research and Development Activities of the Global Alliance for Vaccines and Immunization. Presented at the NFID's Fifth Annual Conference on Vaccine Research. Baltimore, Maryland, May 6-8, 2002.
202. Memory at the Mucosal Level. Presented at the NIFID's Fifth Annual Conference on Vaccine Research. Baltimore, Maryland, May 6-8, 2002.
203. Attenuated *Shigella* and *Salmonella Typhi* Live Vectors to Deliver DNA Vaccines via Mucosal Administration. Presented at the 4th International Meeting, New Approaches to Bacterial Vaccine Development. Munich, Germany, May 26-29, 2002

204. Typhoid Fever: Lessons from the Past and Challenges for the Future. Typhoid Symposium. American Society of Tropical Medicine and Hygiene, Annual Meeting, November 12, 2002, Denver.
205. The Future: Typhoid and Cholera Vaccines. Presentation at the Centennial Celebration of the Pan American Health Organization, November 25, 2002, Washington, D.C.
206. Typhoid. Presentation at the International Vaccine Institute's Inaugural Symposium, New Frontiers in Vaccinology Research, June 26, 2003, Seoul, Korea.
207. Research and Development of Vaccines against Typhoid Fever. Presented at the Global Vaccine Research Forum. July 2, 2003, Seoul, Korea.
208. Sequential stages of clinical trials and overview of issues to be considered. Presented at the Fifth Advanced Course of Vaccinology, Fondation Merieux, Annecy, France. May 12, 2004
209. Activation of Mucosal Immunity. Presented at the Fondation Mérieux meeting on Innate and Adaptive Immunity after Transcutaneous or Mucosal Vaccination. June 18, 2004, Veyrier du Lac, France.
210. The plague cometh: Pandemic influenza in the 21st century. Presented at the University of Maryland School of Medicine's Grand Rounds. February 13, 2004, Baltimore, Maryland.
211. Accomplishments and Lessons from Enteric Vaccines. Presented at the World Health Organization's meeting on Future Needs and Directions for Shigella Vaccines. September 14, 2004, Geneva, Switzerland.
212. Keynote talk, New England Mucosal Biology Society, September 20, 2004. Attenuated *Salmonella typhi* and *Shigella* as Oral Vaccines and as Live Vectors. Harvard University, Boston, Massachusetts.
213. A multivalent live vector oral vaccine to prevent Shigellosis and Enterotoxigenic *Escherichia coli* diarrhea. Presented at the US/Japan Cholera Conference. December 8, 2004, Kyoto, Japan.
214. Diarrhoeal Diseases. Presented at the WHO/TDR Advanced Course on Immunology, Vaccinology and Biototechnology Applied to Infectious Diseases, Havana, Cuba, December 16, 2004.
215. On the Road to Timbuktu: Attenuated *Salmonella Typhi* and *Shigella* as live oral vaccines and live vectors. Presented to the Vaccine Dinner Club, Emory University. April 6, 2005. Atlanta, Georgia.
216. Logistical challenges to delivery of oral vaccines in developing countries. Presented to the WHO Challenges to the Oral Delivery of Live Vaccines Conference. May 6, 2005. Geneva, Switzerland.
217. Aerosol as agents for vaccine delivery. Presented at the American Thoracic Society. May 21, 2005, San Diego, CA.
218. Sequential stages of clinical trials and overview of issues to be considered. Presented at the Advanced Vaccinology Course. May 25, 2005. Annecy, France.
219. Current status of *Shigella* vaccine development. Presented at the WHO Global Research Forum. June 15, 2005. Salvador de Bahia, Brazil.
220. On the road to Timbuktu: Hurdles to developing and introducing vaccines for the world's poorest populations. Presented at Joint Medicine and Pediatric Grand Rounds, The University of Vermont. June 24, 2005. Burlington, Vermont.
221. Attenuated *Salmonella Typhi* and *Shigella* as mucosal vaccines and as live vectors. Presented at the Vaccinology Conference-Berlin: New Approaches to Vaccine Development: From the Bench to the Field. September 10, 2005. Berlin, Germany.
222. Update on vaccines against Typhoid Fever. Presented at the Program for the Third International Rushmore Conference on Enteric Diseases, Rapid City, SD. October 1, 2005

223. Experience with Ty21a, a live oral typhoid vaccine: lessons applicable to new generation oral vaccines. Present at the Sixth International Conference on Typhoid Fever and Other Salmonellosis. November 13, 2005. Guilin, China.
224. Live Oral Typhoid Vaccines. Presented at the American Society of Tropical Medicine and Hygiene Annual Meeting. December 12, 2005. Washington, D.C.
225. Challenges in Global Health. Presented at the St. Jude-Pediatric Infectious Diseases Society Pediatric Microbial Research Conference. February 25, 2006. Memphis, Tennessee.
226. Vaccines: Yesterday, today and tomorrow. Presented at the V International Symposium for Latin American Experts. May 2, 2006, Pucón, Chile.
227. Sequential stages of clinical trials and overview of issues to be considered. Presented at the Advanced Vaccinology Course. May 17, 2006. Annecy, France.
228. Progress with Salmonella Typhi and Shigella Live Vector Vaccines. Presented at FOCIS 2006. June 2, 2006, San Francisco, CA.
229. Principles of Vaccinology. Presented at International Symposium on Cholera and Other Diarrhoeal Diseases. June 10, 2006, Kolkata, India.
230. EPI Vaccine and Preventable Diseases. Presented at the Clinical Tropical Medicine and Parasitology Course, West Virginia University. June 19, 2006. Morgantown, West Virginia.
231. Diarrheal Diseases in Infants and Young Children – Causative Agents, Transmission, Treatment and Prevention. Presented at the National University of Laos School of Medicine. September 5, 2006.
232. Vaccination and Clinical Disease. Presented at ASM Conference on Salmonella; From Pathogenesis to Therapeutics. September 12, 2006, Victoria, BC, Canada.
233. Musing on vaccines against typhoid and paratyphoid fever, shigellosis and enterotoxigenic *Escherichia coli* diarrhea. Presented at the Federal of Infection Societies 2006 conference. December 1, 2006, Cardiff, Wales.
234. Typhoid fever vaccination in adolescents. Presented at the Adolescent Immunization: From Science to Policy meeting, Fondation Merieux, Les Pensieres, Annecy, December 14, 2006
235. Burden and Etiology of Severe Diarrhea. Presented at the Vaccines for Enteric Diseases meeting. April 25, 2007, Lisbon, Portugal.
236. Future of the Immunization in the Pregnant Woman, and, Vaccines Against Enteric Pathogens. Presented at the Sociedad Latinoamericana de Infectología Pediátrica. May 10, 2007, San Jose, Costa Rica.
237. Sequential stages of clinical trials and overview of issues to be considered. Presented at the Advanced Vaccinology Course. May 16, 2007. Annecy, France.
238. Oral Vaccines...More reasons than ever. Presented at the Congress of the International Society of Travel Medicine. May 23, 2007, Vancouver, BC.
239. EPI Vaccine and Preventable Diseases. Presented at the Clinical Tropical Medicine and Parasitology Course, West Virginia University. June 18, 2007. Morgantown, West Virginia.
240. Typhoid Fever in Africa – what do we know? Presented at the WHO Typhoid Vaccine Policy Meeting. August 14, 2007, Geneva, Switzerland.
241. Vaccines against Bacterial Enteric Pathogens and Importance in the Tropics. Presented at the Royal Society of Tropical Medicine and Hygiene Centenary Conference. September 15, 2007, London, UK

242. Differences in Immune Responses in Different Populations. Presented at the Challenges of Global Vaccine Development Conference. October 9, 2007, Cape Town, South Africa.
243. Overview of The Global Enteric Multi-Center Study (GEMS). Presented at the American Society of Tropical Medicine and Hygiene Annual Meeting. November 7, 2007, Philadelphia, PA.
244. Lessons learnt for the new live rotavirus vaccines. Presented at Rotavirus Vaccines: Evaluating Clinical Trial Data and Guiding Future Research meeting. November 29, 2007, CDC, Atlanta, GA.
245. Vaccine priorities for developing countries and the Gates Enteric Multicenter Study. Presented at Aga Khan University, Karachi, Pakistan. December 14, 2007.
246. Cholera, ETEC, Shigella, Typhoid: progress and obstacles in the development of vaccines. Presented at the Institut Pasteur Vaccinology Course. March 31, 2008, Paris, France.
247. Enteric infections in the least developed countries: what is the role for vaccines? Seminar presented at the Institut Pasteur, April 1, 2008, Paris, France.
248. EPI Vaccine and Preventable Diseases. Presented at the Clinical Tropical Medicine and Parasitology Course, West Virginia University. June 16, 2008. Morgantown, West Virginia.
249. Typhoid. Presented at Johns Hopkins School of Public Health Summer Institute in Tropical Medicine 2008, July 24, 2008. Baltimore, MD.
250. Epidemiology of Pneumococcal Disease in Latin America: Insights from Extended, Population-Based Surveillance in Santiago, Chile. Presented at the International Symposium on Vaccines, Sao Paulo, Brazil, August 8, 2008
251. The Global Enteric Multi-Center Study. Presented at the US Experts in Diarrhoeal Disease to the UK, London, UK, October 5, 2008
252. Advocacy as an important role in the fight against Pneumococcal Disease. Presented at the National Press Club on behalf of The American Society of Tropical Medicine and Hygiene (ASTMH) and Pneumococcal Awareness Council of Experts (PACE), October 24, 2008. Washington, DC.
253. An Overview of Vaccinology. Presented at the National Foundation for Infectious Diseases Clinical Vaccinology Course, November 14, 2008. Bethesda, MD.
254. The Global Enteric Multi-Center Study (GEMS). Presented at the US-Japan Cooperative Medical Science Program, Fukuoka, Japan. November 19, 2008
255. Eradication and the role of vaccines. Presented at Barcelona Centre for International Health Research's (CRESIB) launch of Malaria Eradication Research Agenda. November 22, 2008, Montreux, Switzerland.
256. Diarrheal disease in infants and young children in developing countries (The Global Enteric Mutli-Center Study, "GEMS"). Kyushu University, Fukuoka, Japan, November 17-19, 2008.
257. Institute of Medicine Process and Findings from the Intermittent Preventive Treatment in Infants (IPTi) study. Presented at the The American Society of Tropical Medicine and Hygiene (ASTMH). December 10, 2008, New Orleans, LA.
258. Introduction and Overview of Global Enteric Multi-Center (GEMS) Study: The Asian Sites and an Overall Progress Report. Presented at the The American Society of Tropical Medicine and Hygiene (ASTMH). December 10, 2008, New Orleans, LA.

259. Strategies and hurdles in developing a vaccine to prevent invasive non-typhoidal *Salmonella* infections in young children in sub-Saharan Africa. Presented at the Seventh International Conference of Typhoid Fever and Other Invasive Salmonellosis, Kilifi, Kenya. January 28, 2009.
260. Mucosal versus parenteral vaccines. Mucosal Immunology of the Gut, Gates Foundation, Seattle, WA. February 11, 2009.
261. Lachesis muta (silent fate): Burden and prospects for control of paediatric invasive non-typhoidal *Salmonella* infections in sub-Saharan Africa. Presented at the Medical Research Council (MRC) Laboratories, The Gambia. February 9, 2009.
262. Cholera, ETEC, Shigella, Typhoid: progress and obstacles in the development of vaccines. Presented at the International Vaccinology Course, Institut Pasteur School of Infectiology, Annecy, France, March 27, 2009
263. EPI Vaccine and Preventable Diseases. Presented at the Clinical Tropical Medicine and Parasitology Course, West Virginia University, Morgantown, WV. June 15, 2009.
264. Swine origin H1N1 influenza: Lessons from the field. Presented at the 13th Annual Hospital Epidemiology and Infectious Diseases Fellows Course, Johns Hopkins University School of Medicine, Baltimore, MD. July 8, 2009.
265. Typhoid. Presented at the Summer Institute in Tropical Medicine, Johns Hopkins School of Public Health, Baltimore, MD. July 29, 2009.
266. Overview of H1N1. Presented at the IOM Workshop on Personal Protective Equipment for Healthcare Workers in the Workplace Against Novel H1N1 Influenza A, Washington, DC, August 12, 2009
267. Vaccinology. Presented at the Host Defenses and Infectious Diseases course, University of Maryland School of Medicine, Baltimore, MD. September 4, 2009.
268. Invasive non-typhoidal infections: Burden and vaccine development strategies. Presented at the Vaccines for Enteric Diseases, Malaga, Spain. September 9, 2009.
269. Vaccines, global health and social equity. Presented at the Division of Cellular and Molecular Medicine Seminar, St. Georges, University of London. November 5, 2009.
270. Etiology of diarrhoeal and enteric diseases in developing countries. Presented at the WHO Global Vaccine Research Forum, Bamako, Mali. December 9, 2009.
271. Invasive bacteremic *Salmonella* infections; New insights on old pathogens and strategies for prevention. ICDDR,B, Mohakhali, Dhaka, Bangladesh. February 17, 2010.
272. Invasive Bacteremic *Salmonella* Infections: new insights on old pathogens and strategies for prevention. Presented at the 7th International Symposium on Pneumococci & Pneumococcal Diseases, Tel Aviv, Israel, March 14, 2010
273. Multi-antibiotic-resistant invasive non-typhoidal *Salmonella* infections emerging in sub-Saharan Africa and the USA: challenging dogma and developing vaccines. Presented at the Regional Centers of Excellence National Meeting, Las Vegas, NV. April 13, 2010.
274. The tropical barrier to enteric vaccine efficacy. Presented at the Gates Foundation, Underperformance of Vaccines for Enteric/Enterically-Acquired Pathogens in the Developing World, Seattle, WA. April 20, 2010.
275. Live attenuated vaccines against cholera and typhoid. Presented at the Second Greater Boston Symposium on Vaccine Science, Cambridge, MA. April 27, 2010.
276. Safety issues with mucosal adjuvants. Presented at the IABS International Scientific Workshop, Bethesda, MD, USA. April 30, 2010.

277. Sequential stages of clinical trials and overview issues to be considered. Presented at the Advanced Vaccinology Course, Fondation Merieux, Annecy, France. May 12, 2010.
278. Vaccines, global health, disease eradication and social equity. Presented at the Omicron Kappa Upsilon National Dental Honor Society, University of Maryland Dental School, Baltimore, MD. May 19, 2010.
279. EPI Vaccine and Preventable Diseases. Presented at the Clinical Tropical Medicine and Parasitology Course, West Virginia University, Morgantown, WV. June 21, 2010.
280. Vaccines to prevent bacterial enteric infections of importance in middle income countries. Presented at the Merck Vaccines seminar series, North Wales, PA. June 27, 2010.
281. Typhoid. Presented at Johns Hopkins School of Public Health Summer Institute in Tropical Medicine, Baltimore, MD. July 21, 2010.
282. An international consortium to facilitate progress. Presented at the Sanaria Data Analysis Meeting, Bethesda, MD. July 28, 2010.
283. Typhoid and other enteric vaccines. Presented at the Oral Vaccination Response in Developing Countries and the Intestinal Microbiome Meeting, Goa, India. August 17, 2010.
284. The role of research in disease eradication and elimination efforts: lessons learned. Presented at the Symposium on Smallpox Eradication, Rio de Janeiro, Brazil. August 26, 2010.
285. Vaccinology. Presented at the Host Defenses and Infectious Diseases course, University of Maryland School of Medicine, Baltimore, MD. September 7, 2010.
286. Prioritization of the main goals of the GEMS-1 project and timelines/expectations for the final year and beyond. Presented at the The Global Enteric Multi-Center Study (GEMS) Annual Meeting, Maputo, Mozambique. September 28, 2010.
287. Expanding immunization against human *Salmonella* Infections: vaccines to prevent invasive non-typhoidal *Salmonella* infections emerging in sub-Saharan Africa and *Salmonella* Paratyphi A in Asia. Presented at the 4th Vaccine and International Society for Vaccines (ISV) Annual Global Congress, Vienna, Austria. October 3, 2010.
288. The licensed vaccines that exist today and new vaccines that will be available tomorrow. Presented at the ASTMH Annual Meeting, Atlanta, GA. November 4, 2010
289. The White paper, an outside view. Presented at the malERA Symposium held during the ASTMH Annual Meeting, Atlanta, GA. November 6, 2010
290. The Burden of Disease. Presented at the Gates Foundation GUT Integrity Meeting, Seattle, WA. December 15, 2010.
291. New insights on novel non-typhoidal *Salmonella* serovars from sub-Saharan Africa. Presented at the Lorne Infection & Immunity Conference 2011, Lorne, Victoria, Australia. February 17, 2011.
292. Global Enteric Multi-Center Study ("GEMS"): Etiology and Consequences of Severe Paediatric Diarrhoeal Disease in Sub-Saharan Africa and South Asia. Presented at the Department of Microbiology & Immunology, The University of Melbourne. February 22, 2011.
293. Diarrhea: A Worldwide Scourge. An Overview of the Problem. Presented at the AGA/DDW, Chicago, IL, May 10, 2011.
294. Etiology and outcomes of acute moderate and severe diarrheal infections in young children in developing countries: insights from the Global Enteric Multi-center Study (GEMS). Presented at the 6th International Conference on Vaccines for Enteric Diseases, Cannes, France, September 14, 2011.

295. Overview of live oral vaccines against *S. Typhi* and *S. Paratyphi*. Presented at the 6th International Conference on Vaccines for Enteric Diseases, Cannes, France, September 15, 2011.
296. Cholera – Status of Oral, Live Vaccines. Presented at IDSA, Boston, MA. October 20, 2011
297. Lessons learned from the Smallpox Eradication Program, the Global Polio Eradication Initiative and the Measles Mortality Control Initiative. Presented at the Department of Biochemistry Seminar, University of Otago, Dunedin, New Zealand. November 1, 2011.
298. Oral vaccination in developing countries. Presented at the 4th Annual Conference Otago International Health Research Network Scientific Meeting, University of Otago, Dunedin, New Zealand. November 8, 2011.
299. Non-typhoidal *Salmonella*: Dogma re-visited. Presented at the University of Otago Grand Rounds, Christchurch, New Zealand. November 9, 2011.
300. Vaccines to prevent invasive Non-typhoidal *Salmonella* infections in sub-Saharan Africa. Presented at the Department of Microbiology & Immunology Seminar, University of Otago, Dunedin, New Zealand. November 10, 2011.
301. Immunological basis of mucosal vaccines. Presented at the First Course on Vaccinology for Latin America, Lima, Peru. December 12, 2011
302. Concepts of vaccines: Immunogenicity, efficacy, effectiveness. Presented at the First Course on Vaccinology for Latin America, Lima, Peru. December 12, 2011
303. How will current technological developments lead to innovative vaccines in the future? Presented at the Facilitate Vaccine Forum - 2012, Washington, DC. January 31, 2012.
304. Overview cholera vaccines (current & developing). Presented at the World Health Organization, Oral Cholera Vaccine Stockpile, Geneva, Switzerland, April 26, 2012
305. Global Enteric Multi-Center Study (GEMS). Presented at the Pediatric Academic Society Meeting, Boston, MA. April 30, 2012
306. Clinical trials: an overview of issues to be considered. Presented at the International Advanced Vaccinology Course, Fondation Merieux, Annecy, France, May 17, 2012
307. Current efforts to develop new vaccines: target population, new antigens, adjuvants and immunization strategies. Presented at the International Meeting on EPEC and Shigella, Buenos Aires, Argentina, May 27, 2012
308. Polio and Smallpox Eradication. Presented at the Barcelona Institute for Global Health sponsored course held at Harvard Business School, Boston, MA, June 4, 2012
309. The Typhoid Fever Control Program of the Ministry of Health, Republic of Chile, 1979-1992 Fiji Ministry of Health Typhoid Advisory Meeting, Suva, Fiji, August 28, 2012
310. A vaccinologist's view on new adjuvants: Why they are needed and challenges to confirm their safety and effectiveness. Presented at the Third Joint Annual NIAID Adjuvant Development and Adjuvant Discovery Program Meeting, Rockville, MD, October 1, 2012
311. Recent advances in understanding and managing the burden of childhood diarrhea. Presented to the AKU Biennial Pediatric Conference, Karachi, Pakistan. November 4, 2012
312. Enteric fever – epidemiology, diagnostics, and vaccines. Presented to the AKU Biennial Pediatric Conference, Karachi, Pakistan. November 14, 2012

313. Human/animal challenge studies. Presented at the WHO Typhoid ViCV Clinical Working Group Meeting, Royal Society of Medicine, London, UK. January 7, 2013
314. Historical and contemporary perspectives on human microbial challenge models. Presented at the Controlled Human Infections Studies in the Development of Vaccines and Therapeutics, University of Oxford, January 9, 2013
315. Human Typhoid challenge model and vaccine trials. Presented at the Controlled Human Infections Studies in the Development of Vaccines and Therapeutics, University of Oxford, January 10, 2013
316. An Overview of iNTS. Presented at the 8th International Conference on Typhoid Fever and Other Invasive Salmonellosis, Dhaka, Bangladesh, March 1, 2013
317. Oral vaccine approaches to typhoid and paratyphoid. Presented at the 8th International Conference on Typhoid Fever and Other Invasive Salmonellosis, Dhaka, Bangladesh, March 2, 2013
318. Clinical Trials: an overview of issues to be considered. Presented at the 14th Advanced Course of Vaccinology, Annecy, France, May 9, 2013
319. Infectious Diarrhea in Children: A Global Perspective. Presented at the ACVIM Forum, Seattle, WA, June 14, 2013
320. Salmonella Infection: Readjusting Dogma. Presented at the ACVIM Forum, Seattle, WA, June 14, 2013
321. Enteric vaccines development priorities in view of the Global Enteric Multi-Center Study (GEMS) findings. Presented at the School of Public Health, Tel Aviv University, July 14, 2013
322. Cholera and typhoid & non-typhi salmonellosis: Rational for vaccine development. Presented at the School of Public Health, Tel Aviv University, July 14, 2013
323. Cholera and Salmonella Vaccines. Presented at the School of Public Health, Tel Aviv University, July 14, 2013.
324. Development of live-attenuated ETEC vaccines. Presented at the School of Public Health, Tel Aviv University, July 16, 2013.
325. Development of combined Shigella-ETEC vaccines. Presented at the School of Public Health, Tel Aviv University, July 16, 2013.
326. Aetiology and burden of diarrheal disease in Africa and Asia: "GEMS". Presented at the Vaccines for Enteric Diseases Meeting, Bangkok, Thailand, November 6, 2013.
327. Diarrhoea in Africa, South America, and Asia. Presented at the World Society for Pediatric Infectious Diseases, Cape Town, South Africa, November 22, 2013.
328. Invasive Non-typhoidal *Salmonella* in Africa. Presented at ICAAC, Washington, DC, September 9, 2014
329. Lessons from the global Enteric multicenter Study (GEMS); Presented at ICAAC, Washington, DC, September 9, 2014
330. Historical perspective on human challenge trials. Presented at the IABS Human Challenge Trials in Vaccine Development: Scientific and Regulatory Issues, Strasbourg, France, Sept. 29, 2014
331. Control of Ebolavirus disease with judicious use of vaccine. Key target groups for vaccination outside clinical trials if 500, 3000, 15,000, 100,000 or millions of doses were available. WHO Ebola Vaccine Consultation, Geneva, 29 September 2014.
332. WHO Global Advisory Committee on Vaccine Safety. GSK Ebola Vaccine Development. Presented by M.M. Levine on behalf of the ChAd3-EBO Z Ebola Vaccine Consortium, December 4, 2014.

333. Summary comments. Ebola Immunology Workshop. FDA, December 12, 2014.
334. Vaccines and Vaccine Development: Ebola changes the paradigm. Presented at Johns Hopkins Bayview Medical Grand Rounds, January 20, 2015
335. Accelerated Development of Ebola Vaccine. Presented at Johns Hopkins Bloomberg School of Public Health, W. Harry Feinstone Dept. of Molecular Microbiology and Immunology Seminar Series, March 12, 2015.
336. Vaccines and Vaccine Development: Ebola changes the paradigm. Presented at the University of Florida, Emerging Pathogens Institute Research Day, Gainesville, Florida, February 26, 2015.
337. Clinical trials: an overview of issues to be considered. Presented at the 16th Advanced Course of Vaccinology, Centre de Conférences Les Pensieres, Annecy, France, May 13, 2015.
338. Vaccines against West African Ebolavirus, a diarrheal disease. Presented at Royal College of Physicians of Edinburgh, Vaccines for Enteric Diseases, Edinburgh, Scotland, July 8, 2015
339. Clinical studies of enteric vaccine candidates, from early phases to challenge studies and field trials. Presented at STOPENTERICS meeting, University of Oxford, Sept. 30, 2015
340. Challenges in Diagnosis of Enteric Infections in Developing Countries. Presented at Southern California ASM annual meeting, La Jolla, CA, Oct. 15, 2015
341. Antibody biomarker measurements in serum and oral fluid as objective evidence of population immunity, vaccine coverage and the quality of immunization services. Presented at BD Diagnostic Systems Headquarters, San Diego, CA, Oct. 16, 2015
342. Vaccines Against Invasive Salmonella Infections. Presented at International Conference on Vaccines Research and Development-2015, DoubleTree by Hilton Baltimore-BWI Airport, Nov. 2, 2015.
343. Points to consider in designing efficacy studies for vaccines against emerging infectious diseases in developing countries. Presented at 2015 PDA/FDA Vaccines Conference, Bethesda, MD, Dec. 2, 2015
344. Vaccines to Prevent typhoid and cholera. Presented at 2015 Ciro de Quados Vaccinology Course for Latin America, Santiago, Chile, Dec. 8, 2015
345. Immune protection in cholera and immune responses to Cholera vaccination: knowledge from challenged volunteer model. Presented at Correlates of Enteric Vaccine-induced Protection Conference, Annecy, France, March 22, 2016
346. Clinical trials: an overview of issues to be considered. Presented at the 17th Advanced Course of Vaccinology, Centre de Conférences Les Pensieres, Annecy, France, May 25, 2016.
347. CVD 103-HgR, a single-dose live oral cholera vaccine for travelers and for reactive immunization to control “virgin soil” epidemics in immunologically-naïve populations. Presented at Hwasun International Vaccine Forum 2016, Hwasun, S. Korea, June 10, 2016
348. Diarrhoeal diseases: overview of current disease burden, its pathogens and diagnostics in sub-Saharan Africa. Presented at the EDCTP Stakeholder Meeting on Diarrhoeal Diseases, Amsterdam, The Netherlands, July 5, 2016
349. The History of Vaxchora. Presented at the Vaxchora US Launch Meeting in Boston MA, July 19, 2016
350. Lessons Learnt from Clinical Development to Licensure. Presented at 16th ThaiTECT Annual Meeting 2016, Bangkok, Thailand, August 5, 2016

351. My personal vaccine development “bucket list”. Presented at University of Texas Medical Branch, Basic Science Distinguished Seminar, September 13, 2016
352. Can serum vibriocidal antibodies mediate bactericidal activity against *Vibrio cholerae* 01 in the small intestine of persons recovered from wild type cholera and in recipients of live oral vaccine? Presented at International Society for Vaccines (ISV) Annual Congress 2016, Boston, MA, October 4, 2016
353. How to control typhoid: Lessons from the Americas. Presented at the TCV effectiveness studies meeting sponsored by Oxford University, Oxford, UK, October 27, 2016
354. Important stages in vaccine clinical development. Presented at the Vaccinology Course sponsored by Dodet Bioscience at the Fondation Mérieux Conference Center, Veyrier-du-Lac, France, November 29, 2016
355. Typhoid fever, cholera, and other enteric diseases. Presented at the 2016 Ciro de Quadros Vaccinology Course for Latin America sponsored by the Sabin Vaccine Institute in Santiago, Chile, December 6, 2016.
356. Human Experimental Challenge Models in Vaccine Development: A Historical Perspective. Presented at the Emory University Vaccine Dinner Club, Atlanta, Georgia, March 1, 2017
357. A broad-spectrum vaccine to prevent invasive Salmonella disease in sub-Saharan Africa. Presented at the Conference on Typhoid and Other Salmonellosis, Entebbe, Uganda, April 5, 2017
358. Paratyphoid A fever and vaccine development: The importance of vaccines with the rise of antibiotic resistance. Presented at the World Vaccine Congress, Washington, D.C., April 12, 2017
359. Key data on ViPS and Ty21 vaccines – Current policy recommendations and vaccine use. Presented at the WHO SAGE Working Group on Typhoid Vaccines, Geneva, Switzerland, April 29, 2017
360. Key data on ViPS and Ty21 vaccines – current policy recommendations and vaccine use. Presented at Strategic Advisory Group of Experts on immunization (SAGE) Working Group on Typhoid Vaccines meeting, Geneva, Switzerland, May 30, 2017.
361. Control Strategies: Treatment as control, vaccines and WASH strategies. Presented at the American Society of Microbiology Microbe meeting, New Orleans, Louisiana, June 4, 2017
362. CVD multivalent live vector oral vaccine to prevent shigellosis and enterotoxigenic *Escherichia coli* (ETEC) diarrhea. Presented at PaxVax Scientific Advisory Board Meeting, San Diego, California, June 23, 2017
363. Typhoid. Presented at Johns Hopkins School of Public Health Summer Institute in Tropical Medicine and Hygiene, Baltimore, MD. July 27, 2017.
364. Ebola. Presented at Johns Hopkins School of Public Health Summer Institute in Tropical Medicine and Hygiene, Baltimore, MD. July 27, 2017
365. Enteric Vaccines. Presented at Johns Hopkins School of Public Health Summer Institute in Tropical Medicine and Hygiene, Baltimore, MD. July 27, 2017.
366. Typhoid; Ebola; Enteric Vaccines. Presented at the Sabin Institute – R&D Workshop, Washington, DC. August 8, 2017.
367. Historical perspective on human challenge trials. Keynote presented at the IABS 2nd Human Challenge Trials in Vaccine Development conference, Washington, D.C. September 28, 2017.
368. A Multivalent Vaccine to Prevent Invasive Salmonella Disease in Sub-Saharan Africa. Presented at Vaccines for Enteric Diseases (VED), Albufeira, Portugal. October 11, 2017.

369. The future of oral cholera vaccines. Presented at the Goba Task Force on Cholera Control, Lagos, Portugal. October 12, 2017.
370. Evidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines. Presented at the WHO Strategic Advisory Group of Experts (SAGE) on Immunization Meeting, Geneva, Switzerland. October 17, 2017.
371. Understanding the role of chronic carriers in the transmission and control of typhoid fever. Lessons from Chile. Presented at American Society of Tropical Medicine and Hygiene annual meeting, Baltimore, Maryland. November 8, 2017.

Major Invited Speeches

Special Lectures, Named Visiting Professorships:

Howard Florey Memorial Lecturer and Visiting Professor, University of Adelaide, South Australia, September, 1987.

Bazeley Oration, Australian Society for Microbiology, Sydney, 1992.

Felton Bequest Visiting Professor, Royal Children's Hospital, Melbourne, Australia, October, 1994.

Lederle-Praxis Visiting Professor of Vaccinology, Oxford University, December, 1994

Bradford Dixon Memorial Lecture, The University of Alabama at Birmingham and The Children's Hospital, Birmingham, Alabama, May, 2001.

Division Y (Public Health) Divisional Lecture, American Society for Microbiology 103rd General Meeting, Washington, D.C., May 21, 2003

The Holmes Fund Annual Lecture, Uniformed Services University of the Health Sciences. Sept. 13, 2004, Bethesda, Maryland. "On the Road to Timbuktu: Attenuated *Salmonella typhi* and *Shigella* as Oral Vaccines and as Live Vectors".

Henry L. Barnett Lecture, Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, September 28, 2006

Presidential Address, American Society of Tropical Medicine and Hygiene, November 15, 2006, Atlanta, GA. "Once Upon a Time, About 50,000 Years Ago".

Maurice Hilleman Endowed Lecture, Children's Hospital of Philadelphia. October 17, 2007, Philadelphia, PA. "Meeting the Challenge: The Science and Politics of Modern Typhoid Vaccines for Children in Developing Countries".

Medical College of Virginia Alumni Association Grand Rounds in recognition of receiving the Outstanding Medical Alumnus Award. November 1, 2007, Richmond, Va. "Challenges and gratification on the road to Timbuktu - musings on a career in global health.

Nancy Millis Lecture, La Trobe University, July 3, 2008, Melbourne, Australia. Vaccines, Global Health and Social Equity.

Bazeley Oration, Australian Society for Microbiology 2008 Melbourne, Australia, July 7, 2008. *Salmonella enterica*: My enemy, my friend ...

Tulane University First Presidential Symposium, December 5, 2008, New Orleans, LA. "On the Horizon: Typhoid and paratyphoid fever resistant to all antibiotics?"

Infectious Disease Society of America, Joseph Smadel Lecture, October 30, 2009, Philadelphia, PA. "A Tale of Two Salmonellae: Typhoidal and non-typhoidal".

St. George's Hospital Medical School, University of London, Jenner Lecture November 4, 2009, London, UK. "Silent fate; Lethal invasive nTA infections in Africa"

Tel Aviv University, Sackler Faculty of Medicine, Visiting Professor, March 14, 2010, Tel Aviv, Israel. "Invasive bacteremic *Salmonella* Infections: New Insights on Old Pathogens and Strategies for Prevention".

McAuley Oration in International Health, University of Otago, James and Jean Davis Prestige Visiting Fellow, November 7, 2011, Dunedin, New Zealand. "Vaccines, social equity and international health"

Maurice Hilleman/Merck Award lecture, American Society of Microbiology Annual Meeting, June 18, 2012, San Francisco, CA. "Vaccines to prevent emerging invasive *Salmonella* infections of humans"

American College of Veterinary Internal Medicine Forum, State of the Art speaker (SOTA). June 14, 2013, Seattle, WA. "Infectious Diarrhea in Children: A Global Perspective" and "Salmonella Infection: Readjusting Dogma"

Harvard Business School, Science of Eradication: Malaria Leadership Course, Ned Hayes Lecture. June 15, 2015, Boston, MA. "Lessons Learned from Past Eradication Campaigns"

Field Experiences (Partial Listing):

1. Safety testing of *Shigella flexneri* 2 and *Shigella sonnei* oral attenuated vaccines in institutionalized children, 1970.
2. Principal Investigator, U.S. Public Health Service *Shigella sonnei* Vaccine Field Trial, Fort Myers, Florida 1972-1973.
3. Principal Investigator, U.S. Public Health Service *Shigella flexneri* 2 Vaccine Field Trial, Staten Island, New York, 1971-1973.
4. Pan American Health Organization Consultant Epidemiologist to the Ministry of Health of the Dominican Republic to assist in the investigation and control of epidemic poliomyelitis. June-July 1971.
5. Conduction of a rectal swab and sero-survey to determine the prevalence of enteroviruses and enteroviral antibodies in the Republic of Haiti. July 1971.
6. Pan American Health Organization Consultant to Guatemala to discuss Epidemic Shiga Dysentery. August 1971.
7. World Health Organization Temporary Advisor to Morocco to evaluate diarrheal and enteric diseases. June 1972.
8. Site Inspector to report on the status of the U.S. PL 480-funded *Shigella* field trials of Dr. David Mel in Yugoslavia. July 1972.
9. Preliminary inspection of prospective field sites in South and Central America for the conduction of an oral typhoid vaccine field trial. April-June 1973.
10. Pan American Health Organization Consultant for the evaluation of endemicity of typhoid fever in Peru. August 1973.
11. World Health Organization Consultant Epidemiologist to the Smallpox Eradication Program during August, September and October 1975. Service as District Coordinator of Rajshahi District, Bangladesh during this period.

12. World Health Organization/Pan American Health Organization Advisor to Guatemala November 1975, to participate in a symposium and teaching seminar on enteric diseases, "Seminario sobre Nuevas Tendencias para el Diagnostico y Tratamiento del Sindrome Diarreico."
13. Director and Coordinator, "Swine Influenza Vaccine Testing Program," Maryland 1976.
14. Guest of the Ministry of Health, Cuba, to observe the Infant Diarrhea Control Program. September, 1977.
15. Pan American Health Organization Temporary Advisor on Diarrheal Diseases and Oral Fluid Therapy. Dominican Republic, Guatemala, Costa Rica, Panama, and Nicaragua, November, 1977.
16. Pan American Health Organization Advisor to Costa Rica, December 1977 to design, initiate and coordinate an investigation of the efficacy of glucose/electrolyte and rehydration therapy in infantile diarrhea due to rotavirus.
17. Pan American Health Organization Advisor to Costa Rica, July, 1978 to participate as Technical Consultant and Course Manager in Expanded Program on Immunization Course.
18. Pan American Health Organization Temporary Advisor to Surinam to discuss enteric diseases.
19. Pan American Health Organization consultant to Chile to study the epidemiology of endemic typhoid fever and design control measures.
20. Pan American Health Organization Temporary Advisor to Peru to assist as course manager in the Expanded Program on Immunization Course, January 1979.
21. Consultant to the World Health Organization Program on Diarrheal Diseases, Geneva, February 1979. Development of teaching aids and manuals to assist senior health officials to establish diarrhea disease control program.
22. Consultant to the Agency for International Development and the Academy for Educational Development project on use of mass media communication methods to combat diarrheal disease. Tanzania and Cameroon, April 1979.
23. Consultant to the Agency for International Development and the Academy for Educational Development project on use of mass media communication methods to combat diarrheal disease. Honduras and Ecuador, May 1979.
24. Temporary Advisor to Pan American Health Organization to assist in provincial level courses on treatment and control of diarrheal diseases, Amatlan and Huehuetenango, Guatemala, September 1979.
25. Consultant to the Academy for Educational Development project on use of mass media communication methods to combat diarrheal disease. Honduras, September 1979.
26. Temporary Advisor to Pan American Health Organization for the Regional Seminar on Diarrheal Disease Control. Lima Peru, October 1979.
27. U.S. Agency for International Development Consultant to the Government of Honduras to design a five year Diarrheal Disease Control Program, December 1979.
28. Pan American Health Organization consultant to Honduras to initiate oral therapy studies at Hospital Materno Infantil, February 1980.
29. Pan American Health Organization consultant to Peru to teach a course on diarrheal diseases, February 1980.
30. World Health Organization Consultant to Rwanda and Burundi, July 1980, to advise the ministries of health in organizing national diarrheal disease control programs for those countries with oral rehydration activities as the keystone.

31. Consultant to the Ministry of Health, Santiago, Chile on the control of endemic typhoid fever. Approximately two months annually since 1980 are spent supervising activities in Chile where the Center for Vaccine Development maintains a field unit in collaboration with the Ministry of Health.
32. U.S. Agency for International Development consultant to Bangladesh, December, 1982, to review the status of epidemiologic activities at the International Center for Diarrheal Disease Research, Bangladesh.
33. Supervised a large-scale controlled field trial of Ty21a oral typhoid vaccine involving 150,000 schoolchildren in Area Occidente, Santiago, Chile. Vaccination occurred in August and September, 1983. Surveillance for typhoid fever in the cohort was maintained for seven years.
34. Agency for International Development (PRITECH) consultant to Kenya to review the status of oral rehydration activities, 1984.
35. Consultant to the Egyptian Diarrheal Disease Control Project, July 1984.
36. Invited consultant to the Lanzhou Institute of Biological Products, Lanzhou, People's Republic of China, to discuss vaccines against enteric infections, November 1984.
37. U.S. Agency for International Development Consultant to the Vaccine Assistance Program, Delhi, India, to explore the possibility of field trials of new typhoid vaccines. May, 1986.
38. U.S. Agency for International Development Consultant to the International Center for Diarrheal Disease Research, Bangladesh, to evaluate the status of research at the Center. May, 1986.
39. U.S. Agency for International Development Consultant to Mahidol University Vaccine Trial Centre, Bangkok, Thailand, to explore the possibility of Phase 1 and 2 trials of malaria vaccine candidates. June, 1986.
40. Initiation of longitudinal field studies of the etiology and prevention of pediatric diarrhea in Santa Julia, Santiago, Chile in collaboration with the Ministry of Health and the Microbiology Unit of the University of Chile, November, 1986 - present.
41. Co-designed and participated in an AID-supported study of malaria in Yanomami Indians living along the Orinoco River in the Amazon region of Venezuela, 1987.
42. Initiation of collaborative studies of the etiology of persistent diarrhea in children with Dr. M.K. Bhan of the Department of Paediatrics, All-India Institute of Medical Sciences, New Delhi, India June 1987 - present.
43. Consultant to the Department of Preventive Medicine, Israel Defence Forces on the control of diarrheal diseases in soldiers, August, 1987 to present.
44. Initiation of Phase 2 studies of live oral cholera vaccine CVD 103-HgR in Thai university students and in Thai military personnel, Bangkok, Thailand, 1988.
45. Designed and provided overall coordination of Phase 2 pediatric studies of the safety and immunogenicity of CVD 103-HgR live oral cholera vaccine in Indonesian children, Jakarta, Indonesia, 1989-1992.
46. Consultant to the Institute of Epidemiology and Microbiology of the Chinese Academy of Preventive Medicine, Beijing China on enteric vaccine development, September, 1990.
47. Consultant to the Minister of Health, Chile on control of cholera, May, 1991.
48. Ad Hoc invited member, Chilean Cholera Commission, May, 1991.
49. Consultant to Centre Muraz, Bobo Doullasso, Burkina Faso, to explore possible collaborative studies on diarrheal diseases. 1991.

50. Consultant to the Sociedad Colombiana de Medicina Tropical y Parasitologia on the subject of cholera (inspection of two cholera affected areas of Colombia), October, 1991.
51. World Health Organization (Western Pacific Regional Office) Consultant in Vaccine Development to the People's Republic of China, November, 1991.
52. World Health Organization Consultant to the Program for Vaccine Development, 1992-1994.
53. Member of the U.S. Army Data Monitoring Safety Board for HIV Vaccine Field Trials, 1992 to present.
54. Consultant to the Ministry of Health and the Fundación Centro de Estudios Infectologicos, Argentina, February, 1993, to investigate epidemic cholera in Northern Argentina and to review activities of the the National Cholera Control Commission.
55. Evaluation of potential field sites in Mali to conduct phase 2 trial of CVD 103-HgR live oral cholera vaccine in HIV +/- adults. Mali, Africa. February, 1996.
56. Member of Vaccine Action Program and U. S. Malaria Mission. Mumbai and Rajasthan, India. February, 1997.
57. Member of a WHO field site team assessing the feasibility of using leishmanization to assess the efficacy of new *Leishmania* vaccines. Samarkand, Uzbekistan, September, 1997.
58. Participant "Consultative Meeting on Vaccine Development and Immunization Implementation", Harare, Zimbabwe, December 4, 1998.
59. Organizer, "Consultative Meeting on Vaccine Development and Immunization Implementation", Santiago, Chile, January 15 & 16, 1999.
60. Organizer, "Consultative Meeting on Vaccine Development and Immunization Implementation", New Delhi, India, February 9, 1999.
61. Member, initial GAVI mission to China, December, 2000.
62. Member of the CVD team that established, in conjunction with the Ministry of Health of Mali, a clinical bacteriology laboratory in the Gabriel Touré Hospital in Bamako, Mali, February, 2002.
63. WHO consultant participating in the preparation of a field manual for the diagnosis, treatment and prevention of typhoid fever, Hanoi Vietnam, March, 2002.
64. WHO consultant to SEARO, Delhi, India for consultation on aerosol measles vaccine production and licensure track, September, 2002.
65. WHO consultant to SEARO, Delhi, and to the Serum Institute of India for consultation on aerosol measles vaccine production and licensure track, March, 2003.
66. Evaluation of pediatric diarrheal disease burden and treatment programs, Laos, September 2006.
67. Evaluation of Malian Expanded Programme on Immunization Hib Vaccine Introduction Program, January 2007.
68. Inspection of U.S. Department of Defense Avian influenza surveillance activities at Naval medical research Unit 2 (NAMRU-2), Jakarta, Indonesia and Phnom Penh, US Army Medical Research Unit, Kenya and Walter Reed Army Institute of Research Research Unit, Kampala, Uganda, March 2007.
69. Evaluation of potential field sites in three woredas of Ethiopia (Afar, SNSS and Tigray) for possible serosurveys in conjunction with immunization coverage surveys. January 2012.

70. Team Leader, Wellcome Trust Site visit team to the Malawi/Liverpool/Wellcome Trust Unit in Balntyre, Malawi. February 2013.
71. WHO Consultant on Typhoid Fever, Samoa. March 2013.
72. To help prepare CVD-Mali for Phase 1B trials of an Ebola vaccine candidate. Bamako, Mali, September 2014.
73. To assist CVD-Mali staff in performing a Phase 1B clinical trial of a chimpanzee adenovirus 3-vectored Ebola Zaire vaccine. Bamako, Mali, October 2014.
74. Site preparation visit to proposed field sites for a WHO-sponsored field trial of efficacy of an Ebola vaccine. Conakry, Guinea, January, 2015.
75. To re-inforce a capacity building collaboration with the Ethiopian Public Health Institute to transfer technology to measure several vaccine-induced IgG antibodies for support of serosurveys in rural Ethiopia. Addis Ababa, February, 2015.
76. Organization of a Training Course in Good Clinical Practices for Guinean and other investigators who will perform the Phase 3 field trial of efficacy of a candidate Ebola vaccine. February-March 2015

U.S. Post-Doctoral Fellows Mentored by Myron M. Levine, M.D., D.T.P.H. 1976 until Present			
Name	Training period	Title of research project	Last position
Stephen Sotman, M.D.	1976- 1977	Clinical studies with enteropathogenic <i>Escherichia coli</i> strains for infant nursery outbreaks	
Margaret B. Rennels, M.D.	1977-1978	Clinical microbiology of cholera. ETEC colonization factors	Retired Professor of Pediatrics, University of Maryland School of Medicine. Chief Pediatric Clinical Studies Section, CVD
David Hoover, M.D.	1977-1978	Volunteer studies of ETEC and cholera	Head, <i>Brucella</i> Research, Walter Reed Army Institute of Research
Erick J Bergquist, M.D., Ph.D.	1977-1978	Immunity to enterotoxigenic <i>Escherichia coli</i>	Thomas Jefferson Medical College, Philadelphia, PA
Stephen Sears, MD	1981-83	Immunological response to outer membrane proteins of <i>Vibrio cholerae</i>	Private practice of Infectious Diseases
Mary Baldini, PhD	1981-85	Molecular Genetics of enteropathogenic <i>E. coli</i>	Unknown
J. Glenn Morris, Jr.,MD	1982-84	Pathogenesis of <i>Vibrio vulnificus</i>	Director, Emerging Pathogens Institute, University of Florida
Deirdre Herrington, MD	1983-85	<i>Plesiomonas</i> pathogenesis and clinical trials of vaccine candidates	ID Physician, Blue Ridge Medical Associates
Carol O. Tacket, MD	1983-85	<i>E. coli</i> colonization factors and role in vaccines	2009 Retired, Professor, Univ. of MD School of Medicine
Karen Kotloff, MD	1983-86	Epidemiology and etiology of diarrhea in Baltimore children and impact of rotavirus	Professor of Pediatrics, Univ. of MD School of Medicine
David DiJohn, MD	1986-88	Immunological responses to malaria infection and vaccination	New York Univ. Sch. of Med.
Gerald Poley, MD	1987-88	<i>E. coli</i> colonization factors	NIAID, NIH
Stephen Savarino, MD	1988-90	Enterogaagregative <i>E. coli</i> pathogenesis	Head, Department of Enteric Diseases, NMRI; Capt., US Navy
David Hone, PhD	1988-89	Attenuated <i>Salmonella typhi</i> vaccine development	Asst. Prof., Univ. MD, Med. Biotechnology Center
Alessio Fasano, MD	1988-90	Enterotoxins of <i>Shigella</i> and enteroinvasive <i>Escherichia coli</i>	Professor of Pediatrics, Harvard Medical School. Director, Center for Celiac Research, Massachusetts General Hospital for Children, Boston, MA
W. Gray Heppner, MD	1989-92	Development of malaria vaccines	Retired Colonel. Previously, Head of Malaria Research, Walter Reed Army Institute of Research, Silver Spring, MD
Fernando Noriega, MD, MPH	1989-93	<i>Shigella</i> vaccine development	Head of Clinical Translational Vaccinology & Head of Clinical Development Latin America, Sanofi Pasteur Vaccines, Swiftwater, PA
Charles Pumpuni, PhD	1991-92	Malaria vaccine development	Assist. Prof., Univ. of MD
Eileen Barry, Ph.D.	1994-1996		Professor of Medicine. Chief, Shigella Vaccines Section, CVD, UMB, Baltimore, MD
Thames Pickett, Ph.D.	1996-1999	<i>Salmonella</i> live vector vaccines	Office of Biodefense Research Resources and Translational Research, NIAID, NIH, Bethesda, MD
Taraz Samandari, M.D. (Vaccinology)	1998-2001	Protective Immune mechanisms in human <i>Shigella</i> vaccines	Centers for Disease Control & Prevention, Atlanta, GA

U.S. Post-Doctoral Fellows Mentored by Myron M. Levine, M.D., D.T.P.H. 1976 until Present			
Name	Training period	Title of research project	Last position
James D Campbell, M.D.	1998-2001	Detailed measurement of human infant immune response to fractional doses of Hib conjugate vaccine, including antibody avidity	Center for Vaccine Development, University of Maryland School of Medicine
Milagritos Tapia, M.D.	2001 - 2003	Measurement of tetanus antitoxin in oral fluids from Malian infants, children and adults. Measles serosurveys to define the "window of vulnerability" in rural Malian infants	Asst. Prof. Univ. of MD School of Medicine
Jakub Simon, M.D.	2003-2005	Measurement of measles antibodies in Chilean adults immunized with Edmonston Zagreb attenuated measles vaccine administered intranasally or subcutaneously	Director, Clinical Research, Vaccines Merck & Co
Julia Hutter, M.D.	2006-2009	Cross-sectional survey of anti- <i>Haemophilus influenzae</i> type b (Hib) antibody and tetanus antitoxin	DAIDS, NIAID, NIH
Kelly K. Baker, Ph.D.	2009-2011	Comparison of water and sanitation conditions of case versus control households to identify environmental risk factors for the development of severe pediatric diarrheal disease	Assistant Professor, Occupational & Environmental Health, University of Iowa
Raphael Simon. Ph.D.	2009-2012	Development of a bivalent <i>Salmonella</i> Enteritidis/ <i>Salmonella</i> Typhimurium conjugate vaccine to prevent invasive non-typhoidal <i>Salmonella</i> disease in sub-Saharan Africa	Assistant Professor of Medicine, Head Antigen Purification Unit, CVD, Univ. of Maryland School of Medicine
Adetunke Mary Boyd, M.D.	2011-2013	Measurement of serum bactericidal antibody against non-typhoidal <i>Salmonella</i> serovars. Development of an ultra-sensitive quantitative real-time PCR method for identifying invasive <i>Salmonella</i> infections in blood. Setting up a field trial in Karachi, Pakistan to test the sensitivity and specificity of a new qPCR diagnostic versus standard blood culture	Medical Officer, DHHS/CDC/CGH/DGHT - Lusaka, Zambia

International Post-Doctoral Fellows Mentored by Myron M. Levine, M.D., D.T.P.H. 1981 through Present			
Name	Training period	Title of research project	Present position
Roy M. Robins-Browne, MBCh, PhD	1979-1980	Pathogenesis of EPEC diarrhea	Professor of Microbiology, School of Microbiology, University of Melbourne, Parkville, Victoria, AU
Claudio Lanata, PhD (Peru)	1981-1982	Detection of enterotoxigenic <i>E. coli</i> using DNA probes & large scale vaccine field trials	Director General, Inst. for Nutri. Res., Peru
Catherine Ferreccio, M.D.	1982		Professor, Master Director Epidemiology, Pontificia Universidad Catolica de Chile

International Post-Doctoral Fellows Mentored by Myron M. Levine, M.D., D.T.P.H. 1981 through Present			
Name	Training period	Title of research project	Present position
Luis Cisneros, M.D.	1982-1983	Pathogenesis of cholera nad ETEC infections in volunteers	Private Pracice
Jian-Guo Xu, MD (China)	1985-86	ETEC and EHEC vaccine development and diagnostics	National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control and Prevention, Changping Beijing, China
Robert Hall, PhD (U.K.)	1985-90	Cholera pathogenesis & vaccine development	Enteric Diseases Section, DMID, NIAID, NIH
Pablo Vial, MD (Chile)	1985-87	Pathogenesis of enteroaggregative <i>Escherichia coli</i> diarrhea	Dean, Facultad de Medicina, Universidad del Desarrollo, Santiago, Chile
Bernadette Baudry, PhD (France)	1988-91	Molecular genetics of enteroaggregative <i>E. coli</i>	Deceased. Last employment at USUHS, Bethesda, MD
Rosanna Lagos, MD (Chile)	1988-90	<i>Haemophilus influenzae</i> virulence & vaccine testing	Coordinator, CVD-Chile, Santiago, Chile
Oscar Gomez, MD, PhD (Colombia)	1990-1994	Genetic regulation in enteropathogenic <i>E. coli</i>	Assistant Professor, Department of Pediatrics, Vanderbilt University School of Medicine
Jorge Giron, PhD (Mexico)	1991-1994	Enterotoxigenic <i>E. coli</i> vaccines	Emerging Pathogens Institute, University of Florida, Gainesville, FL
Cesar Gonzalez, MD, PhD (Mexico)	1991-1992	Expression of malaria and <i>Leishmania</i> antigens in <i>Salmonella</i>	Assoc. Invest., Social Security Institute, DF, Mexico
Shaoguang Wu (China)	1993-1995	<i>Salmonella</i> live vector vaccines	Johns Hopkins University
Zhao Ying Xiang (China)	1995	<i>Vibrio cholerae</i> 0139 pathogenesis	Unknown
Christoph Tang, MBBS, PhD (U.K.)	1996-1998	Meningococcal and <i>Shigella</i> vaccine development	Glaxo Chair of Cellular Pathology, Sir William Dunn School of Pathology, Oxford University, U.K. Co-Director, Oxford Martin Programme on Vaccines
Richard J. Anderson, PhD (U.K.)	1996-1999	<i>Shigella</i> vaccine construction	Oxford University, U.K.
Nadav Orr, PhD (Israel)	1996-98	Salmonella live vector-based oral diphtheria vaccine	Army Health Branch Research Unit Israel Defense Force
Cecilia Gonzalez, MD (Chile; Emerging Infections)	1998-1999	Emerging infection surveillance, improved diagnosis, collation and exchange of surveillance information as well as disease control interventions.	I.D. Consultant, Roberto del Rio Hospital, Chile
Rodrigo Vergara, MD (Chile; Emerging Infections)	1999-2000	Expression of protein antigens of <i>Streptococcus pneumoniae</i> in attenuated <i>Salmonella</i> Typhi vaccine strains.	Prof. of Microbiology, Universidad de Valparaiso, Chile
Jaime Rodriguez, MD (Chile; Emerging Infections)	1999-2000	Using PCR to detect sequences of <i>Streptococcus pneumoniae</i> in blood or otherwise sterile body fluids of patients with syndromes compatible with invasive pneumococcal disease	Pediatric Infectious Diseases Section, Hospital Roberto del Rio, Santiago, Chile

International Post-Doctoral Fellows Mentored by Myron M. Levine, M.D., D.T.P.H. 1981 through Present			
Name	Training period	Title of research project	Present position
Licheng Zhao, M.D. (China)	2001-2006	Malaria vaccine and S. Typhi-based vaccine to prevent DTP	Research Scientist, Mucosal Biology Research Center, UMB
Mahender Singh, Ph.D. (India)	2000-2001	Clone measles virus H and F genes	Unknown
Miguel A. Ascon, Ph.D.	2000-2001	Expression of <i>Plasmodium falciparum</i> antigens in attenuated <i>Salmonella</i> Typhi	BriJen Biotech, LLC, Co-Founder, President & CEO
Juan Carlos Hormazabal, M.D. (Chile)	2000 - 2002	Molecular epidemiology of meningococcal disease in Chile.	Institute of Public Health, Santiago, Chile
Christofer Vindurampulle, Ph.D. (Australia)	2002 - 2005	Construction and pre-clinical studies of attenuated <i>Salmonella</i> Paratyphi A vaccine strain for oral administration	Patents and Trade Marks, Watermark, Melbourne, Victoria, AU
Man Ki Song, Ph.D. (Korea)	2002 - 2004	Construct Sindbis replicon encoding measles H and both H and F proteins. Animal studies of safety, immunogenicity & efficacy	International Vaccine Institute, Seoul, Korea
Boubou Tamboura, Ph.D. Mali - Emerging Infections	2003 -2004	Molecular and classical microbiologic tools for identification of bacterial pathogens.	Head, Microbiology & Molecular Lab, Centre Pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali
Souleymane Diakite, Ph.D. Mali - Emerging Infections	2003 - 004	Techniques in humoral and mucosal immunology related to vaccine development.	PharmD, ONG in Mali, Africa
Sharon Tennant, Ph.D.	2007-2010	Expression of the SARS glycoprotein S antigen from SARS-CoV in <i>Salmonella</i> Typhi vaccine strain CVD 908- <i>htrA</i> . Development of a multiplex PCR technique for serotyping invasive <i>Salmonella</i> serovars	Assoc. Professor of Medicine, Univ. of Maryland Sch. of Medicine & Chief, Molecular Diagnostics Section, CVD, UMB
Khitam Muhsen, R.N., M.P.H., Ph.D. (Israel)	2011 - 2013	The role of <i>Helicobacter pylori</i> infection on the immune response to oral vaccines. Role of <i>Giardia lamblia</i> as a cause of acute and persistent pediatric diarrheal illness	Senior Lecturer, Dept. of Epidemiology & Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Israel
Ellen Higginson, Ph.D. (Australia)	2013 -	Attenuation of <i>Salmonella</i> Paratyphi B by introducing mutations identified in zero gravity (space)	Current fellow